WO2012150319A1 - Albumin variants - Google Patents
Albumin variants Download PDFInfo
- Publication number
- WO2012150319A1 WO2012150319A1 PCT/EP2012/058206 EP2012058206W WO2012150319A1 WO 2012150319 A1 WO2012150319 A1 WO 2012150319A1 EP 2012058206 W EP2012058206 W EP 2012058206W WO 2012150319 A1 WO2012150319 A1 WO 2012150319A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- albumin
- polypeptide
- fcrn
- fragment
- hsa
- Prior art date
Links
- 108010088751 Albumins Proteins 0.000 title claims abstract description 497
- 102000009027 Albumins Human genes 0.000 title abstract description 454
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 341
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 336
- 229920001184 polypeptide Polymers 0.000 claims abstract description 333
- 230000004927 fusion Effects 0.000 claims abstract description 163
- 229910052727 yttrium Inorganic materials 0.000 claims description 359
- 229910052698 phosphorus Inorganic materials 0.000 claims description 350
- 239000012634 fragment Substances 0.000 claims description 306
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 214
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 214
- 229910052721 tungsten Inorganic materials 0.000 claims description 185
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims description 177
- 230000027455 binding Effects 0.000 claims description 153
- 230000004075 alteration Effects 0.000 claims description 122
- 238000006467 substitution reaction Methods 0.000 claims description 115
- 150000001413 amino acids Chemical class 0.000 claims description 92
- 238000000034 method Methods 0.000 claims description 71
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 64
- 239000000203 mixture Substances 0.000 claims description 62
- 239000002105 nanoparticle Substances 0.000 claims description 56
- 102000040430 polynucleotide Human genes 0.000 claims description 52
- 108091033319 polynucleotide Proteins 0.000 claims description 52
- 239000002157 polynucleotide Substances 0.000 claims description 52
- 238000003780 insertion Methods 0.000 claims description 51
- 230000037431 insertion Effects 0.000 claims description 51
- 210000004027 cell Anatomy 0.000 claims description 43
- 108020004705 Codon Proteins 0.000 claims description 41
- 150000001875 compounds Chemical class 0.000 claims description 38
- 125000000539 amino acid group Chemical group 0.000 claims description 37
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 32
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims description 32
- 230000009286 beneficial effect Effects 0.000 claims description 32
- 150000007523 nucleic acids Chemical class 0.000 claims description 28
- 102000039446 nucleic acids Human genes 0.000 claims description 27
- 108020004707 nucleic acids Proteins 0.000 claims description 27
- 230000001225 therapeutic effect Effects 0.000 claims description 27
- 239000011859 microparticle Substances 0.000 claims description 25
- 102220468836 Albumin_D87N_mutation Human genes 0.000 claims description 22
- 102220468864 Albumin_E84K_mutation Human genes 0.000 claims description 22
- 102220468840 Albumin_L90P_mutation Human genes 0.000 claims description 22
- 102220468717 Protein arginine N-methyltransferase 3_H464A_mutation Human genes 0.000 claims description 22
- 102220024669 rs59270054 Human genes 0.000 claims description 22
- -1 fusion Substances 0.000 claims description 21
- 102220120186 rs886042523 Human genes 0.000 claims description 21
- 230000003993 interaction Effects 0.000 claims description 19
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 19
- 238000003384 imaging method Methods 0.000 claims description 18
- 238000003032 molecular docking Methods 0.000 claims description 18
- 229910052720 vanadium Inorganic materials 0.000 claims description 18
- 230000000069 prophylactic effect Effects 0.000 claims description 17
- 230000014509 gene expression Effects 0.000 claims description 16
- 230000021615 conjugation Effects 0.000 claims description 15
- 229910052740 iodine Inorganic materials 0.000 claims description 12
- 240000007594 Oryza sativa Species 0.000 claims description 11
- 235000007164 Oryza sativa Nutrition 0.000 claims description 11
- 235000009566 rice Nutrition 0.000 claims description 10
- 125000003396 thiol group Chemical group [H]S* 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- 230000001268 conjugating effect Effects 0.000 claims description 6
- 238000004458 analytical method Methods 0.000 claims description 5
- 230000003247 decreasing effect Effects 0.000 claims description 5
- 239000001963 growth medium Substances 0.000 claims description 5
- 210000004962 mammalian cell Anatomy 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 4
- 238000003745 diagnosis Methods 0.000 claims description 3
- 238000011321 prophylaxis Methods 0.000 claims description 3
- 241000196324 Embryophyta Species 0.000 claims description 2
- 102100027211 Albumin Human genes 0.000 claims 43
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 35
- 102220026812 rs63750850 Human genes 0.000 claims 2
- 241000206602 Eukaryota Species 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940050528 albumin Drugs 0.000 description 425
- 241000282414 Homo sapiens Species 0.000 description 113
- 235000001014 amino acid Nutrition 0.000 description 91
- 210000002381 plasma Anatomy 0.000 description 89
- 108090000623 proteins and genes Proteins 0.000 description 71
- 102000004169 proteins and genes Human genes 0.000 description 56
- 235000018102 proteins Nutrition 0.000 description 52
- 238000012217 deletion Methods 0.000 description 45
- 230000037430 deletion Effects 0.000 description 45
- 102000019034 Chemokines Human genes 0.000 description 44
- 108010012236 Chemokines Proteins 0.000 description 44
- 108091026890 Coding region Proteins 0.000 description 39
- 102000005962 receptors Human genes 0.000 description 32
- 108020003175 receptors Proteins 0.000 description 32
- 102000007562 Serum Albumin Human genes 0.000 description 25
- 108010071390 Serum Albumin Proteins 0.000 description 25
- 125000003275 alpha amino acid group Chemical group 0.000 description 22
- 102220553316 Lysosomal acid glucosylceramidase_D63N_mutation Human genes 0.000 description 20
- 230000035772 mutation Effects 0.000 description 19
- 239000002773 nucleotide Substances 0.000 description 17
- 125000003729 nucleotide group Chemical group 0.000 description 17
- 108010076504 Protein Sorting Signals Proteins 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 15
- 108010068617 neonatal Fc receptor Proteins 0.000 description 15
- 210000004899 c-terminal region Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 230000008901 benefit Effects 0.000 description 12
- 229960005486 vaccine Drugs 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 9
- 229910052739 hydrogen Inorganic materials 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 241000894007 species Species 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 8
- 102000001902 CC Chemokines Human genes 0.000 description 7
- 239000004471 Glycine Substances 0.000 description 7
- 238000010276 construction Methods 0.000 description 7
- 238000010586 diagram Methods 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- 238000002741 site-directed mutagenesis Methods 0.000 description 7
- 108700028369 Alleles Proteins 0.000 description 6
- 108010040471 CC Chemokines Proteins 0.000 description 6
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 6
- 206010028347 Muscle twitching Diseases 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 229940040731 human interleukin-12 Drugs 0.000 description 6
- 238000009396 hybridization Methods 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 238000013519 translation Methods 0.000 description 6
- 102000016950 Chemokine CXCL1 Human genes 0.000 description 5
- 108010014419 Chemokine CXCL1 Proteins 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 5
- 241000283073 Equus caballus Species 0.000 description 5
- 241000725303 Human immunodeficiency virus Species 0.000 description 5
- 102000000589 Interleukin-1 Human genes 0.000 description 5
- 108010002352 Interleukin-1 Proteins 0.000 description 5
- 229930012538 Paclitaxel Natural products 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 238000002703 mutagenesis Methods 0.000 description 5
- 231100000350 mutagenesis Toxicity 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 239000002243 precursor Substances 0.000 description 5
- 210000002966 serum Anatomy 0.000 description 5
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 5
- 108010021809 Alcohol dehydrogenase Proteins 0.000 description 4
- 102000007698 Alcohol dehydrogenase Human genes 0.000 description 4
- 102100023688 Eotaxin Human genes 0.000 description 4
- 101710139422 Eotaxin Proteins 0.000 description 4
- 101001055219 Homo sapiens Interleukin-9 receptor Proteins 0.000 description 4
- 102100020880 Kit ligand Human genes 0.000 description 4
- 239000004472 Lysine Substances 0.000 description 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 4
- 241000283973 Oryctolagus cuniculus Species 0.000 description 4
- 241000700159 Rattus Species 0.000 description 4
- 238000002105 Southern blotting Methods 0.000 description 4
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 description 4
- 230000002378 acidificating effect Effects 0.000 description 4
- 239000012876 carrier material Substances 0.000 description 4
- 238000010168 coupling process Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 239000013604 expression vector Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 235000014304 histidine Nutrition 0.000 description 4
- 239000001257 hydrogen Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 239000002853 nucleic acid probe Substances 0.000 description 4
- 239000008194 pharmaceutical composition Substances 0.000 description 4
- 239000013612 plasmid Substances 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 108020001568 subdomains Proteins 0.000 description 4
- 238000013518 transcription Methods 0.000 description 4
- 230000035897 transcription Effects 0.000 description 4
- 238000011144 upstream manufacturing Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 239000004475 Arginine Substances 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 241000701022 Cytomegalovirus Species 0.000 description 3
- 108090000394 Erythropoietin Proteins 0.000 description 3
- 102000003951 Erythropoietin Human genes 0.000 description 3
- 108010039471 Fas Ligand Protein Proteins 0.000 description 3
- 102100028072 Fibroblast growth factor 4 Human genes 0.000 description 3
- 102100020997 Fractalkine Human genes 0.000 description 3
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Chemical class OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
- 101000854520 Homo sapiens Fractalkine Proteins 0.000 description 3
- 101001033233 Homo sapiens Interleukin-10 Proteins 0.000 description 3
- 101000960954 Homo sapiens Interleukin-18 Proteins 0.000 description 3
- 101001033279 Homo sapiens Interleukin-3 Proteins 0.000 description 3
- 101001055222 Homo sapiens Interleukin-8 Proteins 0.000 description 3
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 241000282553 Macaca Species 0.000 description 3
- 108010064136 Monocyte Chemoattractant Proteins Proteins 0.000 description 3
- 102000014962 Monocyte Chemoattractant Proteins Human genes 0.000 description 3
- 101000930477 Mus musculus Albumin Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108091034117 Oligonucleotide Proteins 0.000 description 3
- 102100036154 Platelet basic protein Human genes 0.000 description 3
- 241000282898 Sus scrofa Species 0.000 description 3
- 108700005078 Synthetic Genes Proteins 0.000 description 3
- 102000004903 Troponin Human genes 0.000 description 3
- 108090001027 Troponin Proteins 0.000 description 3
- 235000004279 alanine Nutrition 0.000 description 3
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 230000009137 competitive binding Effects 0.000 description 3
- 230000008878 coupling Effects 0.000 description 3
- 238000005859 coupling reaction Methods 0.000 description 3
- 229940105423 erythropoietin Drugs 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 230000002068 genetic effect Effects 0.000 description 3
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 3
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 3
- 230000013595 glycosylation Effects 0.000 description 3
- 238000006206 glycosylation reaction Methods 0.000 description 3
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 3
- 102000052620 human IL10 Human genes 0.000 description 3
- 102000043959 human IL18 Human genes 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003112 inhibitor Substances 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000004481 post-translational protein modification Effects 0.000 description 3
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 description 3
- 238000002708 random mutagenesis Methods 0.000 description 3
- 102220068520 rs202031614 Human genes 0.000 description 3
- 102220012367 rs397516025 Human genes 0.000 description 3
- 102200091909 rs77752336 Human genes 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- FQVLRGLGWNWPSS-BXBUPLCLSA-N (4r,7s,10s,13s,16r)-16-acetamido-13-(1h-imidazol-5-ylmethyl)-10-methyl-6,9,12,15-tetraoxo-7-propan-2-yl-1,2-dithia-5,8,11,14-tetrazacycloheptadecane-4-carboxamide Chemical compound N1C(=O)[C@@H](NC(C)=O)CSSC[C@@H](C(N)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C)NC(=O)[C@@H]1CC1=CN=CN1 FQVLRGLGWNWPSS-BXBUPLCLSA-N 0.000 description 2
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 2
- 102100034044 All-trans-retinol dehydrogenase [NAD(+)] ADH1B Human genes 0.000 description 2
- 101710193111 All-trans-retinol dehydrogenase [NAD(+)] ADH4 Proteins 0.000 description 2
- 102100034613 Annexin A2 Human genes 0.000 description 2
- 108090000668 Annexin A2 Proteins 0.000 description 2
- BPYKTIZUTYGOLE-IFADSCNNSA-N Bilirubin Chemical compound N1C(=O)C(C)=C(C=C)\C1=C\C1=C(C)C(CCC(O)=O)=C(CC2=C(C(C)=C(\C=C/3C(=C(C=C)C(=O)N\3)C)N2)CCC(O)=O)N1 BPYKTIZUTYGOLE-IFADSCNNSA-N 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 description 2
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 102100036301 C-C chemokine receptor type 7 Human genes 0.000 description 2
- 102100023703 C-C motif chemokine 15 Human genes 0.000 description 2
- 102100021933 C-C motif chemokine 25 Human genes 0.000 description 2
- 101710112540 C-C motif chemokine 25 Proteins 0.000 description 2
- 102100034871 C-C motif chemokine 8 Human genes 0.000 description 2
- 102100036150 C-X-C motif chemokine 5 Human genes 0.000 description 2
- 102100036153 C-X-C motif chemokine 6 Human genes 0.000 description 2
- 102100036170 C-X-C motif chemokine 9 Human genes 0.000 description 2
- 101100315624 Caenorhabditis elegans tyr-1 gene Proteins 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108010014423 Chemokine CXCL6 Proteins 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 241000283074 Equus asinus Species 0.000 description 2
- 102100028417 Fibroblast growth factor 12 Human genes 0.000 description 2
- 108050003239 Fibroblast growth factor 12 Proteins 0.000 description 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 2
- 108090000381 Fibroblast growth factor 4 Proteins 0.000 description 2
- 102100037665 Fibroblast growth factor 9 Human genes 0.000 description 2
- 108090000367 Fibroblast growth factor 9 Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108700007698 Genetic Terminator Regions Proteins 0.000 description 2
- 102100029880 Glycodelin Human genes 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 2
- 101000716065 Homo sapiens C-C chemokine receptor type 7 Proteins 0.000 description 2
- 101000978381 Homo sapiens C-C motif chemokine 14 Proteins 0.000 description 2
- 101000978376 Homo sapiens C-C motif chemokine 15 Proteins 0.000 description 2
- 101000889128 Homo sapiens C-X-C motif chemokine 2 Proteins 0.000 description 2
- 101000947186 Homo sapiens C-X-C motif chemokine 5 Proteins 0.000 description 2
- 101000947172 Homo sapiens C-X-C motif chemokine 9 Proteins 0.000 description 2
- 101000585553 Homo sapiens Glycodelin Proteins 0.000 description 2
- 101001033249 Homo sapiens Interleukin-1 beta Proteins 0.000 description 2
- 101001076430 Homo sapiens Interleukin-13 Proteins 0.000 description 2
- 101001055157 Homo sapiens Interleukin-15 Proteins 0.000 description 2
- 101000960969 Homo sapiens Interleukin-5 Proteins 0.000 description 2
- 101000611183 Homo sapiens Tumor necrosis factor Proteins 0.000 description 2
- 235000003332 Ilex aquifolium Nutrition 0.000 description 2
- 241000209027 Ilex aquifolium Species 0.000 description 2
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical class OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- STECJAGHUSJQJN-USLFZFAMSA-N LSM-4015 Chemical compound C1([C@@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-USLFZFAMSA-N 0.000 description 2
- 101100346932 Mus musculus Muc1 gene Proteins 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 102000002508 Peptide Elongation Factors Human genes 0.000 description 2
- 108010068204 Peptide Elongation Factors Proteins 0.000 description 2
- 102000012288 Phosphopyruvate Hydratase Human genes 0.000 description 2
- 108010022181 Phosphopyruvate Hydratase Proteins 0.000 description 2
- 101710195957 Platelet basic protein Proteins 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- 108010039445 Stem Cell Factor Proteins 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- 108010065729 Troponin I Proteins 0.000 description 2
- 102000013394 Troponin I Human genes 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 239000005547 deoxyribonucleotide Substances 0.000 description 2
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- 229940014425 exodus Drugs 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Chemical class 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 102000056003 human IL15 Human genes 0.000 description 2
- 102000057041 human TNF Human genes 0.000 description 2
- 102000019207 human interleukin-13 Human genes 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 102000010681 interleukin-8 receptors Human genes 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- AEUKDPKXTPNBNY-XEYRWQBLSA-N mcp 2 Chemical compound C([C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CS)NC(=O)[C@H](C)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)C1=CC=CC=C1 AEUKDPKXTPNBNY-XEYRWQBLSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940092253 ovalbumin Drugs 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000008707 rearrangement Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 102220285717 rs1555461680 Human genes 0.000 description 2
- 102220052102 rs35524245 Human genes 0.000 description 2
- 102220026086 rs397518426 Human genes 0.000 description 2
- 102220087235 rs864622622 Human genes 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 239000013589 supplement Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 150000004579 taxol derivatives Chemical class 0.000 description 2
- 150000003573 thiols Chemical class 0.000 description 2
- 210000001541 thymus gland Anatomy 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 125000001493 tyrosinyl group Chemical class [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- DDYAPMZTJAYBOF-ZMYDTDHYSA-N (3S)-4-[[(2S)-1-[[(2S)-1-[[(2S)-5-amino-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S,3R)-1-[[(2S)-6-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-1-[[(2S)-4-amino-1-[[(2S)-4-amino-1-[[(2S,3S)-1-[[(1S)-1-carboxyethyl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-5-carbamimidamido-1-oxopentan-2-yl]amino]-1-oxohexan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-1,4-dioxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1,5-dioxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-hydroxypropanoyl]amino]hexanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]amino]-5-oxopentanoyl]amino]-4-oxobutanoic acid Chemical class [H]N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC1=CNC2=C1C=CC=C2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O DDYAPMZTJAYBOF-ZMYDTDHYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- BGFTWECWAICPDG-UHFFFAOYSA-N 2-[bis(4-chlorophenyl)methyl]-4-n-[3-[bis(4-chlorophenyl)methyl]-4-(dimethylamino)phenyl]-1-n,1-n-dimethylbenzene-1,4-diamine Chemical compound C1=C(C(C=2C=CC(Cl)=CC=2)C=2C=CC(Cl)=CC=2)C(N(C)C)=CC=C1NC(C=1)=CC=C(N(C)C)C=1C(C=1C=CC(Cl)=CC=1)C1=CC=C(Cl)C=C1 BGFTWECWAICPDG-UHFFFAOYSA-N 0.000 description 1
- 102220466243 Acyl-coenzyme A thioesterase MBLAC2_R170A_mutation Human genes 0.000 description 1
- 101150021974 Adh1 gene Proteins 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 241000589155 Agrobacterium tumefaciens Species 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101710163968 Antistasin Proteins 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 101500021165 Aplysia californica Myomodulin-A Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102100031491 Arylsulfatase B Human genes 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000972773 Aulopiformes Species 0.000 description 1
- 108090001008 Avidin Proteins 0.000 description 1
- 108010008014 B-Cell Maturation Antigen Proteins 0.000 description 1
- 102000006942 B-Cell Maturation Antigen Human genes 0.000 description 1
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 102100029516 Basic salivary proline-rich protein 1 Human genes 0.000 description 1
- 108091071247 Beta family Proteins 0.000 description 1
- 102100021277 Beta-secretase 2 Human genes 0.000 description 1
- 101710150190 Beta-secretase 2 Proteins 0.000 description 1
- 101800003265 Beta-thromboglobulin Proteins 0.000 description 1
- 108010049976 Bone Morphogenetic Protein 5 Proteins 0.000 description 1
- 108010049974 Bone Morphogenetic Protein 6 Proteins 0.000 description 1
- 102100028726 Bone morphogenetic protein 10 Human genes 0.000 description 1
- 101710118482 Bone morphogenetic protein 10 Proteins 0.000 description 1
- 102000003928 Bone morphogenetic protein 15 Human genes 0.000 description 1
- 108090000349 Bone morphogenetic protein 15 Proteins 0.000 description 1
- 102100022526 Bone morphogenetic protein 5 Human genes 0.000 description 1
- 102100022525 Bone morphogenetic protein 6 Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 102100031151 C-C chemokine receptor type 2 Human genes 0.000 description 1
- 101710149815 C-C chemokine receptor type 2 Proteins 0.000 description 1
- 102100035875 C-C chemokine receptor type 5 Human genes 0.000 description 1
- 101710149870 C-C chemokine receptor type 5 Proteins 0.000 description 1
- 102100036848 C-C motif chemokine 20 Human genes 0.000 description 1
- 101710112541 C-C motif chemokine 20 Proteins 0.000 description 1
- 102100031102 C-C motif chemokine 4 Human genes 0.000 description 1
- 101710155833 C-C motif chemokine 8 Proteins 0.000 description 1
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 1
- 101710098275 C-X-C motif chemokine 10 Proteins 0.000 description 1
- 102100025248 C-X-C motif chemokine 10 Human genes 0.000 description 1
- 102100039398 C-X-C motif chemokine 2 Human genes 0.000 description 1
- 102100024217 CAMPATH-1 antigen Human genes 0.000 description 1
- 108010046080 CD27 Ligand Proteins 0.000 description 1
- 102100027207 CD27 antigen Human genes 0.000 description 1
- 108010017987 CD30 Ligand Proteins 0.000 description 1
- 108010029697 CD40 Ligand Proteins 0.000 description 1
- 101150013553 CD40 gene Proteins 0.000 description 1
- 102100032937 CD40 ligand Human genes 0.000 description 1
- 108010065524 CD52 Antigen Proteins 0.000 description 1
- 102100025221 CD70 antigen Human genes 0.000 description 1
- 108010055172 CXC chemokine Mig Proteins 0.000 description 1
- 102000010919 CXC chemokine receptor 3 Human genes 0.000 description 1
- 108010061300 CXCR3 Receptors Proteins 0.000 description 1
- 101150004010 CXCR3 gene Proteins 0.000 description 1
- 101100054773 Caenorhabditis elegans act-2 gene Proteins 0.000 description 1
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 1
- 101100440271 Caenorhabditis elegans ccf-1 gene Proteins 0.000 description 1
- 101100327917 Caenorhabditis elegans chup-1 gene Proteins 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 108010082161 Chemokine CCL19 Proteins 0.000 description 1
- 102000003805 Chemokine CCL19 Human genes 0.000 description 1
- 108010078239 Chemokine CX3CL1 Proteins 0.000 description 1
- 102000006579 Chemokine CXCL10 Human genes 0.000 description 1
- 108010008978 Chemokine CXCL10 Proteins 0.000 description 1
- 108020004638 Circular DNA Proteins 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 102100023804 Coagulation factor VII Human genes 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102100031506 Complement C5 Human genes 0.000 description 1
- 108010028773 Complement C5 Proteins 0.000 description 1
- 102400000498 Connective tissue-activating peptide III Human genes 0.000 description 1
- 102000018832 Cytochromes Human genes 0.000 description 1
- 108010052832 Cytochromes Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 101100120663 Drosophila melanogaster fs(1)h gene Proteins 0.000 description 1
- 102000001301 EGF receptor Human genes 0.000 description 1
- 108060006698 EGF receptor Proteins 0.000 description 1
- 101150015836 ENO1 gene Proteins 0.000 description 1
- 102100040897 Embryonic growth/differentiation factor 1 Human genes 0.000 description 1
- 102400001047 Endostatin Human genes 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101000693911 Equus caballus Albumin Proteins 0.000 description 1
- 101150021185 FGF gene Proteins 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 108010023321 Factor VII Proteins 0.000 description 1
- 102000001690 Factor VIII Human genes 0.000 description 1
- 108010054218 Factor VIII Proteins 0.000 description 1
- 108010014173 Factor X Proteins 0.000 description 1
- 108010071289 Factor XIII Proteins 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 102100035290 Fibroblast growth factor 13 Human genes 0.000 description 1
- 108050002072 Fibroblast growth factor 16 Proteins 0.000 description 1
- 102100035307 Fibroblast growth factor 16 Human genes 0.000 description 1
- 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000378 Fibroblast growth factor 3 Proteins 0.000 description 1
- 102100028043 Fibroblast growth factor 3 Human genes 0.000 description 1
- 108090000380 Fibroblast growth factor 5 Proteins 0.000 description 1
- 102100028073 Fibroblast growth factor 5 Human genes 0.000 description 1
- 108090000382 Fibroblast growth factor 6 Proteins 0.000 description 1
- 102100028075 Fibroblast growth factor 6 Human genes 0.000 description 1
- 108090000368 Fibroblast growth factor 8 Proteins 0.000 description 1
- 102100037680 Fibroblast growth factor 8 Human genes 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 102000012673 Follicle Stimulating Hormone Human genes 0.000 description 1
- 108010079345 Follicle Stimulating Hormone Proteins 0.000 description 1
- 102100040977 Follitropin subunit beta Human genes 0.000 description 1
- 101710203050 Follitropin subunit beta Proteins 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 101150094690 GAL1 gene Proteins 0.000 description 1
- 108010093031 Galactosidases Proteins 0.000 description 1
- 102000002464 Galactosidases Human genes 0.000 description 1
- 102100028501 Galanin peptides Human genes 0.000 description 1
- 108010001515 Galectin 4 Proteins 0.000 description 1
- 102000000805 Galectin 4 Human genes 0.000 description 1
- 101000834253 Gallus gallus Actin, cytoplasmic 1 Proteins 0.000 description 1
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 1
- 108700004714 Gelonium multiflorum GEL Proteins 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 108010088406 Glucagon-Like Peptides Proteins 0.000 description 1
- 108010015776 Glucose oxidase Proteins 0.000 description 1
- 239000004366 Glucose oxidase Substances 0.000 description 1
- 108010056771 Glucosidases Proteins 0.000 description 1
- 102000004366 Glucosidases Human genes 0.000 description 1
- 108010017544 Glucosylceramidase Proteins 0.000 description 1
- 102220575517 Glutamate receptor ionotropic, NMDA 2A_Q56A_mutation Human genes 0.000 description 1
- 102100040796 Glycoprotein hormones alpha chain Human genes 0.000 description 1
- 102000006771 Gonadotropins Human genes 0.000 description 1
- 108010086677 Gonadotropins Proteins 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 108010090296 Growth Differentiation Factor 1 Proteins 0.000 description 1
- 108010090290 Growth Differentiation Factor 2 Proteins 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 102000018997 Growth Hormone Human genes 0.000 description 1
- 102100040892 Growth/differentiation factor 2 Human genes 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 108010007267 Hirudins Proteins 0.000 description 1
- 102000007625 Hirudins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 description 1
- 101001125486 Homo sapiens Basic salivary proline-rich protein 1 Proteins 0.000 description 1
- 101000713104 Homo sapiens C-C motif chemokine 1 Proteins 0.000 description 1
- 101000713099 Homo sapiens C-C motif chemokine 20 Proteins 0.000 description 1
- 101000713085 Homo sapiens C-C motif chemokine 21 Proteins 0.000 description 1
- 101000713083 Homo sapiens C-C motif chemokine 22 Proteins 0.000 description 1
- 101000797758 Homo sapiens C-C motif chemokine 7 Proteins 0.000 description 1
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 1
- 101000858088 Homo sapiens C-X-C motif chemokine 10 Proteins 0.000 description 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 1
- 101000837994 Homo sapiens Dynactin-associated protein Proteins 0.000 description 1
- 101001060274 Homo sapiens Fibroblast growth factor 4 Proteins 0.000 description 1
- 101100121078 Homo sapiens GAL gene Proteins 0.000 description 1
- 101001038874 Homo sapiens Glycoprotein hormones alpha chain Proteins 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101001069921 Homo sapiens Growth-regulated alpha protein Proteins 0.000 description 1
- 101000913079 Homo sapiens IgG receptor FcRn large subunit p51 Proteins 0.000 description 1
- 101000960952 Homo sapiens Interleukin-1 receptor accessory protein Proteins 0.000 description 1
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 1
- 101001040964 Homo sapiens Interleukin-36 receptor antagonist protein Proteins 0.000 description 1
- 101001033312 Homo sapiens Interleukin-4 receptor subunit alpha Proteins 0.000 description 1
- 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 description 1
- 101001043807 Homo sapiens Interleukin-7 Proteins 0.000 description 1
- 101000764535 Homo sapiens Lymphotoxin-alpha Proteins 0.000 description 1
- 101000934338 Homo sapiens Myeloid cell surface antigen CD33 Proteins 0.000 description 1
- 101000609255 Homo sapiens Plasminogen activator inhibitor 1 Proteins 0.000 description 1
- 101000742143 Homo sapiens Prenylated Rab acceptor protein 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000980827 Homo sapiens T-cell surface glycoprotein CD1a Proteins 0.000 description 1
- 101000716149 Homo sapiens T-cell surface glycoprotein CD1b Proteins 0.000 description 1
- 101000716124 Homo sapiens T-cell surface glycoprotein CD1c Proteins 0.000 description 1
- 101000597785 Homo sapiens Tumor necrosis factor receptor superfamily member 6B Proteins 0.000 description 1
- 101000851376 Homo sapiens Tumor necrosis factor receptor superfamily member 8 Proteins 0.000 description 1
- 101000920026 Homo sapiens Tumor necrosis factor receptor superfamily member EDAR Proteins 0.000 description 1
- 101000759555 Homo sapiens Zinc finger and BTB domain-containing protein 7C Proteins 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 108010016183 Human immunodeficiency virus 1 p16 protease Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- OUBORTRIKPEZMG-UHFFFAOYSA-N INT-2 Chemical compound Nc1c(ncn1-c1ccc(F)cc1)C(=N)C#N OUBORTRIKPEZMG-UHFFFAOYSA-N 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 108010003381 Iduronidase Proteins 0.000 description 1
- 102000004627 Iduronidase Human genes 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 102220468791 Inositol 1,4,5-trisphosphate receptor type 2_Y167A_mutation Human genes 0.000 description 1
- 108010089308 Insulin Detemir Proteins 0.000 description 1
- 102100020881 Interleukin-1 alpha Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 102000004551 Interleukin-10 Receptors Human genes 0.000 description 1
- 108010017550 Interleukin-10 Receptors Proteins 0.000 description 1
- 102100030694 Interleukin-11 Human genes 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 102000004560 Interleukin-12 Receptors Human genes 0.000 description 1
- 108010017515 Interleukin-12 Receptors Proteins 0.000 description 1
- 102000014154 Interleukin-12 Subunit p35 Human genes 0.000 description 1
- 108010011301 Interleukin-12 Subunit p35 Proteins 0.000 description 1
- 102000013691 Interleukin-17 Human genes 0.000 description 1
- 108050003558 Interleukin-17 Proteins 0.000 description 1
- 102000004554 Interleukin-17 Receptors Human genes 0.000 description 1
- 108010017525 Interleukin-17 Receptors Proteins 0.000 description 1
- 102000003810 Interleukin-18 Human genes 0.000 description 1
- 108090000171 Interleukin-18 Proteins 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000010790 Interleukin-3 Receptors Human genes 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 241000235649 Kluyveromyces Species 0.000 description 1
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 description 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 description 1
- 102100026238 Lymphotoxin-alpha Human genes 0.000 description 1
- 108090000362 Lymphotoxin-beta Proteins 0.000 description 1
- 102100033342 Lysosomal acid glucosylceramidase Human genes 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101000928454 Macaca mulatta Albumin Proteins 0.000 description 1
- 108700018351 Major Histocompatibility Complex Proteins 0.000 description 1
- 101710091437 Major capsid protein 2 Proteins 0.000 description 1
- 108010037274 Member 9 Tumor Necrosis Factor Receptor Superfamily Proteins 0.000 description 1
- 102000011769 Member 9 Tumor Necrosis Factor Receptor Superfamily Human genes 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101000878182 Mus musculus Fibroblast growth factor 15 Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108010027520 N-Acetylgalactosamine-4-Sulfatase Proteins 0.000 description 1
- 230000004988 N-glycosylation Effects 0.000 description 1
- 108091007491 NSP3 Papain-like protease domains Proteins 0.000 description 1
- 244000061176 Nicotiana tabacum Species 0.000 description 1
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 101000930455 Ovis aries Albumin Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102220466388 PRA1 family protein 2_H166A_mutation Human genes 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 102100038619 Prenylated Rab acceptor protein 1 Human genes 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 101710180012 Protease 7 Proteins 0.000 description 1
- 102100039063 Protein IL-40 Human genes 0.000 description 1
- 101710200420 Protein IL-40 Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 108020004518 RNA Probes Proteins 0.000 description 1
- 239000003391 RNA probe Substances 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101000930457 Rattus norvegicus Albumin Proteins 0.000 description 1
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 101100010928 Saccharolobus solfataricus (strain ATCC 35092 / DSM 1617 / JCM 11322 / P2) tuf gene Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101900354623 Saccharomyces cerevisiae Galactokinase Proteins 0.000 description 1
- 101900084120 Saccharomyces cerevisiae Triosephosphate isomerase Proteins 0.000 description 1
- 101000832889 Scheffersomyces stipitis (strain ATCC 58785 / CBS 6054 / NBRC 10063 / NRRL Y-11545) Alcohol dehydrogenase 2 Proteins 0.000 description 1
- 102000013008 Semaphorin-3A Human genes 0.000 description 1
- 108010090319 Semaphorin-3A Proteins 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108020004459 Small interfering RNA Proteins 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 102100021669 Stromal cell-derived factor 1 Human genes 0.000 description 1
- 101710088580 Stromal cell-derived factor 1 Proteins 0.000 description 1
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 description 1
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 description 1
- 102100024219 T-cell surface glycoprotein CD1a Human genes 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101150001810 TEAD1 gene Proteins 0.000 description 1
- 101150074253 TEF1 gene Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102100029898 Transcriptional enhancer factor TEF-1 Human genes 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 102000005924 Triose-Phosphate Isomerase Human genes 0.000 description 1
- 108700015934 Triose-phosphate isomerases Proteins 0.000 description 1
- 102000013534 Troponin C Human genes 0.000 description 1
- 102000004987 Troponin T Human genes 0.000 description 1
- 108090001108 Troponin T Proteins 0.000 description 1
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 1
- 102100032100 Tumor necrosis factor ligand superfamily member 8 Human genes 0.000 description 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 description 1
- 102100035284 Tumor necrosis factor receptor superfamily member 6B Human genes 0.000 description 1
- 102100036857 Tumor necrosis factor receptor superfamily member 8 Human genes 0.000 description 1
- 102100030810 Tumor necrosis factor receptor superfamily member EDAR Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IXKSXJFAGXLQOQ-XISFHERQSA-N WHWLQLKPGQPMY Chemical compound C([C@@H](C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@@H](N)CC=1C2=CC=CC=C2NC=1)C1=CNC=N1 IXKSXJFAGXLQOQ-XISFHERQSA-N 0.000 description 1
- 101001060278 Xenopus laevis Fibroblast growth factor 3 Proteins 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 102100023250 Zinc finger and BTB domain-containing protein 7C Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 150000001483 arginine derivatives Chemical class 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 1
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 108010051210 beta-Fructofuranosidase Proteins 0.000 description 1
- 230000001588 bifunctional effect Effects 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229940019700 blood coagulation factors Drugs 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 102220371053 c.160G>C Human genes 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 229960004015 calcitonin Drugs 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 238000009566 cancer vaccine Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 230000021235 carbamoylation Effects 0.000 description 1
- 238000012219 cassette mutagenesis Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 229960005004 cholera vaccine Drugs 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000001142 circular dichroism spectrum Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 108010035886 connective tissue-activating peptide Proteins 0.000 description 1
- 108060002021 cyanovirin N Proteins 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000013024 dilution buffer Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000222 eosinocyte Anatomy 0.000 description 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 1
- 229960005420 etoposide Drugs 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 229940012413 factor vii Drugs 0.000 description 1
- 229960000301 factor viii Drugs 0.000 description 1
- 229940012426 factor x Drugs 0.000 description 1
- 229940012444 factor xiii Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 108090000370 fibroblast growth factor 18 Proteins 0.000 description 1
- 102000003977 fibroblast growth factor 18 Human genes 0.000 description 1
- 108700014844 flt3 ligand Proteins 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940116332 glucose oxidase Drugs 0.000 description 1
- 235000019420 glucose oxidase Nutrition 0.000 description 1
- 125000000291 glutamic acid group Chemical group N[C@@H](CCC(O)=O)C(=O)* 0.000 description 1
- 239000002622 gonadotropin Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 229940025294 hemin Drugs 0.000 description 1
- BTIJJDXEELBZFS-QDUVMHSLSA-K hemin Chemical compound CC1=C(CCC(O)=O)C(C=C2C(CCC(O)=O)=C(C)\C(N2[Fe](Cl)N23)=C\4)=N\C1=C/C2=C(C)C(C=C)=C3\C=C/1C(C)=C(C=C)C/4=N\1 BTIJJDXEELBZFS-QDUVMHSLSA-K 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940006607 hirudin Drugs 0.000 description 1
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 102000043282 human CCL1 Human genes 0.000 description 1
- 102000043711 human CCL21 Human genes 0.000 description 1
- 102000043802 human CCL22 Human genes 0.000 description 1
- 102000046157 human CSF2 Human genes 0.000 description 1
- 102000055297 human CXCL1 Human genes 0.000 description 1
- 102000046438 human CXCL10 Human genes 0.000 description 1
- 102000046353 human CXCL2 Human genes 0.000 description 1
- 102000052624 human CXCL8 Human genes 0.000 description 1
- 102000046828 human IL1RAP Human genes 0.000 description 1
- 102000046824 human IL1RN Human genes 0.000 description 1
- 102000054663 human IL4R Human genes 0.000 description 1
- 102000055228 human IL5 Human genes 0.000 description 1
- 102000052611 human IL6 Human genes 0.000 description 1
- 102000052622 human IL7 Human genes 0.000 description 1
- 102000043283 human SERPINE1 Human genes 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 230000002637 immunotoxin Effects 0.000 description 1
- 239000002596 immunotoxin Substances 0.000 description 1
- 231100000608 immunotoxin Toxicity 0.000 description 1
- 229940051026 immunotoxin Drugs 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 229940028885 interleukin-4 Drugs 0.000 description 1
- 229940100601 interleukin-6 Drugs 0.000 description 1
- 229940096397 interleukin-8 Drugs 0.000 description 1
- XKTZWUACRZHVAN-VADRZIEHSA-N interleukin-8 Chemical compound C([C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@@H](NC(C)=O)CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCSC)C(=O)N1[C@H](CCC1)C(=O)N1[C@H](CCC1)C(=O)N[C@@H](C)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CCC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC(O)=CC=1)C(=O)N[C@H](CO)C(=O)N1[C@H](CCC1)C(N)=O)C1=CC=CC=C1 XKTZWUACRZHVAN-VADRZIEHSA-N 0.000 description 1
- 230000010039 intracellular degradation Effects 0.000 description 1
- 239000001573 invertase Substances 0.000 description 1
- 235000011073 invertase Nutrition 0.000 description 1
- 229940102988 levemir Drugs 0.000 description 1
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000000921 morphogenic effect Effects 0.000 description 1
- 231100000219 mutagenic Toxicity 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 229940105132 myristate Drugs 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 108010058731 nopaline synthase Proteins 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 101800000857 p40 protein Proteins 0.000 description 1
- 229960002566 papillomavirus vaccine Drugs 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 230000001124 posttranscriptional effect Effects 0.000 description 1
- 239000013615 primer Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 102220244677 rs1555802245 Human genes 0.000 description 1
- 239000012146 running buffer Substances 0.000 description 1
- 235000019515 salmon Nutrition 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007614 solvation Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N tetradecanoic acid Chemical compound CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003587 threonine derivatives Chemical class 0.000 description 1
- 229940034208 thyroxine Drugs 0.000 description 1
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 239000002753 trypsin inhibitor Substances 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000002477 vacuolizing effect Effects 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the invention relates to variants of albumin or fragments thereof or fusion polypeptides comprising variant albumin or fragments thereof having a change in binding affinity to FcRn and/or a change in half-life compared to the albumin, fragment thereof or fusion polypeptide comprising albumin or a fragment thereof.
- the invention allows tailoring of binding affinity and/or half-life of an albumin to the requirements and desires of a user or application.
- Albumin is a protein naturally found in the blood plasma of mammals where it is the most abundant protein. It has important roles in maintaining the desired osmotic pressure of the blood and also in transport of various substances in the blood stream. Albumins have been characterized from many species including human, pig, mouse, rat, rabbit and goat and they share a high degree of sequence and structural homology.
- FcRn neonatal Fc receptor
- BrambeN neonatal Fc receptor
- FcRn is a membrane bound protein, expressed in many cell and tissue types. FcRn has been found to salvage albumin from intracellular degradation (Roopenian D. C. and Akilesh, S. (2007), Nat. Rev. Immunol 7, 715-725.). FcRn is a bifunctional molecule that contributes to maintaining a high level of IgGs and albumin in serum in mammals such as human beings.
- HSA Human serum albumin
- the plasma half-life of HSA has been found to be approximately 19 days.
- a natural variant having lower plasma half-life has been identified (Peach, R. J. and Brennan, S. 0., (1991 ) Biochim Biophys Acta.1097:49-54) having the substitution D494N.
- This substitution generated an N- glycosylation site in this variant, which is not present in the wild-type albumin. It is not known whether the glycosylation or the amino acid change is responsible for the change in plasma half- life.
- Albumin has a long plasma half-life and because of this property it has been suggested for use in drug delivery.
- Albumin has been conjugated to pharmaceutically beneficial compounds (WO 2000/69902A), and it was found that the conjugate maintained the long plasma half-life of albumin.
- the resulting plasma half-life of the conjugate was generally considerably longer than the plasma half-life of the beneficial therapeutic compound alone.
- albumin has been genetically fused to therapeutically beneficial peptides (WO 2001/79271 A and WO 2003/59934 A) with the typical result that the fusion has the activity of the therapeutically beneficial peptide and a considerably longer plasma half-life than the plasma half- life of the therapeutically beneficial peptides alone.
- Galliano et al (1993) Biochim. Biophys. Acta 1225, 27-32 discloses a natural variant E505K.
- Minchiotti et al (1990) discloses a natural variant K536E.
- Minchiotti et al (1987) Biochim. Biophys. Acta 916, 41 1 -418 discloses a natural variant K574N.
- Takahashi et al (1987) Proc. Natl. Acad. Sci. USA 84, 4413-4417 discloses a natural variant D550G. Carlson et al (1992).
- Proc. Nat. Acad. Sci. USA 89, 8225- 8229 discloses a natural variant D550A.
- WO2011/051489 discloses a number of point mutations in albumin which modulate the binding of albumin to FcRn
- WO2010/092135 discloses a number of point mutations in albumin which increase the number of thiols available for conjugation in the albumin, the disclosure is silent about the affect of the mutations on the binding of the albumin to FcRn
- WO201 1/103076 discloses albumin variants, each containing a substitution in Domain III of HSA.
- Albumin has the ability to bind a number of ligands and these become associated (associates) with albumin. This property has been utilized to extend the plasma half-life of drugs having the ability to non-covalently bind to albumin. This can also be achieved by binding a pharmaceutical beneficial compound, which has little or no albumin binding properties, to a moiety having albumin binding properties. See review article and reference therein, Kratz (2008) Journal of Controlled Release 132, 171-183.
- Albumin is used in preparations of pharmaceutically beneficial compounds, in which such a preparation maybe for example, but not limited to, a nanoparticle or microparticle of albumin.
- delivery of a pharmaceutically beneficial compound or mixture of compounds may benefit from alteration in the albumin's affinity to its receptor where the beneficial compound has been shown to associate with albumin for the means of delivery.
- Kenanova e t a I (2010, Protein Engineering, Design & Selection 23(10): 789-798; WO2010/1 18169) discloses a docking model comprising a structural model of domain III of HSA (solved at pH 7 to 8) and a structural model of FcRn (solved at pH 6.4).
- Kenanova et al discloses that positions 464, 505, 510, 531 and 535 in domain III potentially interact with FcRn.
- the histidines at positions 464, 510 and 535 were identified as being of particular interest by Chaudhury et al., (2006) and these were shown to have a significant reduction in affinity and shorter half-life in mouse by Kenanova (2010).
- the studies of Kenanova et al are limited to domain II I of HSA and therefore do not consider HSA in its native intact configuration.
- the identified positions result in a decrease in affinity for the FcRn receptor.
- International patent application WO201 1/051489 discloses a first class of variant albumins having modulated (i.e. increased or decreased) binding affinity to FcRn receptor due to the presence of one or more point mutations in the albumin sequence.
- International patent application WO201 1/124718 discloses a second class of variant albumins having modulated binding affinity to FcRn receptor, the variants comprise domain III of an albumin with one or more other domains of albumin and optionally include one or more point mutations.
- the present invention further variants having modulated binding affinity to the FcRn receptor and, through provision of a range of molecules, allows binding affinity (and therefore) half- life to be tailored according to requirements.
- Such tailoring may range from a large increase in binding affinity to FcRn and/or half-life to a small increase in binding affinity to FcRn and/or half-life, a small decrease in binding affinity to FcRn and/or half-life to a large decrease in binding affinity to FcRn and/or half-life.
- the albumin moiety or moieties may therefore be used to tailor the binding affinity to FcRn and/or half-life of fusion polypeptides, conjugates, associates, nanoparticles and compositions comprising the albumin moiety.
- the invention provides a method of identifying and/or designing variants of albumin which have improved properties compared to a parent albumin.
- WO201 1/051489 discloses a number of point mutations in albumin which modulate the binding of albumin to FcRn. The point mutations were used to prepare a docking model comprising HSA and FcRn. The docking model was used to identify regions of albumin which interact with FcRn during binding and therefore whose mutation will alter binding affinity between albumin and FcRn, relative to the binding affinity between wild-type HSA and FcRn.
- the invention provides variants of an albumin with improved properties compared to its parent or reference.
- the invention provides variants of an albumin having altered binding affinity to FcRn and/or an altered plasma half-life compared to its parent or reference.
- the invention relates to isolated variants of albumin or fragments thereof, or fusion polypeptides comprising variant albumin or fragments thereof, of a parent or reference albumin, comprising an alteration at one or more (several) positions corresponding to positions in an albumin equivalent to positions in SEQ ID NO: 2 selected from: (a) 492 to 538; (b) 505, 531 , 524, 472, 108, 190, 197 and 425; (c) 186 to 201 ; (d) 457 to 472; (e) 414 to 426; (f) 104 to 120; (g) 75 to 91 ; (h) 144 to 150; (i) 30 to 41 , (j) 550 to 585 and (k) 276, 410 and 414 with one or more (several) of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y and/or a stop codon at a
- the invention also comprises introduction of a stop codon at a position from residue 497 to 585, i.e. any of positions 497, 498, 499, 500, 501 , 502, 503, 504, 505, 506, 507, 508, 509, 510, 51 1 , 512, 513, 514, 515, 516, 517, 518, 519, 520, 521 , 522, 523, 524, 525, 526, 527, 528, 529, 530, 531 , 532, 533, 534, 535, 536, 537, 538, 539, 540, 541 , 542, 543, 544, 545, 546, 547, 548, 549, 550, 551 , 552, 553, 554, 555, 556, 557, 558, 559, 560, 561 , 562, 563, 564, 565, 566, 567, 568, 569, 570, 571 , 572
- I ntroduction of a stop codon may be instead of or together with the one or more (several) alterations mentioned herein.
- the invention provides an albumin variant or fragment thereof having altered binding affinity to FcRn compared with a parent or reference albumin, comprising an alteration (such as a substitution, deletion or insertion) at:
- the altered binding affinity of the variant or fragment thereof is relative to the binding affinity of a reference such as a parent albumin or fragment which does not comprise the alteration.
- the positions described in (a) (above) may be in a first Domain (e.g. Domai n I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (b) (above) may be in a second Domain (e.g. Domain I I ) of a polypeptide such as an albumin , e.g. HSA.
- the positions described in (c) (above) may be in a third Domain (e.g. Domain M M) of a polypeptide such as an albumin, e.g. HSA.
- the albumin variant or fragment thereof may further comprise an alteration (such as a substitution or insertion) at one more (several) positions corresponding to the following positions of SEQ ID No: 2:
- the parent albumin and/or the variant albumin comprises or consists of: (a) a polypeptide having at least 60% sequence identity to the mature polypeptide of SEQ ID NO: 2;
- polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1 , or (ii) the full-length complement of (i);
- the alteration at one or more position may independently be selected among substitutions, insertions and deletions, where substitutions are preferred.
- the invention also relates to isolated polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of producing the variants.
- the invention also relates to conjugates or associates comprising the variant albumin or fragment thereof according to the invention and a beneficial therapeutic moiety or to a fusion polypeptide comprising a variant albumin or fragment thereof of the invention and a fusion partner polypeptide.
- the invention further relates to compositions comprising the variant albumin, fragment thereof, fusion polypeptide comprising variant albumin or fragment thereof or conjugates comprising the variant albumin or fragment thereof, according to the invention or associates comprising the variant albumin or fragment thereof, according to the invention.
- the compositions are preferably pharmaceutical compositions.
- the invention further relates to a pharmaceutical composition
- a pharmaceutical composition comprising a variant albumin, fragment thereof, fusion polypeptide comprising variant albumin or fragment thereof or conjugates comprising the variant albumin or fragment thereof, or associates comprising the variant albumin or fragment thereof, wherein said variant albumin, fragment thereof, fusion polypeptide comprising variant albumin or fragment thereof or conjugates comprising the variant albumin or fragment or associates of variant albumin or fragment thereof has altered binding affinity to FcRn and/or an altered plasma half-life compared to the corresponding binding affinity and/or plasma half-life of the HSA or fragment thereof, fusion polypeptide comprising HSA or fragment thereof or conjugates or associates of HSA or, fragment thereof, comprising HSA or fragment thereof.
- Figure 1 Multiple alignment of amino acid sequences of (i) full length mature HSA (Hu_1_2_3), (ii) an albumin variant comprising domain I and domain I II of HSA (Hu_1_3), (iii) an albumin variant comprising domain I I and domain II I of HSA (Hu_2_3), (iv) full-length Macaca mulatta albumin (Mac_mul), (v) full-length Rattus norvegicus albumin (Rat) and (vi) full-length Mus musculus albumin (Mouse). Positions 500, 550 and 573 (relative to full length HSA) are indicated by arrows. In Figure 4, Domains I, II and III are referred to as 1 , 2 and 3 (respectively).
- Figure 2 Multiple alignment of amino acid sequence of mature albumin from human, sheep, mouse, rabbit and goat and immature albumins from chimpanzee ("Chimp"), macaque, hamster, guinea pig, rat, cow, horse, donkey, dog, chicken, and pig.
- the Start and End amino acids of domains 1 , 2 and 3 are indicated with respect to mature human albumin.
- Figure 3 conserveed groups of amino acids based on their properties.
- FIG. 4 Domain architecture of HSA and shFcRn binding properties of HSA hybrid molecules.
- A Overall structure of shFcRn showing the location of the pH-dependent flexible loop (orange ribbon immediately below 'His 166' label)) and His-166 relative to the IgG binding site (red residues in ball-and-stick (ball and stick residues below ' ⁇ 2' label and to left of 'Glu1 15, Glu1 16' and 'IgG' labels) (23).
- B The crystal structure of full-length HSA consists of three a-helical domains; Dl (pink), DM (orange) and DIM (cyan/blue) (19).
- the DIM is split into sub-domains Dllla (cyan) and Dlllb (blue).
- C Domain organization of constructed hybrid HSA molecules (DI-DII, Dl- D III, DII-DIM, DIM; the domains are shaded in the same scheme as Figures 4A and 4B).
- D SDS- PAGE gel migration of the HSA domain variants.
- E SPR sensorgrams of WT HSA and domain combinations injected over immobilized shFcRn at pH 6.0.
- F ELISA showing pH dependent binding of WT HSA, HSA Dllla and HSA Bartin to shFcRn at pH 7.4 and pH 6.0.
- Figure 5 The structural implications of HSA Casebrook on shFcRn binding.
- FIG. 6 conserved histidines are fundamental for binding to shFcRn.
- A Location of selected residues in DIM of HSA. Residues in the loop connecting the sub-domains Dllla and Dlllb selected for mutagenesis (Asp-494, Glu-495, Lys-500 and Glu-501 ) as well as additional residues close to the connecting loop such as the conserved histidines (His-464, His-510 and His-536) and Lys-536 and Pro-537 are displayed as ball-and-stick (maroon). The non-conserved His-440 is distally localized. The last C-terminal a-helix is highlighted in yellow (labeled 'C-terminal a-helix').
- FIG. 7 His-166 stabilizes a flexible loop in a pH-dependent manner. Close up view of the FcRn HC loop area at different pH conditions.
- A At low pH (4.2), the positively charged His-166 forms charge-stabilized hydrogen bond interactions with Glu-54 and Tyr-60 within the surface exposed loop in shFcRn (23).
- B At high pH (8.2), the uncharged His-166 loosens the interactions with Glu-54 and Tyr-60, and the loop between residues Trp-51 and Tyr-60 becomes flexible and structurally disordered (represented by the dashed line) (8).
- C Binding of shFcRn WT and mutants (E54Q, Q56A and H166A) to titrated amount of HSA coated in ELISA wells at pH 6.0.
- Figure 8 A proposed shFcRn-HSA docking model.
- Possible salt-bridges are formed between Lys-150 and Glu-151 of shFcRn with Glu-501 and Lys-500 of HSA.
- a cleft on the HSA surface is formed between the loop connecting Dllla and Dlllb and the a-helix encompassing residues 520- 535.
- His-161 of shFcRn may interact with Glu-531 of HSA at low pH, and the complex could be further reinforced by the salt bridge between shFcRn Glu-168 and HSA Lys-524.
- C Interaction interface between shFcRn (green surface (space filling diagram at bottom left of figure) and HSA (pink, blue and cyan cartoon (ribbon diagram)) in the docking model.
- a ⁇ -hairpin loop in shFcRn is wedged in-between domains Dl (pink, including labels Lys190, Asp108 and Arg197) and Dllla (cyan, including labels Glu425 and His464) in HSA.
- the shFcRn Asp1 10 could be a partner to either Lys190 or Arg197 of HSA following some structural rearrangements in this interface.
- the conserved His464 is located in the Dllla a-helix contacting the ⁇ -hairpin loop.
- FIG. 9 Representation of shFcRn-HSA docking model.
- A-B Two orientations of the complex are shown. Albumin is shown by a space-filling diagram, FcRn is shown as a ribbon diagram. The core binding interface of HSA is highlighted in pink (in grey-scale this is seen as the darkest (almost black) region; Dl (CBI)), while the area distally localized from the interface is shown as DM (orange) and DIM is split into sub-domains Dllla (cyan) and Dlllb (blue).
- Figure 10 Binding of shFcRn-GST to HSA Casebrook mutations series (100-0.045 ⁇ g/ml) at pH 6.0 and pH 7.4.
- the ELISA values represent the mean of duplicates.
- Figure 11 Binding of Casebrook HSA variant isolated from a heterozygous individual and WT HSA (200-1.625 ⁇ g/ml) to shFcRn-GST at pH6.0.
- Figure 12 CD spectra of WT HSA and Casebrook variants at pH 6.0. 5 ⁇ of each variant was evaluated and the spectra shown represent the average of 5 runs.
- Figure 13 Reducing SDS-PAGE analysis of histidine variants of HSA.
- Lane 1 SeeBlue® Plus2 (6 ⁇ ) and ⁇ [ ⁇ g per lane of each (2) H440Q, (3) H464Q, (4) H510Q and (5) H535Q.
- Figure 14 Binding of truncated WT HSA and HSA variant 568stop (truncated variant that lacks the last 17 amino acids). Binding of C-terminal truncated HSA variant HSA to shFcRn. 10 ⁇ of each was injected over immobilised shFcRn (2000 RU) at pH 6.0.
- Figure 15 Binding of shFcRn-GST to WT HSA and HSA E168A (200-0.045 ⁇ g/ml) at pH 6.0 and pH 7.4.
- the ELISA values represent the mean of duplicates.
- Figure 16 A proposed shFcRn-HSA docking model showing, in two orientations, the simultaneous binding of the two ligands (IgG and HSA) to FcRn.
- Figure 17 Comparison of the fatty acid bound and the free state of HSA showing no substantial rearrangements within sub-domain DIM of HSA upon binding, but a considerable shift in orientation of HSA Dl relative to HSA DIM.
- Myr myristate; 32m: 32-microglobulin
- Figure 18 is an extract of the alpha carbons from the PDB file of HSA (SEQ ID No. 2) from the docking model of HSA and FcRn described in Example 1.
- Figure 19 is an extract of the alpha carbons from the PDB file of FcRn (SEQ I D No. of FcRn) from the docking model of HSA and FcRn described in Example 1.
- Figure 20 Binding of C-terminal truncated HSA variants to shFcRn. 10 ⁇ of each variant was injected over immobilized shFcRn-GST (2000 RU) at pH 6.0.
- Figure 21 Competitive binding of C-terminal truncated HSA variants.
- Competitive binding was measure by injecting shFcRn-GST (100nM) alone or together with serial dilutions of HSA variants over immobilized HSA (-2200 RU) at pH 6.0
- Figure 22 Point mutations in the C-terminal end of HSA modulate binding to shFcRn. 10 ⁇ of HSA WT and HSA (A) HSA Q580A, (B) HSA K574A and (C) HSA K573P/Q580A were injected over immobilized shFcRn-GST (-2000 RU) at pH 6.0.
- FIG. 23 shFcRn binding of WT HSA, HSA K573P and HSA N1 1 1 Q/K573P at pH5.5, samples were injected over immobilized shFcRn-HIS (-1500-2500 RU) at pH 5.5.
- Figure 24 A proposed shFcRn-HSA docking model, showing the spatial relationship between shFcRn (space filling diagram) and HSA (ribbon diagram) Dl, DM and DIM including loops of HSA comprising positions 78-88 and 108-1 12.
- the invention relates to isolated variants of albumin or fragments thereof, or fusion polypeptides comprising variant albumin or fragments thereof, of a parent or reference albumin, comprising an alteration at one or more (several) positions which affect and/or are involved in the interaction between albumin and FcRn, preferably an alteration at one or more (several) positions corresponding to positions 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 , 414 to 426, 457 to 472, 492 to 538, 550 to 585, 276, 410, and/or 41 1 of the mature polypeptide of SEQ ID NO: 2, wherein, it is preferred that, when the variant, fragment or fusion thereof comprises one or more (several) substitutions at positions selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506, 510, 535, 5
- the variant, fragment or fusion thereof also comprises one or more (several) alterations at a position selected from group consisting of 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 104, 105, 106, 107, 108, 109, 1 10, 1 1 1 1 , 1 12, 1 13, 1 14, 1 15, 1 16, 1 17, 1 18, 1 19, 120, 144, 145, 146, 147, 148, 149, 150, 186, 187, 188, 189, 190, 191 , 192, 19
- Preferred alterations include those made at positions equivalent to 534, 505, 1 1 1 , 527, 510 and/or 108 (positions are with reference to SEQ ID No: 2). More preferred are substitutions K534V, E505Q, N1 1 1 D, T527M, H510D and D108A or such substitutions at positions equivalent thereto. Substitutions K534I , K534L, D108E and N 1 1 1 E, or such substitutions at positions equivalent thereto, are also preferred because they are highly conserved substitutions of K534V, D108A and N1 1 1 D.
- positions equivalent to a loop comprising positions 105 to 120 are preferred, more preferred are positions equivalent to positions 106 to 1 15 and even more preferred positions equivalent to 108, 109, 1 10, 1 1 1 and 1 12.
- the skilled person can identify positions equivalent to those of SEQ ID No: 2 as described herein.
- the invention provides an albumin variant or fragment thereof having altered binding affinity to FcRn compared with a parent or reference albumin, comprising an alteration (such as a substitution, deletion or insertion) at:
- the altered binding affinity of the variant or fragment thereof is relative to the binding affinity of a reference such as a parent albumin or fragment which does not comprise the alteration.
- the positions described in (a) (above) may be in a first Domain (e.g. Domai n I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (b) (above) may be in a second Domain (e.g. Domain I I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (c) (above) may be in a third Domain (e.g. Domain M M) of a polypeptide such as an albumin, e.g. HSA.
- the albumin variant or fragment thereof may further comprise an alteration (such as a substitution or insertion) at one more (several) positions corresponding to the following positions of SEQ ID No: 2:
- non-Cys residue to Cys and/or a deletion of or substitution of one or more (several) of positions 91 , 200, 461 , 514, 558, 559, 567 from Cys, to a non-Cys residue), and/or
- parent albumin and/or the variant albumin comprises or consists of:
- polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions with (i) the mature polypeptide coding sequence of SEQ I D NO: 1 , or (ii) the full-length complement of (i);
- the alteration at one or more position may independently be selected among substitutions, insertions and deletions, where substitutions are preferred.
- the invention also comprises introduction of a stop codon at a position from residue 497 to 585 (or equivalent position, relative to SEQ ID NO: 2) or from residue 497 (or equivalent position, relative to SEQ ID NO: 2) to the last residue of the mature sequence of the albumin.
- Introduction of a stop codon may be instead of or together with the one or more (several) alterations mentioned herein.
- the invention allows the binding affinity (and therefore the half-life) of an albumin moiety for the FcRn receptor to be tailored to meet the requirements of a particular user or application. Such tailoring may range from a large increase in half-life to a small increase in half-life, a small decrease in half-life to a large decrease in half-life.
- the albumin moiety or moieties may therefore be used to tailor the half-life of fusion polypeptides, conjugates, associates, nanoparticles and compositions comprising the albumin moiety.
- the invention is particularly applicable to pharmaceuticals. Some pharmaceuticals benefit from a long half-life, e.g. to increase dosage intervals. Some pharmaceuticals benefit from a short plasma half-life, e.g. to accelerate clearance from the body of a patient. Therefore, use of an albumin moiety according to the invention in pharmaceuticals allows the half-life of the pharmaceutical to be tailored as desired.
- variant means a polypeptide derived from a parent albumin by one or more (several) alteration(s), i.e., a substitution, insertion, and/or deletion, at one or more (several) positions.
- a substitution means a replacement of an amino acid occupying a position with a different amino acid;
- a deletion means removal of an amino acid occupying a position; and
- an insertion means adding 1 or more, such as 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10, preferably 1 -3 amino acids immediately adjacent an amino acid occupying a position.
- 'immediately adjacent' may be to the N-side ('upstream') or C-side ('downstream') of the amino acid occupying a position ('the named amino acid'). Therefore, for an amino acid named/numbered 'X', the insertion may be at position 'X+1 ' ('downstream') or at position 'X-1 ' ('upstream').
- Mutant means a polynucleotide encoding a variant.
- Wild-Type Albumin means albumin having the same amino acid sequence as naturally found in an animal or in a human being.
- FcRn and shFcRn The term "FcRn" means the human neonatal Fc receptor (FcRn).
- shFcRn is a soluble recombinant form of FcRn.
- hFcRn is a heterodimer of SEQ I D NO: 30 (truncated heavy chain of the major histocompatibility complex class l-like Fc receptor (FCGRT)) and SEQ ID NO: 31 (beta-2-microglobulin). Together, SEQ ID NO: 30 and 31 form hFcRn.
- smFcRn is a soluble recombinant form of the mouse neonatal Fc Receptor.
- Isolated variant means a variant that is modified by the hand of man and separated completely or partially from at least one component with which it naturally occurs.
- the variant may be at least 1 % pure, e.g. , at least 5% pure, at least 10% pure, at least 20% pure, at least 40% pure, at least 60% pure, at least 80% pure, and at least 90% pure, as determined by SDS-PAGE or GP-HPLC.
- substantially pure variant means a preparation that contains at most 10%, at most 8%, at most 6%, at most 5%, at most 4%, at most 3%, at most 2%, at most 1 %, and at most 0.5% by weight of other polypeptide material with which it is natively or recombinantly associated.
- the variant is at least 92% pure, e.g., at least 94% pure, at least 95% pure, at least 96% pure, at least 97% pure, at least 98% pure, at least 99%, at least 99.5% pure, and 100% pure by weight of the total polypeptide material present in the preparation.
- the variants of the invention are preferably in a substantially pure form. This can be accomplished, for example, by preparing the variant by well-known recombinant methods and by purification methods.
- Mature polypeptide means a polypeptide in its final form following translation and any post-translational modifications, such as N-terminal processing, C-terminal truncation, glycosylation, phosphorylation, etc.
- the mature polypeptide may be amino acids 1 to 585 of SEQ ID NO: 2, with the inclusion of any post-translational modifications.
- Mature polypeptide coding sequence means a polynucleotide that encodes a mature albumin polypeptide.
- the mature polypeptide coding sequence may be nucleotides 1 to 1758 of SEQ ID NO: 1.
- Sequence Identity The relatedness between two amino acid sequences or between two nucleotide sequences is described by the parameter "sequence identity”.
- the degree of sequence identity between two amino acid sequences is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et a/., 2000, Trends Genet. 16: 276-277), preferably version 3.0.0 or later.
- the optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
- the output of Needle labelled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:
- the d eg ree of seq ue nce identity between two deoxyribonucleotide sequences is determ ined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, supra) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et a/., 2000, supra), preferably version 3.0.0 or later.
- the optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EDNAFULL (EMBOSS version of NCBI NUC4.4) substitution matrix.
- the output of Needle labeled "longest identity" (obtained using the -nobrief option) is used as the percent identity and is calculated as follows:
- fragment means a polypeptide having one or more (several) amino acids deleted from the amino and/or carboxyl terminus of an albumin and/or an internal region of albumin that has retained the ability to bind to FcRn. Fragments may consist of one uninterrupted sequence derived from HSA or it may comprise two or more (several) sequences derived from HSA.
- the fragments according to the invention have a size of more than approximately 20 amino acid residues, preferably more than 30 amino acid residues, more preferred more than 40 amino acid residues, more preferred more than 50 amino acid residues, more preferred more than 75 amino acid residues, more preferred more than 100 amino acid residues, more preferred more than 200 amino acid residues, more preferred more than 300 amino acid residues, even more preferred more than 400 amino acid residues and most preferred more than 500 amino acid residues.
- a fragment may comprise or consist of one more domains of albumin such as Dl + DM, Dl + DIM, DM + DIM, DIM + DIM, Dl + DIM + DIM, DIM + DIM +DIII, or fragments of such domains or combinations of domains.
- HSA domains I, II and III may be defined with reference to HSA (SEQ ID NO: 2).
- HSA domain I may consist of or comprise amino acids 1 to 194 ( ⁇ 1 to 15 amino acids) of SEQ ID NO: 2
- HSA domain II may consist of or comprise amino acids 192 ( ⁇ 1 to 15 amino acids) to 387 ( ⁇ 1 to 15 amino acids) of SEQ I D NO: 2
- domain I I I may consist of or comprise amino acid residues 381 ( ⁇ 1 to 15 amino acids) to 585 ( ⁇ 1 to 15 amino acids) of SEQ ID NO: 2.
- ⁇ 1 to 15 amino acids means that the residue number may deviate by 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, or 15 amino acids to the C-terminus and/or to the N-terminus of the stated amino acid position.
- Examples of domains I , I I and I I I are described by Dockal et al (The Journal of Biological Chemistry, 1999, Vol. 274(41 ): 29303-29310) and Kjeldsen et al (Protein Expression and Purification, 1998, Vol 13: 163-169) and are tabulated below.
- the skilled person can identify domains I, I I and III in non-human albumins by amino acid sequence alignment with HSA, for example using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et al., 2000, Trends Genet. 16: 276-277), preferably version 3.0.0 or later.
- the optional parameters used are gap open penalty of 10, gap extension penalty of 0.5, and the EBLOSUM62 (EMBOSS version of BLOSUM62) substitution matrix.
- Other suitable software includes MUSCLE ((Multiple sequence comparison by log-expectation, Robert C.
- allelic variant means any of two or more alternative forms of a gene occupying the same chromosomal locus. Allelic variation arises naturally through mutation, and may result in polymorphism within populations. Gene mutations can be silent (no change in the encoded polypeptide) or may encode polypeptides having altered amino acid sequences.
- An allelic variant of a polypeptide is a polypeptide encoded by an allelic variant of a gene.
- Coding sequence means a polynucleotide, which directly specifies the amino acid sequence of its translated polypeptide product.
- the boundaries of the coding sequence are generally determined by an open reading frame, which usually begins with the ATG start codon or alternative start codons such as GTG and TTG and ends with a stop codon such as TAA, TAG, and TGA.
- the coding sequence may be a DNA, cDNA, synthetic, or recombinant polynucleotide.
- cDNA means a DNA molecule that can be prepared by reverse transcription from a mature, spliced, mRNA molecule obtained from a eukaryotic cell. cDNA lacks intron sequences that may be present in the corresponding genomic DNA. The initial, primary RNA transcript is a precursor to mRNA that is processed through a series of steps, including splicing, before appearing as mature spliced mRNA.
- Nucleic acid construct means a nucleic acid molecule, either single- or double-stranded, which is isolated from a naturally occurring gene or is modified to contain segments of nucleic acids in a manner that would not otherwise exist in nature or which is synthetic. The term nucleic acid construct is synonymous with the term “expression cassette” when the nucleic acid construct contains the control sequences required for expression of a coding sequence of the invention.
- control sequences means all components necessary for the expression of a polynucleotide encoding a variant of the invention.
- Each control sequence may be native or foreign to the polynucleotide encoding the variant or native or foreign to each other.
- control sequences include, but are not limited to, a leader, polyadenylation sequence, propeptide sequence, promoter, signal peptide sequence, and transcription terminator.
- the control sequences include a promoter, and transcriptional and translational stop signals.
- the control sequences may be provided with linkers for the purpose of introducing specific restriction sites facilitating ligation of the control sequences within the coding region of the polynucleotide encoding a variant.
- operably linked means a configuration in which a control sequence is placed at an appropriate position relative to the coding sequence of a polynucleotide such that the control sequence directs the expression of the coding sequence.
- expression includes any step involved in the production of the variant including, but not limited to, transcription, post-transcriptional modification, translation, post- translational modification, and secretion.
- Expression vector means a linear or circular DNA molecule that comprises a polynucleotide encoding a variant and is operably linked to additional nucleotides that provide for its expression.
- host cell means any cell type that is susceptible to transformation, transfection, transduction, and the like with a nucleic acid construct or expression vector comprising a polynucleotide of the invention.
- host cell encompasses any progeny of a parent cell that is not identical to the parent cell due to mutations that occur during replication.
- Plasma half-life is ideally determined in vivo in suitable individuals. However, since it is time consuming and expensive and there inevitable are ethical concerns connected with doing experiments in animals or man it is desirable to use an in vitro assay for determining whether plasma half-life is extended or reduced. It is known that the binding of albumin to its receptor FcRn is important for plasma half-life and the correlation between receptor binding and plasma half-life is that a higher affinity of albumin to its receptor leads to longer plasma half-life. Thus for the invention a higher affinity of albumin to FcRn is considered indicative of an increased plasma half-life and a lower affinity of albumin to its receptor is considered indicative of a reduced plasma half-life.
- a longer plasma half-life with respect to a variant albumin of the invention means that the variant has longer plasma half-life than the corresponding albumin having the same sequences except for the alteration(s) described herein, e.g.
- the variant, fragment or fusion polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506, 510, 535, 536, 537, 538, 540, 550, 573, 574, 575, 577, 578, 579, 580, 581 , 582 and 584, (ii) the group consisting of positions 34, 38, 40, 75, 76, 80, 82, 83, 86, 90, 91 ,
- a reference is an albu min , fusion , conjugate, com position , associate or nanoparticle to which an albumin variant, fusion, conjugate, composition, associate or nanoparticle is compared.
- the reference may comprise or consist of full length albumin (such as HSA or a natu ral al lele thereof) of a fragm ent thereof.
- a reference m ay also be referred to as a 'corresponding' albumin, fusion, conjugate, composition, associate or nanoparticle to which an albumin variant, fusion, conjugate, composition, associate or nanoparticle.
- a reference may co m prise or co nsist of H SA (S EQ I D N O : 2) o r a fragment, fusion, conjugate, associate, nanoparticle or microparticle thereof.
- the reference is identical to the polypeptide, fusion polypeptide, conjugate, composition , associate, nanoparticle or microparticle according to the invention ("being studied") with the exception of the albumin moiety.
- the albumin moiety of the reference comprises or consists of an albumin (e.g. HSA, S EQ I D NO: 2) or a fragment thereof.
- the amino acid sequence of the albumin moiety of the reference may be longer than, shorter than or, preferably, the same ( ⁇ 1 to 15 amino acids) length as the amino sequence of the albu min moiety of the polypeptide, fusion polypeptide, conjugate, composition , associate, nanoparticle or microparticle according to the invention ("being studied").
- Equivalent amino acid positions are defined in relation to full-length mature human serum albumin (i.e. without leader sequence, SEQ ID NO: 2). However, the skilled person understands that the invention also relates to variants of non-human albumins e.g. those disclosed herein) and/or fragments of a human or non-human albumin. Equivalent positions can be identified in fragments of human serum albumin, in animal albumins and in fragments, fusions and other derivative or variants thereof by comparing amino acid sequences using pairwise (e.g. ClustalW) or multiple (e.g. MUSCLE) alignments. For example, Fig.
- Table 1 Example of identification of equivalent positions in HSA, animal albumins and albumin fragments Organism Albumin Position equivalent to (accession human serum albumin n u m b e r of (native amino acid):
- Fig.1 was generated by MUSCLE using the default parameters including output in ClustalW 1.81 format.
- the raw output data was shaded using BoxShade 3.21 (http://www.ch.embnet.org/software/BOX form.html) using Output Format: RTF_new; Font Size: 10; Consensus Line: no consensus line; Fraction of sequences (that must agree for shading): 0.5; Input sequence format: ALN. Therefore, throughout this specification amino acid positions defined in human serum albumin also apply to equivalent positions in fragments, derivatives or variants and fusions of human serum albumin, animals from other species and fragments and fusions thereof. Such equivalent positions may have (i) a different residue number in its native protein and/or (ii) a different native amino acid in its native protein.
- Fig.2 shows that equivalent positions can be identified in fragments (e.g. domains) of an albumin with reference to SEQ ID NO: 2 (HSA).
- the mature polypeptide disclosed in SEQ ID NO: 2 is used to determine the corresponding amino acid residue in another albumin.
- the amino acid sequence of another albumin is aligned with the mature polypeptide disclosed in SEQ ID NO: 2, and based on the alignment, the amino acid position number corresponding to any amino acid residue in the mature polypeptide disclosed in SEQ ID NO: 2 is determined using the Needleman-Wunsch algorithm (Needleman and Wunsch, 1970, J. Mol. Biol. 48: 443-453) as implemented in the Needle program of the EMBOSS package (EMBOSS: The European Molecular Biology Open Software Suite, Rice et a/., 2000, Trends Genet. 16: 276-277), preferably version 3.0.0 or later.
- EMBOSS European Molecular Biology Open Software Suite, Rice et a/., 2000, Trends Genet. 16: 276-277
- proteins of known structure For proteins of known structure, several tools and resources are available for retrieving and generating structural alignments. For example the SCOP superfamilies of proteins have been structurally aligned, and those alignments are accessible and downloadable.
- Two or more protein structures can be aligned using a variety of algorithms such as the distance alignment matrix (Holm and Sander, 1998, Proteins 33: 88-96) or combinatorial extension (Shindyalov and Bourne, 1998, Protein Engineering 11 : 739-747), and implementations of these algorithms can additionally be utilized to query structure databases with a structure of interest in order to discover possible structural homologs (e.g., Holm and Park, 2000, Bioinformatics 16: 566-567).
- an insertion may be to the N-side ('upstream', 'X-1 ') or C- side ('downstream', 'X+1 ') of the amino acid occupying a position ('the named (or original) amino acid', 'X').
- the inserted amino acid residue(s) are numbered by the addition of lower case letters to the position number of the amino acid residue preceding the inserted amino acid residue(s).
- the sequence would thus be:
- variants comprising multiple alterations are separated by addition marks ("+"), e.g., "Arg 170Tyr+Gly195Glu” or “R170Y+G195E” representing a substitution of tyrosine and glutamic acid for arginine and glycine at positions 170 and 195, respectively.
- Albumins are proteins and constitute the most abundant protein in plasma in mammals and albumins from a long number of mammals have been characterized by biochemical methods and/or by sequence information.
- Several albumins e.g., human serum albumin (HSA) have also been characterized crystallographically and the structure determined (HSA: He XM, Carter DC (July 1992). "Atomic structure and chemistry of human serum albumin”. Nature 358 (6383): 209-15; horse albumin: Ho, J.X. et al. (2001 ). X-ray and primary structure of horse serum albumin (Equus caballus) at 0.27-nm resolution. Eur J Biochem. 215(1 ):205-12).
- parent or parent albumin means an albumin to which an alteration is made by the hand of man to produce the albumin variants of the invention.
- the parent may be a naturally occurring (wild-type) polypeptide or an allele thereof, or even a variant thereof.
- albumin means a protein having the same and/or very similar three dimensional structure as HSA or HSA domains and has similar properties. Similar three dimensional structures are for example the structures of the albumins from the species mentioned under parent albumin. Some of the major properties of albumin is its ability to regulate of plasma volume since it contributes to 85% of the osmotic effect of normal plasma, a long plasma half-life of around 19 days ⁇ 5 days, l igand-binding, e.g. binding of endogenous molecules such as acidic, lipophilic compounds including bilirubin, fatty acids, hemin and thyroxine (see also Table 1 of Kragh-Hansen et al, 2002, Biol. Pharm. Bull.
- HSA is a preferred albumin according to the invention and is a protein consisting of 585 amino acid residues and has a molecular weight of 67 kDa. In its natural form it is not glycosylated.
- the amino acid sequence of HSA is shown in SEQ ID NO: 2.
- natural alleles may exist having essentially the same properties as HSA but having one or more amino acid changes compared to SEQ I D NO: 2, and the inventors also contemplate the use of such natural alleles as parent albumin according to the invention.
- Albumins have generally a long plasma half-life of approximately 20 days or longer, e.g., HSA has a plasma half-life of 19 days. It is known that the long plasma half-life of HSA is mediated via interaction with its receptor FcRn , however, an understanding or knowledge of the exact mechanism behind the long half-life of HSA is not essential for the invention.
- albumin means a protein having the same, or very similar three dimensional structure as HSA and having a long plasma half-life.
- human serum albumin e.g. AAA98797 or P02768-1 , S EQ I D NO: 2 (mature), S EQ I D NO: 4 (immature)
- primate serum albumin e.g. chimpanzee serum albumin (e.g. predicted sequence XP_517233.2 SEQ I D NO: 5)
- gorilla serum albumin or macaque serum albumin e.g.
- NP_001 182578, SEQ I D NO: 6 rodent serum albumin (such as hamster serum albumin (e.g. A6YF56, SEQ I D NO: 7), guinea pig serum albumin (e.g. Q6WDN9-1 , SEQ I D NO: 8), mouse serum albumin (e.g. AAH49971 or P07724-1 Version 3, SEQ I D NO: 9) and rat serum albumin (e.g. AAH85359 or P02770-1 Version 2, SEQ I D NO: 10))), bovine serum albumin (e.g. cow serum albumin P02769-1 , SEQ I D NO: 1 1 ), equine serum albumin such as horse serum albumin (e.g.
- rodent serum albumin such as hamster serum albumin (e.g. A6YF56, SEQ I D NO: 7), guinea pig serum albumin (e.g. Q6WDN9-1 , SEQ I D NO: 8),
- SEQ I D NO: 12 or donkey serum albumin (e.g. Q5XLE4-1 , SEQ ID NO: 13), rabbit serum albumin (e.g. P49065-1 Version 2, SEQ ID NO: 14), goat serum albumin (e.g. ACF 10391 , S EQ I D NO: 1 5), sheep serum albumin (e.g. P14639-1 , SEQ I D NO: 16), dog serum albumin (e.g. P49822-1 , SEQ I D NO: 17), chicken serum albumin (e.g. P19121 -1 Version 2, SEQ I D NO: 18) and pig serum albumin (e.g.
- P08835-1 Version 2 SEQ ID NO: 19
- a polypeptide having at least 70, 75, 80, 85, 90, 91 , 92, 93, 94, 95, 96, 97, 98 or at least 99% amino acid identity to such an albumin P08835-1 Version 2, SEQ ID NO: 19
- the parent or reference albumin may be an artificial variant such as HSA K573P (SEQ ID NO: 3) or a chimeric albumin such as the N-terminal of HSA and the C-terminal of macaca albumin (SEQ I D NO: 20), N-terminal of HSA and the C- terminal of mouse albumin (S EQ I D NO: 21 ), N-terminal of HSA and the C-terminal of rabbit albumin (SEQ ID NO: 22), N-terminal of HSA and the C-terminal of sheep albumin (SEQ ID NO: 23).
- HSA K573P SEQ ID NO: 3
- a chimeric albumin such as the N-terminal of HSA and the C-terminal of macaca albumin (SEQ I D NO: 20), N-terminal of HSA and the C- terminal of mouse albumin (S EQ I D NO: 21 ), N-terminal of HSA and the C-terminal of rabbit albumin (SEQ ID NO: 22), N-terminal of
- albumin which are also included in the scope of this application, include ovalbumin (e.g. P01012.pro: chicken ovalbumin; 073860. pro: turkey ovalbumin).
- HSA as disclosed in SEQ ID NO: 2 or any naturally occurring allele thereof, is the preferred albumin according to the invention.
- the parent albumin, a fragment thereof, or albumin part of a fusion polypeptide comprising albumin or a fragment thereof according to the invention has generally a sequence identity to the sequence of HSA shown in SEQ ID NO: 2 of at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 86%, preferably at least 87%, preferably at least 88%, preferably at least 89%, preferably at least 90%, preferably at least 91 %, preferably at least 92%, preferably at least 93%, preferably at least 94%, preferably at least 95%, more preferred at least 96%, more preferred at least 97%, more preferred at least 98% and most preferred at least 99%.
- the sequence identity may be over the full-length of SEQ I D NO: 2 or over a molecule consisting or comprising of a fragment such as one or more domains of SEQ ID NO: 2 such as a molecule consisting of or comprising domain III (e.g. SEQ ID NO: 27), a molecule consisting of or comprising domain II and domain III (e.g. SEQ ID NO: 25), a molecule consisting of or comprising domain I and domain III (e.g. SEQ ID NO: 24), a molecule consisting of or comprising two copies of domain III (e.g. SEQ ID NO: 26), a molecule consisting of or comprising three copies of domain III (e.g. SEQ ID NO: 28) or a molecule consisting of or comprising domain I and two copies of domain III (e.g. SEQ ID NO: 29).
- a molecule consisting or comprising of a fragment such as one or more domains of SEQ ID NO: 2 such as a molecule consisting of or comprising domain
- the parent preferably comprises or consists of the amino acid sequence of SEQ ID NO: 4.
- the parent may comprise or consist of the mature polypeptide of SEQ ID NO: 2.
- the parent is an allelic variant of the mature polypeptide of SEQ ID NO: 2.
- the parent albumin many be encoded by a polynucleotide that hybridizes under very low stringency conditions, low stringency conditions, medium stringency conditions, medium-high stringency conditions, high stringency conditions, or very high stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1 , (ii) the mature polypeptide coding sequence of SEQ ID NO: 1 , or (iii) the full-length complementary strand of (i) or (ii) (J. Sambrook, E.F. Fritsch, and T. Maniatis, 1989, Molecular Cloning, A Laboratory Manual, 2d edition, Cold Spring Harbor, New York).
- the polynucleotide of SEQ ID NO: 1 or a subsequence thereof, as well as the amino acid sequence of SEQ ID NO: 2 or a fragment thereof, may be used to design nucleic acid probes to identify and clone DNA encoding a parent from strains of different genera or species according to methods well known in the art.
- probes can be used for hybridization with the genomic or cDNA of the genus or species of interest, following standard Southern blotting procedures, in order to identify and isolate the corresponding gene therein.
- Such probes can be considerably shorter than the entire sequence, but should be at least 14, e.g., at least 25, at least 35, or at least 70 nucleotides in length.
- the nucleic acid probe is at least 100 nucleotides in length, e.g., at least 200 nucleotides, at least 300 nucleotides, at least 400 nucleotides, at least 500 nucleotides, at least 600 nucleotides, at least 700 nucleotides, at least 800 nucleotides, or at least 900 nucleotides in length.
- Both DNA and RNA probes can be used.
- the probes are typically labelled for detecting the corresponding gene (for example, with 32 P, 3 H, 35 S, biotin, or avidin). Such probes are encompassed by the invention.
- a genomic DNA or cDNA library prepared from such other organisms may be screened for DNA that hybridizes with the probes described above and encodes a parent.
- Genomic or other DNA from such other organisms may be separated by agarose or polyacrylamide gel electrophoresis, or other separation techniques.
- DNA from the libraries or the separated DNA may be transferred to and immobilized on nitrocellulose or other suitable carrier material.
- the carrier material is used in a Southern blot.
- hybridization indicates that the polynucleotide hybridizes to a labelled nucleotide probe corresponding to the polynucleotide shown in SEQ I D NO: 1 , its complementary strand, or a subsequence thereof, under low to very high stringency conditions.
- Molecules to which the probe hybridizes can be detected using, for example, X-ray film or any other detection means known in the art.
- the nucleic acid probe may comprise or consist of the mature polypeptide coding sequence of SEQ ID NO: 1 , i.e. nucleotides 1 to 1785 of SEQ ID NO: I .
- the nucleic acid probe may comprise or consist of a polynucleotide that encodes the polypeptide of SEQ ID NO: 2 or a fragment thereof.
- very low to very high stringency conditions are defined as pre-hybridization and hybridization at 42°C in 5X SSPE, 0.3% SDS, 200 micrograms/ml sheared and denatured salmon sperm DNA, and either 25% formamide for very low and low stringencies, 35% formamide for medium and medium-high stringencies, or 50% formamide for high and very high stringencies, following standard Southern blotting procedures for 12 to 24 hours optimally.
- the carrier material is finally washed three times each for 15 minutes using 2X SSC, 0.2% SDS at 45°C (very low stringency), 50°C (low stringency), 55°C (medium stringency), 60°C (medium-high stringency), 65°C (high stringency), or 70°C (very high stringency).
- stringency conditions are defined as pre-hybridization and hybridization at about 5°C to about 10°C below the calculated T m using the calculation according to Bolton and McCarthy (1962, Proc. Natl. Acad. Sci. USA 48: 1390) in 0.9 M NaCI, 0.09 M Tris-HCI pH 7.6, 6 mM EDTA, 0.5% NP ⁇ IO, 1X Denhardt's solution, 1 mM sodium pyrophosphate, 1 mM sodium monobasic phosphate, 0.1 mM ATP, and 0.2 mg of yeast RNA per ml following standard Southern blotting procedures for 12 to 24 hours optimally. The carrier material is finally washed once in 6X SCC plus 0.1 % SDS for 15 minutes and twice each for 15 minutes using 6X SSC at 5°C to 10°C below the calculated T m .
- the parent may be encoded by a polynucleotide with a sequence identity to the mature polypeptide coding sequence of SEQ ID NO: 1 of at least 60%, e.g., at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or 100%, which encodes a polypeptide which is able to function as an albumin.
- the parent is encoded by a polynucleotide comprising or consisting of SEQ ID NO: 1.
- albumin part of a fusion polypeptide, conjugate, associate, nanoparticle or composition comprising the albumin variant or fragment thereof according to the invention may be referred to as an 'albumin moiety' or 'albumin component'.
- a polypeptide according to the invention may comprise or consist of an albumin moiety. Particular aspects of the invention are discussed below:
- a first aspect of the invention relates to a method for preparing a polypeptide which is a variant albumin, fragment thereof, or fusion polypeptide comprising variant albumin or a fragment thereof, preferably having a binding affinity to FcRn (preferably shFcRn) or half-life (e.g. in plasma) which is altered relative to a reference albumin, the method comprising the steps of:
- c Modifying the nucleic acid provided in b., so that the one or more (several) amino acid residue located at the positions identified in a., there is an alteration such as a deletion, substitution or an insertion, most preferably a substitution; d. Expressing the modified nucleic acid in a suitable host cell; and
- the identification of one or more (several) amino acid residue positions being important for the binding of albumin to FcRn or half-life (e.g. in plasma), in albumin, fragment thereof or the albumin part of a fusion polypeptide can be done in several ways including, but not limited to, random mutagenesis followed by analysis of the generated mutants and comparison with the non- mutated parent or reference molecule, and identification based on structural considerations optionally followed by generation of variants having the identified alterations and comparison with the non-mutated patent molecule.
- Reference albumins are disclosed herein, it is particularly preferred that the reference albumin is HSA (SEQ ID No: 2).
- a preferred method for identification of one or more (several) amino acid residue positions to be changed to in order to prepare a variant HSA having an altered binding to FcRn or half-life (e.g. in plasma) compared with natural HSA comprises the following steps:
- Step iii) and iv) can be done using techniques well known to the skilled person.
- the docking model may be prepared using any suitable method or software.
- Suitable software includes fast fourier based software such as ZDOCK Fast Fourier Transform based protein docking program (Chen R et al (2003). Proteins 52(1 ):80-87).
- the model of albumin comprises domain III and at least one of domain I or domain II, preferably all domains.
- the albumin is HSA (e.g. SEQ ID NO: 2).
- the model of albumin is resolved at pH 7 to 8.
- the model of albumin may be, or be based on the crystal structure of HSA at 2.5A (PDB code 1 bm0 (Sugio S et al (1999) Protein Eng 12(6):439-446).
- the FcRn is a human FcRn and most preferably soluble human FcRn.
- the model of FcRn is solved at a pH lower than 6.4, for example at a pH equal to or lower than pH 6.3, 6.2, 6.1 , 6, 5.9, 5.8, 5.7, 5.6, 5.5, 5.4, 5.3, 5.2, 5.1 , 5.0, 4.9, 4.8, 4.7, 4.6, 4.5, 4.4, 4.3, 4.2, 4.1 , 4.0, 3.9, 3.8, 3.7, 3.6, 3.5, 3.4, 3.3, 3.2, 3.1 , 3.0. More preferably the pH is from 3.7 to 4.7, 4.0 to 4.4 and most preferably 4.2.
- An advantage of a low pH is that it is more representative of the natural physiological environment in which albumin and FcRn bind.
- the model of FcRn may be, or be based on, the 2.7A resolution structure of FcRn at pH 8.2 (PDB code 1 exu).
- a second FcRn model may be used in addition to the first FcRn model and it is preferred that the second model is solved at a different pH to the first model, e.g. a higher pH such as a pH equal to or higher than 6.4, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 8.2, 8.4, 8.6, 8.8 or 9.0.
- a higher pH such as a pH equal to or higher than 6.4, 6.8, 7.0, 7.2, 7.4, 7.6, 7.8, 8.0, 8.2, 8.4, 8.6, 8.8 or 9.0.
- Identification of amino acid residues in the albumin which interact with FcRn or are involved in the interaction with FcRn may be done manually and/or visually
- the method of preparing and/or method of identification may com prise comparing the primary structure and/or the tertiary structure of a second albumin (e.g. a non- human albumin) with the primary structure and/or the tertiary structure of the albumin of (i) to identify equivalent amino acids to those identified in (iv).
- Primary structure comparison may be done by sequence alignment between the second albumin and the albumin of (i).
- Secondary structure comparison may be done using publicly available software such as PDBeFold (also known as SSM),an interactive service for comparing protein structures in 3D (e.g.
- the method of preparing and/or method of identification may comprise preparing variants of albumin at the positions identified in (iv) or (v) and confirming (e.g. by binding affinity analysis) that the prepared variants have altered binding to FcRn compared to a reference such as the albumin of (i).
- Binding affinity analysis may be carried out by surface plasmon resonance (e.g. as disclosed herein) and/or by ELISA (e.g. as disclosed in WO201 1 /051489 (PCT/EP10/066572), incorporated herein by reference) and/or confirming that the prepared variants have altered half- lives, e.g. in plasma, compared a reference such as the albumin of (i).
- ELISA e.g. as disclosed in WO201 1 /051489 (PCT/EP10/066572
- a reference such as the albumin of (i).
- the skilled person will appreciate that other methods may be used to identify polypeptides having different binding properties to FcR
- the amino acid resides of albumin which affect the binding of the albumin to FcRn or half-life (e.g. in plasma) are located in one or more (several) of the following regions: (a) 505, 531 , 524, 472, 108, 190, 197 and 425; (b) 492 to 538; (c) 186 to 201 ; (d) 457 to 472; (e) 414 to 426; (f) 104 to 120; (g) 75 to 91 ; (h) 144 to 150; (i) 30 to 41 , (j) 550 to 585 and (k) 276, 410 and 414 with one or more (several) of A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y and/or a stop codon at a position from 497 to 585; wherein, it is preferred that, when the poly
- a stop codon may be made at any of positions 497 to 585, i.e. any of positions 497, 498, 499, 500, 501 , 502, 503, 504, 505, 506, 507, 508, 509, 510, 51 1 , 512, 513, 514, 515, 516, 517, 518, 519, 520, 521 , 522, 523, 524, 525, 526, 527, 528, 529, 530, 531 , 532, 533, 534, 535, 536, 537, 538, 539, 540, 541 , 542, 543, 544, 545, 546, 547, 548, 549, 550, 551 , 552, 553, 554, 555, 556, 557, 558, 559, 560, 561 , 562, 563, 564, 565, 566, 567, 568, 569, 570, 571 , 572, 573
- the first aspect of the invention provides an albumin variant or fragment thereof having altered binding affinity to FcRn compared with a parent or reference albumin, comprising an alteration (such as a substitution, deletion or insertion) at:
- the positions described in (a) (above) may be in a first Domain (e.g. Domai n I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (b) (above) may be in a second Domain (e.g. Domain I I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (c) (above) may be in a third Domain (e.g. Domain M M) of a polypeptide such as an albumin, e.g. HSA.
- the albumin variant or fragment thereof may further comprise an alteration (such as a substitution or insertion) at one more (several) positions corresponding to the following positions of SEQ ID No: 2:
- non-Cys residue to Cys and/or a deletion of or substitution of one or more (several) of positions 91 , 200, 461 , 514, 558, 559, 567 from Cys, to a non-Cys residue), and/or
- parent albumin and/or the variant albumin comprises or consists of: (a) a polypeptide having at least 60% sequence identity to the mature polypeptide of SEQ
- polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1 , or (ii) the full-length complement of (i);
- a second aspect of the invention relates to a method for obtaining a variant albumin or fragments thereof, or fusion polypeptides comprising the variant albumin or fragments thereof, or associates of variant albumin or fragment thereof comprising:
- positions may be selected from one or more (several) of: 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 104, 105, 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119, 120, 144, 145, 146, 147, 148, 149, 150, 186, 187, 188, 189, 190, 191, 192, 193, 194, 195, 196, 197, 198, 199, 200, 201, 276, 410, 411, 414, 415, 416, 417, 418, 419, 420, 421, 422, 423, 424, 425, 426, 457, 458, 459, 460, 46
- a stop codon may be made at any of positions 497 to 585, i.e. any of positions 497, 498, 499, 500, 501, 502, 503, 504, 505, 506, 507, 508, 509, 510, 511, 512, 513, 514, 515, 516, 517, 518, 519, 520, 521 , 522, 523, 524, 525, 526, 527, 528, 529, 530, 531 , 532, 533, 534, 535, 536, 537, 538, 539, 540, 541 , 542, 543, 544, 545, 546, 547, 548, 549, 550, 551 , 552, 553, 554, 555, 556, 557, 558, 559, 560, 561 , 562, 563, 564, 565, 566, 567, 568, 569, 570, 571 , 572, 573, 5
- the second aspect of the invention relates to a method for obtaining a variant albumin or fragments thereof, or fusion polypeptides comprising the variant albumin or fragments thereof, or associates of variant albumin or fragment thereof comprising:
- the positions described in (a) (above) may be in a first Domain (e.g. Domai n I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (b) (above) may be in a second Domain (e.g. Domain I I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (c) (above) may be in a third Domain (e.g. Domain M M) of a polypeptide such as an albumin, e.g. HSA.
- the albumin variant or fragment thereof may further comprise an alteration (such as a substitution or insertion) at one more (several) positions corresponding to the following positions of SEQ ID No: 2:
- non-Cys residue to Cys and/or a deletion of or substitution of one or more (several) of positions 91 , 200, 461 , 514, 558, 559, 567 from Cys, to a non-Cys residue), and/or
- parent albumin and/or the variant albumin comprises or consists of:
- polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1 , or (ii) the full- length complement of (i);
- the variants can be prepared by those skilled persons using any mutagenesis procedure known in the art, such as site-directed mutagenesis, synthetic gene construction, semi-synthetic gene construction, random mutagenesis, shuffling, etc.
- Site-directed mutagenesis is a technique in which one or more (several) mutations (alterations) are created at one or more (several) defined sites in a polynucleotide encoding the parent.
- Site-directed mutagenesis can be accomplished in vitro by PCR involving the use of oligonucleotide primers containing the desired mutation. Site-directed mutagenesis can also be performed in vitro by cassette mutagenesis involving the cleavage by a restriction enzyme at a site in the plasmid comprising a polynucleotide encoding the parent and subsequent ligation of an oligonucleotide containing the mutation in the polynucleotide. Usually the restriction enzyme that digests at the plasmid and the oligonucleotide is the same, permitting ligation of the plasmid and insert to one another. See, e.g., Scherer and Davis, 1979, Proc. Natl. Acad. Sci. USA 76: 4949- 4955; and Barton et al., 1990, Nucleic Acids Res. 18: 7349-4966.
- Site-directed mutagenesis can also be accomplished in vivo by methods known in the art. See, e.g., U.S. Patent Application Publication NO: 2004/0171 154; Storici et al., 2001 , Nature Biotechnol. 19: 773-776; Kren et al., 1998, Nat. Med. 4: 285-290; and Calissano and Macino, 1996, Fungal Genet. Newslett. 43: 15-16.
- Any site-directed mutagenesis procedure can be used in the invention.
- Synthetic gene construction entails in vitro synthesis of a designed polynucleotide molecule to encode a polypeptide of interest. Gene synthesis can be performed utilizing a number of techniques, such as the multiplex microchip-based technology described by Tian et al. (2004, Nature 432: 1050-1054) and similar technologies wherein oligonucleotides are synthesized and assembled upon photo-programmable microfluidic chips.
- Single or multiple amino acid substitutions, deletions, and/or insertions can be made and tested using known methods of mutagenesis, recombination, and/or shuffling, followed by a relevant screening procedure, such as those disclosed by Reidhaar-Olson and Sauer, 1988, Science 241 : 53-57; Bowie and Sauer, 1989, Proc. Natl. Acad. Sci. USA 86: 2152-2156; WO 95/17413; or WO 95/22625.
- Other methods that can be used include error-prone PCR, phage display (e.g., Lowman et al., 1991 , Biochemistry 30: 10832-10837; U.S. Patent NO: 5,223,409; WO 92/06204) and region-directed mutagenesis (Derbyshire et al., 1986, Gene 46: 145; Ner et al., 1988, DNA 7: 127).
- Mutagenesis/shuffling methods can be combined with high-throughput, automated screening methods to detect activity of cloned, mutagenized polypeptides expressed by host cells (Ness et al., 1999, Nature Biotechnology 17: 893-896). Mutagenized DNA molecules that encode active polypeptides can be recovered from the host cells and rapidly sequenced using standard methods in the art. These methods allow the rapid determination of the importance of individual amino acid residues in a polypeptide.
- Semi-synthetic gene construction is accomplished by combining aspects of synthetic gene construction, and/or site-directed mutagenesis, and/or random mutagenesis, and/or shuffling.
- Semisynthetic construction is typified by a process utilizing polynucleotide fragments that are synthesized, in combination with PCR techniques. Defined regions of genes may thus be synthesized de novo, while other regions may be amplified using site-specific mutagenic primers, while yet other regions may be subjected to error-prone PCR or non-error prone PCR amplification. Polynucleotide sub sequences may then be shuffled.
- a third aspect of the invention provides variant albumins or fragments thereof, or fusion polypeptides comprising the variant albumin or fragments thereof, of a parent albumin, comprising an alteration at one or more (several) positions corresponding to positions 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 , 414 to 426, 457 to 472, 492 to 538, 550 to 585, 276, 410 and/or 41 1 of the mature polypeptide of SEQ I D NO: 2, wherein, it is preferred that, when the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506, 510, 535, 536, 537, 538, 540, 550, 573, 574, 575, 577, 578, 579, 580, 581 , 582
- Fu rthermore a stop codon m ay be introduced at any of positions 497 to 585.
- the introduction may be made by insertion or substitution.
- Introduction of such a stop codon may be in addition to or instead of a mutation described herein.
- the third aspect of the invention provides variant albumins or fragments thereof, or fusion polypeptides comprising the variant albumin or fragments thereof, of a parent albumin, comprising an alteration (such as a substitution, deletion or insertion) at:
- the positions described in (a) (above) may be in a first Domain (e.g. Domai n I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (b) (above) may be in a second Domain (e.g. Domain I I ) of a polypeptide such as an albumin, e.g. HSA.
- the positions described in (c) (above) may be in a third Domain (e.g. Domain M M) of a polypeptide such as an albumin, e.g. HSA.
- the albumin variant or fragment thereof may further comprise an alteration (such as a substitution or insertion) at one more (several) positions corresponding to the following positions of SEQ ID No: 2:
- non-Cys residue to Cys and/or a deletion of or substitution of one or more (several) of positions 91 , 200, 461 , 514, 558, 559, 567 from Cys, to a non-Cys residue), and/or
- parent albumin and/or the variant albumin comprises or consists of:
- polypeptide encoded by a polynucleotide that hybridizes under low stringency conditions with (i) the mature polypeptide coding sequence of SEQ ID NO: 1 , or (ii) the full- length complement of (i);
- the variant albumin, a fragment thereof, or albumin part of a fusion polypeptide comprising variant albumin or a fragment thereof according to the invention has generally a sequence identity the sequence of HSA shown in SEQ ID NO: 2 of at least 60%, preferably at least 70%, preferably at least 80%, preferably at least 85%, preferably at least 90 %, more preferred at least 95%, more preferred at least 96%, more preferred at least 97%, more preferred at least 98% and most preferred at least 99%.
- the number of alterations in the variants of the invention is 1-20, e.g., 1-10 and 1-5, such as 1 , 2, 3, 4, 5, 6, 7, 8, 9 or 10 alterations.
- the variant albumin, a fragment thereof or fusion polypeptide comprising the variant albumin or fragment thereof has altered binding affinity to FcRn and/or an altered plasma half-life compared with the corresponding parent or reference albumin, fragment thereof, or fusion polypeptide comprising the variant albumin or fragment thereof and/or an altered binding affinity to FcRn.
- the parent or reference albumin is HSA and the variant albumin, a fragment thereof or fusion polypeptide comprising the variant albumin or fragment thereof has altered binding affinity to FcRn and/or an altered plasma half-life compared with the HSA, the corresponding fragment or fusion polypeptide comprising HSA or fragment thereof and/or an altered binding affinity to FcRn.
- transgenic mouse having the natural mouse FcRn replaced with human FcRn has a higher serum albumin level than normal mouse (J Exp Med. (2003) 197(3):315-22).
- human FcRn has a higher affinity to mouse serum albumin than mouse FcRn has to mouse serum albumin and, therefore, the observed increase in serum albumin in the transgenic mice corresponds with a higher affinity between serum albumin and its receptor, confirming the correlation between albumin binding to FcRn and plasma half-life.
- variants of albumin that have little or no binding to FcRn have been shown to have reduced half-life in a mouse model, Kenanova et al (2009) J. Nucl. Med.; 50 (Supplement 2):1582).
- variant albumins having a KD that is lower than the KD for natural HSA is considered to have a higher plasma half-life than HSA and variant albumins having a KD that is higher than the KD for natural HSA is considered to have a lower plasma half-life than HSA.
- the variants of albumin or fragments thereof or fusion polypeptides comprising albumin or fragments thereof comprise one or more (several) alterations, such as substitutions, deletions or insertions at one or more (several) positions corresponding to the positions in HSA selected from the group consisting of 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 , 414 to 426, 457 to 472, 492 to 538, 550 to 585, 276, 410 and/or 41 1 of the mature polypeptide of SEQ I D NO: 2 and/or introduction of a stop codon may be made at any of positions 497 to 585 of the mature polypeptide of SEQ ID NO: 2, wherein, it is preferred that, when the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506,
- the introduction may be made by insertion or substitution. Introduction of such a stop codon may be in addition to or instead of an alteration described herein.
- the substitution may be any substitution where the amino acid in the natural albumin sequence is substituted with a different amino acid selected among the remaining 19 natural occurring amino acids.
- a variant comprises an alteration at one or more (several) positions corresponding to positions 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 , 414 to 426, 457 to 472, 492 to 538, 550 to 585, 276, 410 and/or 41 1 of the mature polypeptide of SEQ ID NO: 2, wherein, it is preferred that, when the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506, 510, 535, 536, 537, 538, 540, 550, 573, 574, 575, 577, 578, 579, 580, 581 , 582 and 584, (ii) the group consisting of positions 34, 38, 40, 75, 76, 80, 82, 83, 86
- a variant comprises an alteration at two or more (several) positions corresponding to any of 30 to 41, 75 to 91, 104 to 120, 144 to 150, 186 to 201, 414 to 426, 457 to 472, 492 to 538, 550 to 585, and/or 276, 410, 411 of the mature polypeptide of SEQ ID NO: 2, wherein, it is preferred that, when the variant, fragment or fusion thereof comprises one or more (several) substitutions at positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506, 510, 535, 536, 537, 538, 540, 550, 573, 574, 575, 577, 578, 579, 580, 581, 582 and 584 the variant, fragment or fusion thereof also comprises one or more (several) substitutions at a position selected from group consisting of 30, 31, 32, 33, 34, 35, 36
- the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506, 510, 535, 536, 537, 538, 540, 550, 573, 574, 575, 577, 578, 579, 580, 581 , 582 and 584, (ii) the group consisting of positions 34, 38, 40, 75, 76, 80, 82, 83, 86, 90, 91 , 104, 1 13, 1 15, 1 16, 200, 461 , 471 , 496, 498, 501 , 503, 504, 505, 506, 512, 514, 538, 550, 558, 559, 560, 562, 564, 565, 567, 573, 574, 577, 578, 579, 580, 581 , 582, 584
- polypeptide also comprises one or more (several) alterations
- a variant comprises an alteration at three positions corresponding to any of positions 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 , 414 to 426, 457 to 472, 492 to 538, 550 to 585, 276, 410, and/or 41 1 of the mature polypeptide of SEQ I D NO: 2, wherein, it is preferred that, when the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505,
- SEQ ID NO: 2 however the invention also includes equivalent positions in sequences other than SEQ ID No: 2.
- HSA SEQ ID NO: 2
- the invention also includes variants of non-human albumins and/or fragments of human or non-human albumin having the herein mentioned alterations at positions equivalent to those stated for HSA.
- the skilled person can identify equivalent positions by sequence alignment with SEQ ID NO: 2.
- the variant may further comprise alterations are at one or more (several) positions selected from the group consisting of 34, 38, 40, 75, 76, 80, 82, 83, 86, 90, 91 , 104, 113, 115, 1 16, 200, 461 , 471 , 496, 498, 501 , 503, 504, 505, 506, 512, 514, 538, 550, 558, 559, 560, 562, 564, 565, 567, 573, 574, 577, 578, 579, 580, 581 , 582, 584, 585 (numbers relative to SEQ I D No.
- non-Cys residue to Cys to introduce a Cys which may be available for conjugation via its thiol group and/or a deletion of or substitution of one or more (several) of positions 91 , 200, 461 , 514, 558, 559, 567 from Cys, to a non-Cys residue which may break an existing disulphide bond to generate a Cys which may be available for conjugation via its thiol group.
- One or more (several) of these positions may be altered alone or, more preferably, in combination with another position or positions disclosed herein.
- the variant may further comprise alterations are at one or more (several) positions selected from the group consisting of 63, 82, 84, 87, 90, 106, 1 14, 1 19, 146, 464, 201 , 494, 501 , 503, 505, 510, 513, 518, 525, 529, 533, 535, 536, 537, 550, 550, 557, 560, 563, 565, 570, 573, 574, 574, 584 (numbers relative to SEQ ID No. 2), .
- One or more (several) of these positions may be altered alone or, more preferably, in combination with another position or positions disclosed herein.
- variants of albumin comprising a C-terminal truncation of from 1 to 88 amino acids are included in all aspects of the invention and also form an aspect of the invention in their own right. Therefore, a variant may comprise or consist of an albumin having a sequence equivalent to positions 1 to 497 to 1 to 584 of SEQ ID NO: 2.
- Such a variant may be prepared by introducing a stop codon at any of positions 497, 498, 499, 500, 501 , 502, 503, 504, 505, 506, 507, 508, 509, 510, 51 1 , 512, 513, 514, 515, 516, 517, 518, 519, 520, 521 , 522, 523, 524, 525, 526, 527, 528, 529, 530, 531 , 532, 533, 534, 535, 536, 537, 538, 539, 540, 541 , 542, 543, 544, 545, 546, 547, 548, 549, 550, 551 , 552, 553, 554, 555, 556, 557, 558, 559, 560, 561 , 562, 563, 564, 565, 566, 567, 568, 569, 570, 571 , 572, 573, 574, 575, 576
- the albumin may be truncated by 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88 relative to the parent albumin, or fragment thereof, from which it is derived.
- the truncation is no longer than 88 amino acids, therefore it is preferred that the albumin is be truncated by at most 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 42, 43, 44, 45, 46, 47, 48, 49, 50, 51 , 52, 53, 54, 55, 56, 57, 58, 59, 60, 61 , 62, 63, 64, 65, 66, 67, 68, 69, 70, 71 , 72, 73, 74, 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88 amino acids relative to the parent albumin, or fragment thereof, from which it is derived.
- the variant comprises a stop codon at position 406, 407, 408, 409, 410, 41 1 or 585.
- the variant may or may not comprise one or more (several) other alterations as described herein. Truncations may be referred to as 'fragments'.
- Preferred truncations are at positions from 500 to 584, such as from 573 or 574 to 584.
- variants are thus truncated relative to a parent albumin, e.g. HSA (SEQ ID NO: 2), but apply equally to fragments of albumin such as DM + DI N, DI M , or Dl + Di l l .
- the skilled person can determine the location of the truncation within such a fragment by alignment of the fragment with HSA.
- the variant may comprise or consist of the N-terminal at least 85 to 99.5% of a parent albumin or fragment thereof, such as the N-terminal at least 85, 86, 87, 88, 89, 90, 91 , 92, 93, 94, 95, 96, 97, 98, 99 or 99.5%.
- Preferred truncations comprise the N-terminal 85, 86, 97 or 98% of a parent albumin or fragment thereof. Accordingly, methods of preparation, fragments, fusions, conjugates, nanoparticles, associates and compositions may comprise such a truncated variant. It is preferred that the truncated variant retains position 573 (or equivalent thereof). It is further preferred that the amino acid at 573 is Pro, Trp or Tyr.
- the variant albumin or fragments thereof, or fusion polypeptides comprising the variant albumin or fragments thereof according to the invention contains one substitution at a position corresponding to a position in HSA selected from the group consisting of 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 75, 76, 77, 78, 79, 80, 81 , 82, 83, 84, 85, 86, 87, 88, 89, 90, 91 , 104, 105, 106, 107, 108, 109, 1 10, 1 1 1 1 , 1 12, 1 13, 1 14, 1 15, 1 16, 1 17, 1 18, 1 19, 120, 144, 145, 146, 147, 148, 149, 150, 186, 187, 188, 189, 190, 191 , 192, 193, 194, 195, 196, 197, 198, 199, 200, 201 , 276, 410, 41 1 , 414, 415,
- the variant albumin or fragments thereof, or fusion polypeptides comprising the variant albumin or fragments thereof according to the invention contains one substitution at a position corresponding to a position in HSA selected from the group consisting of 30, 31 , 32, 33, 35, 36, 37, 39, 41 , 77, 78, 79, 81 , 84, 85, 87, 88, 89, 105, 106, 107, 108, 109, 1 10, 1 1 1 1 , 1 12, 1 17, 1 18, 120, 144, 145, 146, 147, 148, 149, 150, 186, 187, 188, 189, 190, 191 , 192, 193, 194, 195, 196, 197, 198, 199, 201 , 276, 410, 41 1 , 414, 415, 416, 418, 419, 420, 421 , 422, 423, 424, 425, 426, 457, 458, 459, 460, 462,
- variant albumin, fragment thereof or fusion polypeptides comprising variant albumin or a fragment thereof according to the invention may comprise additional substitutions, insertions or deletions at one or more (several) positions corresponding to other positions in HSA.
- the variant albumin or fragments thereof, or fusion polypeptides comprising variant albumin or fragments thereof according to the invention contains two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or even more substitutions at positions corresponding to positions in HSA selected from the group consisting of 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 , 414 to 426, 457 to 472, 492 to 538, 550 to 585, 276, 410 and/or 41 1 of the mature polypeptide of SEQ ID NO: 2, wherein, it is preferred that, when the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505, 506, 510, 535, 536, 537, 538,
- non-Cys residue to Cys and/or a deletion of or substitution of one or more (several) of positions 91 , 200, 461 , 514, 558, 559, 567 from Cys, to a non-Cys residue), or the group consisting of positions (iii) 63, 82, 84, 87, 90, 106, 1 14, 1 19, 146, 464, 201 , 494, 501 , 503, 505, 510, 513, 518, 525, 529, 533, 535, 536, 537, 550, 550, 557, 560,
- polypeptide also comprises one or more (several) alterations at a position selected from group consisting of positions 30, 31 , 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 , 75, 76, 77,
- the variants of albumin or fragments thereof, or fusion polypeptides comprising variant albumin or a fragment thereof according to the invention have a plasma half-life that is longer than the plasma half-life of the parent or reference albumin fragment thereof or fusion polypeptide comprising the parent or reference albumin or a fragment thereof and/or an stronger binding affinity to FcRn.
- the variants of albumin or fragments thereof, or fusion polypeptides comprising variant albumin or fragments thereof according to the invention have a plasma half-life that is shorter than the plasma half-life of the parent or reference albumin fragment thereof or fusion polypeptide comprising the parent or reference albumin or a fragment thereof and/or an weaker binding affinity to FcRn.
- Such additional substitutions, deletions or insertions may be useful in order to alter other properties of the molecules such as but not limited to altered glycosylation; introduction of reactive groups of the surface such a thiol groups, removing/generating a carbamoylation site; etc.
- Residues that might be altered in order to provide reactive residues on the surface and which advantageously could be applied to the invention has been disclosed in WO2010/092135 (incorporated herein by reference). Particular preferred residues include the positions corresponding to positions in SEQ ID NO: 2.
- cysteine residue may be added to the N or C terminal of albumin.
- the term 'reactive thiol' means and/or includes a thiol group provided by a Cys which is not disulphide bonded to a Cysteine and/or which is sterically available for binding to a partner such as a conjugation partner.
- a fourth aspect of the invention relates to isolated polynucleotides that encode any of the variants of the invention.
- the polynucleotide may be an isolated polynucleotide.
- the polynucleotide may be comprised a in a vector (such as a plasmid) and/or in a host cell.
- the invention also relates to nucleic acid constructs comprising a polynucleotide encoding a variant of the invention operably linked to one or more (several) control sequences that direct the expression of the coding sequence in a suitable host cell under conditions compatible with the control sequences.
- a polynucleotide may be manipulated in a variety of ways to provide for expression of a variant. Manipulation of the polynucleotide prior to its insertion into a vector may be desirable or necessary depending on the expression vector. The techniques for modifying polynucleotides utilizing recombinant DNA methods are well known in the art.
- the control sequence may be a promoter sequence, which is recognized by a host cell for expression of the polynucleotide.
- the promoter sequence contains transcriptional control sequences that mediate the expression of the variant.
- the promoter may be any nucleic acid sequence that shows transcriptional activity in the host cell including mutant, truncated, and hybrid promoters, and may be obtained from genes encoding extracellular or intracellular polypeptides either homologous or heterologous to the host cell.
- useful promoters are obtained from the genes for Saccharomyces cerevisiae enolase (ENO-1 ), Saccharomyces cerevisiae protease A (PRA1 ), Saccharomyces cerevisiae protease B (PRB1 ), Saccharomyces cerevisiae translation elongation factor (TEF1 ), Saccharomyces cerevisiae translation elongation factor (TEF2), Saccharomyces cerevisiae galactokinase (GAL1 ), Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde- 3-phosphate dehydrogenase (ADH 1 , ADH2/GAP), Saccharomyces cerevisiae triose phosphate isomerase (TPI), Saccharomyces cerevisiae metallothionein (CUP1 ), and Saccharomyces cerevisiae 3-phosphoglycer
- ENO-1 Sacchar
- useful promoters are obtained from cauliflower mosaic virus 35S RNA gene (CaMV35S), maize alcohol dehydrogenase (Adh1 ) and alpha Amy3.
- useful promoters are obtained from Cytomegalovirus (CMV) and CAG hybrid promoter (hybrid of CMV early enhancer element and chicken beta-actin promoter), Simian vacuolating virus 40 (SV40).
- CMV Cytomegalovirus
- CAG hybrid promoter hybrid of CMV early enhancer element and chicken beta-actin promoter
- SV40 Simian vacuolating virus 40
- the control sequence may also be a suitable transcription terminator sequence, which is recognized by a host cell to terminate transcription.
- the terminator sequence is operably linked to the 3'-terminus of the polynucleotide encoding the variant. Any terminator that is functional in the host cell may be used.
- Preferred terminators for yeast host cells are obtained from the genes for Saccharomyces cerevisiae enolase, Saccharomyces cerevisiae cytochrome C (CYC1 ), Saccharomyces cerevisiae alcohol dehydrogenase (AD H 1 ) and Saccharomyces cerevisiae glyceraldehyde-3-phosphate dehydrogenase.
- useful terminators for yeast host cells are described by Romanos et a/., 1992, supra.
- Other useful terminators for yeast host cells are described by Romanos et a/., 1992, supra.
- useful terminators for use in rice and mammalian cells such as CHO or HEK.
- preferred terminators are obtained from Agrobacterium tumefaciens nopaline synthase (Nos) and cauliflower mosaic virus 35S RNA gene (CaMV35S)
- the control sequence may also be a suitable leader sequence, a nontranslated region of an mRNA that is important for translation by the host cell.
- the leader sequence is operably linked to the 5'-terminus of the polynucleotide encoding the variant. Any leader sequence that is functional in the host cell may be used.
- Suitable leaders for yeast host cells are obtained from the genes for Saccharomyces cerevisiae en ol ase ( E N O-1 ), Saccharomyces cerevisiae 3-phosphoglycerate kinase, Saccharomyces cerevisiae alpha-facto r , a n d Saccharomyces cerevisiae alcohol dehydrogenase/glyceraldehyde-3-phosphate dehydrogenase (ADH2/GAP).
- the control sequence may also be a polyadenylation sequence, a sequence operably linked to the 3'-terminus of the variant-encoding sequence and, when transcribed, is recognized by the host cell as a signal to add polyadenosine residues to transcribed mRNA. Any polyadenylation sequence that is functional in the host cell may be used.
- the control sequence may also be a signal peptide coding region that encodes a signal peptide linked to the N-terminus of a variant and directs the variant into the cell's secretory pathway.
- the 5'-end of the coding sequence of the polynucleotide may inherently contain a signal peptide coding region naturally linked in translation reading frame with the segment of the coding region that encodes the variant.
- the 5'-end of the coding sequence may contain a signal peptide coding region that is foreign to the coding sequence.
- the foreign signal peptide coding region may be required where the coding sequence does not naturally contain a signal peptide coding region.
- the foreign signal peptide coding region may simply replace the natural signal peptide coding region in order to enhance secretion of the variant.
- any signal peptide coding region that directs the expressed variant into the secretory pathway of a host cell may be used.
- Useful signal peptides for yeast host cells are obtained from the genes for Saccharomyces cerevisiae alpha-factor and Saccharomyces cerevisiae invertase. Other useful signal peptide coding sequences are described by Romanos et a/., 1992, supra. The skilled person knows useful signal peptides for use in rice and mammalian cells, such as CHO or HEK.
- the propeptide region is positioned next to the N-terminus of the variant and the signal peptide region is positioned next to the N-terminus of the propeptide region.
- a fifth aspect of the invention relates to methods of preparation of a variant according to the invention.
- the variants of the invention can be prepared using techniques well known to the skilled person. One convenient way is by cloning nucleic acid encoding the parent albumin or a fragment thereof or fusion polypeptide comprising albumin or a fragment thereof, modifying said nucleic acid to introduce the desired substitution(s) at one or more (several) positions corresponding to positions 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 , 414 to 426, 457 to 472, 492 to 538, 550 to 585, 276, 410 and/or 41 1 of the mature polypeptide of SEQ ID NO: 2, wherein, it is preferred that, when the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501 , 503, 504, 505,
- the variant polypeptide of the invention may also be connected to a signal sequence in order to have the variant polypeptide secreted into the growth medium during culturing of the transformed host organism. It is generally advantageous to have the variant polypeptide secreted into the growth medium in order to ease recovery and purification.
- Albumins have been successfully expressed as recombinant proteins in a range of hosts including fungi (including but not limited to Aspergillus (WO06066595), Kluyveromyces (Fleer 1991 , Bio/technology 9, 968-975), Pichia (Kobayashi 1998 Therapeutic Apheresis 2, 257-262) and Saccharomyces (Sleep 1990, Bio/technology 8, 42-46)), bacteria (Pandjaitab 2000, J. Allergy Clin. Immunol.
- fungi including but not limited to Aspergillus (WO06066595), Kluyveromyces (Fleer 1991 , Bio/technology 9, 968-975), Pichia (Kobayashi 1998 Therapeutic Apheresis 2, 257-262) and Saccharomyces (Sleep 1990, Bio/technology 8, 42-46)
- bacteria Pandjaitab 2000, J. Allergy Clin. Immunol.
- the variant polypeptide of the invention is preferably produced recombinantly in a suitable host cell.
- any host cell capable of producing a polypeptide in suitable amounts may be used and it is within the skills of the average practitioner to select a suitable host cell according to the invention .
- a preferred host organism is yeast, preferably selected among Saccharomycacae, more preferred Saccharomyces cerevisiae.
- variant polypeptides of the invention may be recovered and purified from the growth medium using a combination of known separation techniques such as filtration, centrifugation, chromatography, and affinity separation techniques etc. It is within the skills of the average practitioner to purify the variants of the invention using a particular combination of such known separation steps.
- purification techniques that may be applied to the variants of the invention can be mentioned the teaching of WO00/44772.
- the variant polypeptides of the invention may be used for delivering a therapeutically beneficial compound (including prophylactically beneficial compound such as a vaccine) to an animal or a human individual in need thereof.
- a therapeutically beneficial compound including prophylactically beneficial compound such as a vaccine
- therapeutically beneficial compounds include, but are not limited, to labels and readily detectable compounds for use in diagnostics, such as various imaging techniques; pharmaceutical active compounds such as drugs, or specifically binding moieties such as antibodies.
- the variants of the invention may even be connected to two or more (several) different therapeutically beneficial compounds, e.g., an antibody and a drug, which gives the combined molecule the ability to bind specifically to a desired target and thereby provide a high concentration of the connected drug at that particular target.
- a sixth aspect of the invention relates to fusion polypeptides. Therefore, the variants of albumin or fragments thereof according to the invention may be fused with a non-albumin polypeptide fusion partner.
- the fusion partner may in principle be any polypeptide but generally it is preferred that the fusion partner is a polypeptide having therapeutic, prophylactic (including vaccine), diagnostic, imaging or other beneficial properties. Such properties may be referred to as 'pharmaceutically beneficial properties'.
- Fusion polypeptides comprising albumin or fragments thereof are known in the art. It has been found that such fusion polypeptides comprising albumin or a fragment thereof and a fusion partner polypeptide have a longer plasma half-life compared to the unfused fusion partner polypeptide alone.
- the invention it is possible to alter the plasma half-life of the fusion polypeptides accord ing to the i nvention com pared to the corresponding fusion polypeptides of the prior art.
- 'Alter' includes both increasing the plasma half- life or decreasing the plasma half-life. Increasing the plasma half-life is preferred.
- the invention allows tailoring of half-life to a term desired.
- One or more (several) therapeutic, prophylactic (including vaccine), diagnostic, imaging or other beneficial may be fused to the N-terminus, the C-terminus of albumin, inserted into a loop in the albumin structure or any combination thereof. It may or it may not comprise linker sequences separating the various components of the fusion polypeptide.
- WO 2001/79271 A (particularly page 9 and/or Table 1 ), WO 2003/59934A (particularly Table 1 ), WO03/060071 (particularly Table 1 ) and WO01/079480 (particularly Table 1 ) (each incorporated herein by reference in their entirety) also contain examples of therapeutic, prophylactic (including vaccine), diagnostic, imaging or other beneficial polypeptides that may be fused to albumin or fragments thereof, and these examples apply also to the invention. Further preferences for the sixth aspect of the invention are provided below the thirteenth aspect of the invention.
- a seventh aspect of the invention relates to conjugates (conjugations). Therefore, the variants of albumin or fragments thereof according to the invention may be conjugated to a second molecule ('conjugation partner') using techniques known within the art.
- the conjugation partner may be a therapeutic, prophylactic (including vaccine), diagnostic, imaging or other beneficial moiety.
- Said conjugation partner may be a polypeptide or a non-polypeptide chemical .
- the conjugation partner may be a polypeptide, chemical (e.g. chemically synthesised drug) or a nucleic acid (e.g. DNA, RNA, siRNA).
- the conjugate may be useful as a diagnostic tool such as in imaging; or the second molecule may be a therapeutic or prophylactic (e.g. vaccine) compound and in this embodiment the conjugate may be used for therapeutic or prophylactic (e.g. vaccination) purposes where the conjugate will have the therapeutic or prophylactic properties of the therapeutic or prophylactic compound as well as the desirable plasma half-life provided by the albumin part of the conjugate.
- the second molecule may be a therapeutic or prophylactic (e.g. vaccine) compound and in this embodiment the conjugate may be used for therapeutic or prophylactic (e.g. vaccination) purposes where the conjugate will have the therapeutic or prophylactic properties of the therapeutic or prophylactic compound as well as the desirable plasma half-life provided by the albumin part of the conjugate.
- Conjugates of albumin and a therapeutic molecule are known in the art and it has been verified that such conjugates have long plasma half-life compared with the non-conjugated, free therapeutic molecule as such. According to the invention it is possible to alter the binding affinity to FcRn and/or plasma half-life of the conjugate according to the invention compared to the corresponding conjugates of the prior art.
- 'Alter' includes both increasing the plasma half-life and decreasing the plasma half-life binding affinity to FcRn and/or increasing the binding affinity and decreasing the binding affinity to FcRn. Increasing the plasma half-life and/or binding affinity to FcRn is preferred.
- the conjugates may conveniently be linked via a free thiol group present on the surface of HSA (amino acid residue 34 of mature HSA) using well known chemistry.
- the variant albumin or fragment thereof is conjugated to a beneficial therapeutic or prophylactic (including vaccine) compound and the conjugate is used for treatment of a condition in a patient in need thereof, which condition is responsive to the particular selected therapeutic compound .
- a beneficial therapeutic or prophylactic (including vaccine) compound and the conjugate is used for treatment of a condition in a patient in need thereof, which condition is responsive to the particular selected therapeutic compound .
- Techniques for conj ugating such a therapeutical ly useful compound to the variant albumin or fragment thereof are known in the art.
- WO 2009/019314 (incorporated herein by reference in its entirety) discloses examples of techniques suitable for conjugating a therapeutically compound to a polypeptide which techniques can also be applied to the invention.
- WO 2009/019314 discloses examples of compounds and moieties that may be conjugated to substituted transferrin and these examples may also be applied to the invention. The teaching of WO 2009/019314 is included herein by reference.
- HSA contains in its natural form one free thiol group (at Cys34) that conveniently may be used for conjugation.
- the variant albumin or fragment thereof may comprise further modifications provided to generate additional free thiol groups on the surface. This has the benefit that the payload of the variant album in or fragment thereof is increased so that more than one molecule of the therapeutic (e.g.
- prophylactic) compound can be conjugated to each molecule of variant albumin or fragment thereof, or two or more (several) different therapeutic compounds may be conjugated to each molecule of variant albumin or fragment thereof, e.g., a compound having targeting properties such as an antibody specific for example a tumour; and a cytotoxic drug conjugated to the variant albumin or fragment thereof thereby creating a highly specific drug against a tumour.
- a compound having targeting properties such as an antibody specific for example a tumour
- a cytotoxic drug conjugated to the variant albumin or fragment thereof thereby creating a highly specific drug against a tumour.
- the conjugation partner may alternatively be conjugated to a fusion polypeptide (described herein), resulting in a molecule comprising a fusion partner fused to the albumin as well as a conjugation partner conjugated to the same albumin or even to the fusion partner.
- a fusion polypeptide described herein
- an eighth aspect of the invention relates to associates. Therefore, the variants of albumin or fragments thereof may further be used i n form of "associates".
- the term "associate” is intended to mean a compound comprising a variant of albumin or a fragment thereof and another compound bound or associated to the variant albumin or fragment thereof by non- covalent binding.
- an associate consisting variant albumin and a lipid associated to albumin by a hydrophobic interaction.
- Such associates are known in the art and they may be prepared using well known techniques.
- an associate comprising variant albumin and a taxane, a taxol or taxol derivative (e.g.paclitaxel).
- Further examples of associates comprise a therapeutic, prophylactic (including vaccine), diagnostic, imaging or other beneficial moiety.
- the half-life of an albumin associate according to the invention may be longer or shorter than the half-life of the Other compound' alone.
- the half-life of an albumin associate according to the invention may be longer or shorter than the half-life of the analogous / equivalent albumin associate comprising or consisting of a reference albumin such as native HSA (instead of an albumin variant or derivative according to the invention) and the Other compound'.
- the binding affinity to FcRn an albumin associate according to the invention may be stronger or weaker than the binding affinity to FcRn of the analogous / equivalent albumin associate comprising or consisting of a reference albumin such as native HSA (instead of an albumin variant or derivative according to the invention) and the Other compound'.
- a reference albumin such as native HSA (instead of an albumin variant or derivative according to the invention) and the Other compound'.
- Methods for the preparation of associates are well-known to the skilled person, for example, formulation (by association) of HSA with Lipo- compounds is described in Hussain, R. and Siligardi, G. (2006) International Journal of Peptide Research and Therapeutics, Vol. 12, NO: 3, pp. 31 1-315. Further preferences for the eighth aspect of the invention are provided below the thirteenth aspect of the invention. Other uses
- a ninth aspect of the invention relates to use of a variant albumin, fragment, fusion or conjugate thereof or nanoparticle or associate thereof.
- the variant albumin or fragments thereof or fusion polypeptides comprising variant albumin or fragments thereof according to the invention have the benefit that their binding affinity to FcRn and/or plasma half-life is altered compared to the parent or reference albumin or fragments thereof or fusion polypeptides comprising parent or reference albumin or fragments thereof.
- a conjugate, associate or fusion polypeptide used for imaging purposes in animals or human beings where the imaging moiety has an very short half-life and a conjugate or a fusion polypeptide comprising HSA has a plasma half-life that is far longer than needed for the imaging purposes it would be advantageous to use a variant albumin or fragment thereof of the invention having a shorter plasma half-life than the parent or reference albumin or fragment thereof, to provide conjugates of fusion polypeptides having a plasma half-life that is sufficiently long for the imaging purpose but sufficiently short to be cleared form the body of the particular patient on which it is applied.
- an associate or fusion polypeptide comprising a therapeutic compound effective to treat or alleviate a particular condition in a patient in need for such a treatment it would be advantageous to use the variant albumin or fragment thereof having a longer plasma half-life than the parent or reference albumin or fragment thereof, to provide associates or conjugates or fusion polypeptides having longer plasma half-lives which would have the benefit that the administration of the associate or conjugate or fusion polypeptide of the invention would be needed less frequently or reduced dose with less side effects compared to the situation where the parent or reference albumin or associates thereof or fragment thereof was used.
- the invention provides a method of treating a proliferative disease in an individual, comprising administering the individual an effective amount of an associate according to the invention in which the associate comprises a taxane, a taxol or taxol derivative (e.g. paclitaxel).
- the associate comprises a taxane, a taxol or taxol derivative (e.g. paclitaxel).
- compositions comprising the variant albumin, associates thereof or fragment thereof, variant albumin fragment or associates thereof or fusion polypeptide comprising variant albumin or fragment thereof according to the invention .
- the compositions are preferably pharmaceutical compositions.
- the composition may be prepared using te ch n i q u es kn ow n i n th e a re a s u ch as disclosed in recognized handbooks within the pharmaceutical field. Since the albumin, variant, fragment, fusion, conjugate or associate thereof has a binding affinity to FcRn and/or plasma half-life which is modulated (i.e.
- the composition also has a binding affinity to FcRn and/or modulated plasma half-life relative to an equivalent composition comprising the reference molecule in place of the albumin, variant, fragment, fusion, conjugate or associate thereof as described herein.
- the composition may be a vaccine.
- the polypeptide according to the invention may be an active pharmaceutical or an excipient.
- the composition is provided in unit dosage form.
- the albumin , variant, fragment, fusion, conjugate or associate thereof has a plasma half-life that is longer than the plasma half-life of the reference molecule e.g. the same composition except that the albumin component (e.g. albumin, variant, fragment, fusion, conjugate or associate) is wild-type albumin (e.g. HSA) or a variant, fragment, fusion, conjugate or associate.
- albumin component e.g. albumin, variant, fragment, fusion, conjugate or associate
- HSA wild-type albumin
- a variant, fragment, fusion, conjugate or associate is wild-type albumin (e.g. HSA) or a variant, fragment, fusion, conjugate or associate.
- compositions comprise a variant albumin or a fragment thereof according to the invention and a compound comprising a pharmaceutically beneficial moiety and an albumin binding domain (ABD).
- ABD means a site, moiety or domain capable of binding to circulating albumin in vivo and thereby conferring transport in the circulation of the ABD and any compound or moiety bound to said ABD.
- ABD's are known in the art and have been shown to bind very tight to albumin so a compound comprising an ABD bound to albumin will to a certain extent behave as a single molecule.
- the inventors have realized by using the variant albumin or fragment thereof according to the invention together with a compound comprising a pharmaceutically beneficial moiety and an ABD makes it possible to alter the binding affinity to FcRn and/or plasma half-life of the compound comprising a pharmaceutically beneficial moiety and an ABD compared to the situation where said compound were injected as such in a patient having need thereof or administered in a formulation comprising natural albumin or a fragment thereof.
- variant albumin or fragments thereof, conjugates comprising variant albumin or a fragment thereof or fusion polypeptide comprising variant albumin or a fragment thereof, or an associate comprising variant albumin or a fragment thereof according to the invention may also be incorporated into nano- or microparticles using techniques well known within the art.
- a preferred method for preparing nano- or microparticles that may be applied to the variant albumins or fragments thereof according to the invention is disclosed in WO 2004/071536 or WO2008/007146 or Oner & Groves (Pharmaceutical Research, Vol 10(9), 1993, pages 1387 to 1388) which are incorporated herein by reference.
- a tenth aspect of the invention relates to compositions. Therefore the invention is also directed to the use of a variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, or a conjugate comprising a variant of albumin or a fragment thereof, or an associate comprising a variant of albumin or a fragment thereof for the manufacture of a pharmaceutical composition, wherein the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, or a conjugate comprising a variant of albumin or a fragment thereof, or an associate comprising a variant of albumin or a fragment thereof has an altered binding affinity to FcRn and/or an altered plasma half-life compared with HSA or the corresponding fragment thereof or fusion polypeptide comprising HSA or fragment thereof or conjugate comprising HSA.
- the corresponding fragment of HSA is intended to mean a fragment of HSA that aligns with and has same number of amino acids as the fragment of the variant albumin with which it is compared.
- the corresponding fusion polypeptide comprising HSA or conjugate comprising HSA is intended to mean molecules having same size and amino acid sequence as the fusion polypeptide of conjugate comprising variant albumin, with which it is compared. Further preferences for the tenth aspect of the invention are provided below the thirteenth aspect of the invention.
- An eleventh aspect of the invention relates to a nanoparticle comprising a variant, fusion, conjugate, associate, nanoparticle, composition or polynucleotide as disclosed herein.
- the average diameter of a nano-particle is from 5 to 1000 nm, more preferably 5, 10, 20, 30, 40, 50, 80, 100, 130, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 999 to 5, 10, 20, 30, 40, 50, 80, 100, 130, 150, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nm.
- An advantage of a microparticle less than 200 nm diameter, and more particularly less than 130 nm, is that is amenable to sterilisation by filtration through a 0.2 ⁇ (micron) filter.
- the average diameter of a micro-particle is from 1000 nm (1 ⁇ (micron)) to 100 ⁇ (micron), more preferably from 1 , 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 to 1 , 2, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100 ⁇ (micron).
- a twelfth aspect of the invention relates to use of a variant, fusion, conjugate, associate, nanoparticle, composition or polynucleotide as disclosed herein in a method of treatment or prophylaxis or diagnosis.
- an albumin, variant, fragment, fusion, conjugate or associate or composition thereof having a longer plasma half-life than the reference molecule or composition since this would have the benefit that the administration of the albumin, variant, fragment, fusion, conjugate or associate or composition thereof would be needed less frequently or at a reduced dose (and consequently with fewer side effects) compared to the situation where the reference molecule or composition was used.
- the albumin moiety may comprise one more alterations as disclosed herein.
- a thirteenth aspect of the invention provides a method for altering the half-life of a molecule comprising:
- Examples of 'molecule' include those useful in therapy, prophylaxis (including those used in vaccines either as an active pharmaceutical ingredient or as an excipient), imaging and diagnosis, such as those described herein.
- the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition may have a plasma half-life that is either longer or shorter, preferably longer, than the plasma half- life than a corresponding albumin or a fragment thereof or fusion polypeptides comprising albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition or a binding to FcRn that is stronger or weaker, preferably weaker.
- the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition has a plasma half-life that is longer than the plasma half-life of HSA or the correspondi ng al bum i n or a fragment thereof or fusion polypeptides comprising albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition.
- this may be expressed as the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition having a KD to FcRn (e.g. shFcRn) that is lower that the corresponding KD for HSA to FcRn or the corresponding fragment thereof or fusion polypeptide comprising HSA or fragment thereof.
- a KD to FcRn e.g. shFcRn
- the KD for the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition is less than 0.9X KD for HSA to FcRn, more preferred less than 0.5X KD for HSA to FcRn, more preferred less than 0.1 X KD for HSA to FcRn, even more preferred less than 0.05X KD for HSA to FcRn, even more preferred less than 0.02X KD for HSA to FcRn and most preferred less than 0.01 X KD for HSA to FcRn (where X means 'multiplied by').
- the KD of the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition may be between the KD of WT albumin (e.g. SEQ I D No. 2) for FcRn and the KD of HSA K573P (SEQ I D No. 3) for FcRn.
- WT albumin e.g. SEQ I D No. 2
- HSA K573P SEQ I D No. 3
- Such KDs represent binding affinities that are higher than the binding affinity between HSA and FcRn. A higher binding affinity indicates a longer half-life, for example plasma half-life.
- the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition has a plasma half-life that is shorter than the plasma half-life of H SA o r th e corresponding fragment thereof or fusion polypeptide comprising HSA or fragment thereof.
- Th is may be expressed as the variant of al bu m i n or a fragm ent thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition having a KD to FcRn that is higher that the corresponding KD for HSA to FcRn or the corresponding of albumin or a fragment thereof or fusion polypeptides comprising albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition .
- the KD for the variant of album in or a frag ment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, or a conjugate comprising a variant of albumin or a fragment thereof is more than 2X KD for HSA to FcRn, more preferred more than 5X KD for HSA to FcRn, more preferred more than 10X KD for HSA to FcRn, even more preferred more than 25X KD for HSA to FcRn, even most preferred more than 50X KD for HSA to FcRn.
- the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition may be a null binder to FcRn.
- the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, or a conjugate or nanoparticle or associate or composition comprising a variant of albumin or a fragment thereof is preferably the variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, or a conjugate or nanoparticle or associate or composition comprising a variant of albumin or a fragment thereof according to the invention.
- a lower binding affinity indicates a shorter half-life, for example plasma half-life.
- One advantage of the invention is that it allows the half-life of albumin, a variant of albumin or a fragment thereof or fusion polypeptides comprising variant albumin or fragments thereof, fragment thereof, conjugate, nanoparticle, associate or composition to be tailored in order to achieve a binding affinity or half-life which meets the needs of the user.
- FcRn human FcRn, preferably soluble human FcRn, optionally coupled to a tag such as
- Coupling chemistry amine coupling chemistry (e.g. as described in the protocol provided by the manufacturer of the instrument).
- Coupling method The coupling may be performed by injecting 10 ⁇ g/ml of the protein in 10 mM sodium acetate pH 5.0 (GE Healthcare). Phosphate buffer (67 mM phosphate buffer, 0.15 M NaCI , 0.005% Tween 20) at pH 6.0) may be used as running buffer and dilution buffer. Regeneration of the surfaces may be done using injections of HBS-EP buffer (0.01 M HEPES, 0.15 M NaCI, 3 mM EDTA, 0.005% surfactant P20) at pH 7.4 (Biacore AB).
- test molecule e.g. HSA or variant
- Flow rate of injection constant, e.g. 40 ⁇ /ml
- the invention discloses positions in SEQ ID NO: 2 (and therefore equivalent positions in albumins and fragments from human serum and albumin and non-human serum albumins) which may be altered in order to modulate (increase of decrease) the binding affinity and/or half-life e.g. plasma half-life of an albumin, fragment, fusion, conjugate, associate, nanoparticle or composition.
- An alteration may be a substitution, insertion or deletion. Substitution is preferred.
- a substitution or insertion may or may not comprise introduction of a conserved amino acid, i.e. conserved in relation to the amino acid at the position of interest.
- conserved amino acids are shown by the groups of Fig. 3: aliphatic, aromatic, hydrophobic, charged, polar, positive, tiny and small.
- Preferred positions are those which interact with FcRn during binding and/or affect the interaction of the albumin, fragment, fusion, conjugate, associate, nanoparticle or composition with FcRn.
- Preferred positions correspond to positions in SEQ ID NO: 2 selected from: (a) 492 to 538; (b) 505, 531 , 524, 472, 108, 190, 197 and 425; (c) 186 to 201 ; (d) 457 to 472; (e) 414 to 426; (f) 104 to 120; (g) 75 to 91 ; (h) 144 to 150; (i) 30 to 41 , (j) 550 to 585 and (k) 276, 410 and 414 with one or more (several) of A, C, D, E, F, G, H, I , K, L, M, N, P, Q, R, S, T, V, W, Y and/or a stop codon at a position from 497 to 585;
- the polypeptide comprises one or more (several) alterations selected from (i) the group consisting of positions 417, 464, 492, 493, 494, 495, 496, 499, 500, 501, 503, 504, 505, 506, 510, 535, 536, 537, 538, 540, 550, 573, 574, 575, 577, 578, 579, 580, 581 , 582 and 584, (ii) the group consisting of positions 34, 38, 40, 75, 76, 80, 82, 83, 86, 90, 91, 104, 113, 115, 116, 200, 461, 471, 496, 498, 501, 503, 504, 505, 506, 512, 514, 538, 550, 558, 559, 560, 562, 564, 565, 567, 573, 574, 577, 578, 579, 580, 581, 582, 584, 5
- the polypeptide comprises one or more (several) alterations selected from (ii) the (ii) group consisting of positions 34, 38, 40, 75, 76, 80, 82, 83, 86, 90, 91, 104, 113, 115, 116, 200, 461, 471, 496, 498, 501, 503, 504, 505, 506, 512, 514, 538, 550, 558, 559, 560, 562, 564, 565, 567, 573, 574, 577, 578, 579, 580, 581, 582, 584, 585 (particularly a substitution of one or more (several) of positions 34, 38, 40, 76, 80, 82, 83, 86, 104, 113, 115, 116, 471, 496, 498, 501, 503, 504, 505, 506, 512, 538, 550, 560, 562, 564, 565, 573, 574, 577, 577, 5
- an albumin variant comprises an alteration selected from D63N, E82K, E84K, D87N, L90P, K106E, R1 14G, E1 19K, V146E, H464A, C201 F, D494N, E501 K, E503K, E505K, H510A, I513N, D518N, K525E, E529K, V533M, H535A, K536E, I537N, D550G, D550A, V557M, K560E, D563N, E565K, E570K, K573E, K574N, K574E, K584E, then the alteration is provided in combination with one or more (several) alterations described herein.
- a stop codon may introduced at any of positions 497 to 585, i.e. any of positions 497, 498, 499, 500, 501 , 502, 503, 504, 505, 506, 507, 508, 509, 510, 51 1 , 512, 513, 514, 515, 516, 517, 518, 519, 520, 521 , 522, 523, 524, 525, 526, 527, 528, 529, 530, 531 , 532, 533, 534, 535, 536, 537, 538, 539, 540, 541 , 542, 543, 544, 545, 546, 547, 548, 549, 550, 551 , 552, 553, 554, 555, 556, 557, 558, 559, 560, 561 , 562, 563, 564, 565, 566, 567, 568, 569, 570, 571 , 572, 573, 574,
- amino acid residue of HSA interacting with FcRn is considered to be any amino acid residues of HSA being located less than 10A (for example less than 5A) from an amino acid in the FcRn or any amino acid residue that is involved in a hydrogen bond, a salt bridge or a polar or nonpolar interaction with an amino acid residue that is located less than lOAfrom an amino acid in the FcRn.
- amino acid in HSA residues are located less than lOAfrom amino acids in the FcRn, more preferred less than 6Afrom amino acids in the FcRn and most preferred less than 3A from amino acids in the FcRn.
- amino acids residues of albumin which affect the binding of the albumin to FcRn are located in the binding surface, such as a binding surface defined in Figure 9 (pink (in grey-scale this is seen as the darkest (almost black) region)).
- the amino acids may be in a part of the binding surface provided by domain I or in a part of the binding surface provided by domain III of albumin.
- the one or more (several) alterations may be in domain I , e.g. at positions selected from the group consisting of 30 to 41 , 75 to 91 , 104 to 120, 144 to 150, 186 to 201 .
- the one or more alterations may be in domain II , e.g. position 276.
- the one or more alterations may be in domain I I I , e.g. at positions selected from the group consisting of 414 to 426, 457 to 472, 492- 538, 550 to 585.
- the polypeptide retains substantially the same tertiary structure (or, for a fragment, the relevant part of the structure) as a reference or parent albumin such as HSA.
- a reference or parent albumin such as HSA.
- the skilled person understand the term 'substantially the same tertiary structure' bearing in mind that some degree of variation in tertiary structure is expected as all proteins have some degree of structural flexibility. This applies particularly to polypeptides have a higher binding affinity to FcRn than the parent or reference albumin (e.g. HSA) has to FcRn.
- His residues may or may not be maintained relative to the parent albumin.
- one or more of the following His residues may be maintained: 3, 9, 39, 67, 105, 128, 146, 242, 247, 288, 338, 367, 440, 464, 510, 535.
- One or more, preferably all, of the His residues in domain I are maintained (i.e. 3, 9, 39, 67, 105, 128, 146.).
- One or more, preferably all, of the His residues in domain I I are maintained (i.e. 242, 247, 288, 338, 367).
- One or more, preferably all, of the His residues in domain I I I are maintained (i.e. 440, 464, 510, 535).
- One or more or all three of His 464, 510, 535 may be maintained.
- At least 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 1 1 , 12, 13, 14, 15, 16 or 17 of the disulphide bonds of the albumin are maintained in the polypeptide.
- all disulphide bonds usually present in that albumin are maintained.
- all disulphide bonds usually present in that fragment are maintained.
- Cys-34 (or equivalent in non-human albumins) is maintained.
- an alteration does not comprise substitution with a Cys, insertion of a Cys and/or deletion of a residue which disrupts a disulphide bond and therefore provides an additional conjugatable Cys within the polypeptide.
- the alteration(s) at one or more (several) of positions 75, 90, 91 , 200, 461 , 514, 558, 559 and 567 is not a substitution from Cys to any other amino acid (A, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, W, Y), is not deletion of the Cys, is not substitution or deletion of the disulphide binding partner of that Cys, therefore preferably Cys at one more of positions 53, 62, 75, 90, 91 , 101 , 124, 168, 169, 177, 200, 245, 246, 253, 265, 278, 279, 289, 316, 360, 361 , 369, 392, 437, 438, 448, 461 , 476, 477, 487, 514, 558, 559, 567 are not deleted, substituted and/or subjected to an insertion.
- position 573 (or equivalent thereof) is a
- position 573 is Pro, Trp or Tyr.
- fusion partner polypeptides and/or conjugates may comprise one or more (several) of: 4-1 BB ligand , 5-helix, A h u m an C-C chemokine, A human L105 chemokine, A human L105 chemokine designated huL105_3., A monokine induced by gamma- interferon (MIG), A partial CXCR4B protein, A platelet basic protein (PBP), a1 -antitrypsin, ACRP-30 Homologue; Complement Component C1 q C, Adenoid-expressed chemokine (ADEC), aFGF; FGF-
- AGF AGF Protein
- albumin an etoposide
- angiostatin Anthrax vaccine
- Antibodies specific for collapsin, antistasin, Anti-TGF beta family antibodies antithrombin III, APM-1 ; ACRP-30; Famoxin, apo-lipoprotein species, Arylsulfatase B, b57 Protein, BCMA, Beta-thromboglobulin protein (beta- TG), bFGF
- FGF2 Blood coagulation factors, BMP Processing Enzyme Furin, BMP-10, BMP-12, BMP-15, BMP-17, BMP-18, BMP-2B, BMP-4, BMP-5, BMP-6, BMP-9, Bone Morphogenic Protein-
- Chemokine hl L-8 Chemokine hMCP1 , Chemokine hMCPI a, Chemokine hMCPI b, Chemokine hMCP2, Chemokine hMCP3, Chemokine hSDFI b, Chemokine MCP ⁇ l, chemokine TECK and TECK variant, Chemokine-like protein I L-8M1 Full- Length and Mature, Chemokine-like protein I L-8M 10 Full-Length and Mature, Chemokine-like protein IL-8M3, Chemokine-like protein IL-8M8 Full-Length and Mature, Chemokine-like protein IL- 8M9 Full-Length and Mature, Chemokine-like protein PF4-414 Full-Length and Mature, Chemokine- like protein PF4-426 Full-Length and Mature, Chemokine-like protein PF4-M2 Full-Length and Mature,
- IL-1 i IL-1 mature, IL-10 receptor, IL- , IL- , IL-12 p40 subunit., IL-13, IL-14, IL-15, IL-15 receptor, IL- 17, IL-17 receptor, 11-17 receptor, 11-17 receptor, IL-19, IL-1 i fragments, IL1 -re
- IL-3 mutant proteins IL-3 variants, IL-3 variants, IL-4, IL-4 mutein, IL-4 mutein Y124G, IL-4 mutein Y124X, IL-4 muteins, II-5 receptor, IL-6, II-6 receptor, IL-7 receptor clone, I L-8 receptor, I L-9 mature protein variant (Met1 17 version), immunoglobulins or immunoglobulin-based m olecu les or fragment of either (e.g.
- SMIP Small Modular ImmunoPharmaceutical
- dAb Fab' fragments, F(ab')2, scAb, scFv or scFv fragment
- I P-10 Interferon gamma-inducible protein
- interferons such as interferon alpha species and subspecies, interferon beta species and sub-species, interferon gamma species and sub-species
- interferons such as interferon alpha species and sub-species, interferon beta species and sub-species, interferon gamma species and sub-species
- interferons such as interferon alpha species and sub-species, interferon beta species and subspecies, interferon gamma species and sub-species
- Interleukin 6, Interleukin 8 (IL-8) receptor I nterleukin 8 receptor B , I nterleukin 8 (IL-8) receptor, I nterleukin 8 receptor B , I nter
- interleukin-9, lnterleukin-9 (I L-9) mature protein Thr1 17 version
- interleukins such as I L10, IL1 1 and IL2
- interleukins such as IL10, IL1 1 and IL2
- Japanese encephalitis vaccine Kalikrein Inhibitor, Keratinocyte growth factor, Kunitz domain protein (such as aprotinin, amyloid precursor protein and those described in WO 03/066824, with or without albumin fusions), Kunitz domain protein (such as aprotinin, amyloid precursor protein and those described in WO 03/066824, with or without albumin fusions), LACI, lactoferrin, Latent TGF-beta binding protein II, leptin, Liver expressed chemokine-1 (LVEC-1 ), Liver expressed chemokine-2 (LVEC-2), LT-alpha, LT-beta, Luteinization Hormone, Lyme Vaccine, Lymphot
- anticalin(s), adnectin(s), fibrinogen fragment(s), nanobodies such as camelid nanobodies, infestin, and/or any of the molecules mentioned in WO01/79271 (particularly page 9 and/or Table 1 ), WO 2003/59934 (particularly Table 1 ), WO03/060071 (particularly Table 1 ) or WO01/079480 (particularly Table 1 ) (each incorporated herein by reference in their entirety).
- conjugates may comprise one or more (several) of chemotherapy drugs such as: 13-cis-Retinoic Acid, 2-CdA, 2-Chlorodeoxyadenosine, 5-Azacitidine, 5-Fluorouracil, 5-FU, 6- Mercaptopurine, 6-MP, 6-TG, 6-Thioguanine, A, Abraxane, Accutane ® , Actinomycin-D, Adriamycin ® , Adrucil ® , Agrylin ® , Ala-Cort ® , Aldesleukin, Alemtuzumab, ALIMTA, Alitretinoin, Alkaban-AQ ® , Alkeran ® , All-transretinoic Acid , Al pha I nterferon, Altretamine, Amethopterin, Amifostine, Aminoglutethimide, Anagrelide, Anandron ® , Anastrozole, Arabinosylcytosine, Ara-
- Paclitaxel or Paclitaxel Protein-bound Pamidronate, Panitumumab, Panretin ® , Paraplatin ® , Pediapred ® , PEG Interferon, Pegaspargase, Pegfilgrastim, PEG-INTRONTM, PEG-L-asparaginase, PEMETREXED, Pentostatin, Phenylalanine Mustard, Platinol ® , Platinol-AQ ® , Prednisolone, Prednisone, Prelone ® , Procarbazine, PROCRIT ® , Proleukin ® , Prolifeprospan 20 with Carmustine Implant, Purinethol ® , R, Raloxifene, Revlimid ® , Rheumatrex ® , Rituxan ® , Rituximab, Roferon-A ® (Interferon Alfa-2a), Rubex ® , Rubidomycin hydrochloride, Sando
- fusion partners, conjugation partners and/or molecules for inclusion in a nanoparticle, associate or composition according to the invention include: acromegaly drugs e.g. somatuline, lanreotide, octreotide, Sandostatin; antithrombotics e.g. bivalirudin, Angiomax, dalteparin, Fragmin, enoxaparin, Lovenox, Drotrecogin alfa (e.g. Activated), Xigris, heparin; assisted reproductive therapy compounds e.g. choriogonadotropin, Ovidrel, follitropin, alpha/beta; enzymes e.g.
- acromegaly drugs e.g. somatuline, lanreotide, octreotide, Sandostatin
- antithrombotics e.g. bivalirudin, Angiomax, dalteparin, Fragmin, enoxaparin
- hyaluronidase Hylenex
- diabetes drugs e.g. exenatide, Byetta, glucagon, insulin, liraglutide, albiglutide, GLP-1 agonists, exendin or an exendin analog
- compounds useful in diagnosis e.g. protirelin, Thyrel TRH Thypinone, secretin (e.g. synthetic human), Chirhostim, thyrotropin (e.g. alpha), Thyrogen' erythropoiesis drugs e.g. Darbepoetin alfa, Aranesp, Epoetin alfa, Epogen, Eprex, drugs for the treatment of genetic defects e.g.
- pegademase drugs for the treatment of growth failure e.g. Adagen, mecasermin, rinfabate, drugs for the treatment of cystic fibrosis e.g. Dornase alfa, Pulmozyme, drugs for the treatment of metaoblic disorders e.g. Agalsidase beta, Fabrazyme, alglucosidase alpha, Myozyme, Laronidase, Aldurazyme, drugs for the treatment of genital wart intralesional e.g. Interferon alfa-n3, Alferon N, drugs for the treatment of granulomatous disease e.g.
- Interferon gamma-1 b Actimmune; drugs for the treatment of growth failure e.g. pegvisomant, Somavert, somatropin, Genotropin, Nutropin, Humatrope.Serostim, Protropin; drugs for the treatment of heart failure e.g. nesiritide, Natrecor; drugs for the treatment of hemophilia e.g. a coagulation factor e.g. Factor VI I I , Helixate FS, Kogenate FS, Factor IX, BeneFIX, Factor Vi la, Novoseven, desmopressin, Stimate, DDAVP; hemopoetic drugs e.g.
- growth failure e.g. pegvisomant, Somavert, somatropin, Genotropin, Nutropin, Humatrope.Serostim, Protropin
- drugs for the treatment of heart failure e.g. nesiritide, Natrecor
- G-CSF Filgrastim
- Neupogen Oprelvekin
- Neumega Pegfilgrastim
- Neulasta Sargramostim
- Leukine drugs for the treatment of hepatitis C e.g. Interferon alfa-2a, Roferon A, Interferon alfa-2b, Intron A, Interferon alfacon-1 , Infergen, Peginterferon alfa-2a, Pegasys, Peginterferon alfa-2b, PEG-lntron
- drugs for the treatment of HIV e.g. enfuvirtide, Fuzeon
- Fabs e.g.
- Fab antithrombin
- Abciximab ReoPro
- monoclonal antibodies e.g. Daclizumab, Zenapax
- antiviral monoclonal antibodies e.g. Palivizumab, Synagis
- monoclonal antibodies for the treatment of asthma e.g. Omalizumab, Xolair
- monoclonal antibodies for use in diagnostic imaging e.g. Arcitumomab, CEA- Scan, Capromab Pendetide, ProstaScint, Satumomab Pendetide, OncoScint CR/OV
- Fabs for use in diagnostic imaging e.g.
- Nofetumomab, Verluma iimmuno-supressant monoclonal antibodies e.g. Basiliximab, Simulect, Muromonab-CD3, Orthoclone OKT3; monoclonal antibodies for the treatment of malignancy e.g. Alemtuzumab, Campath, Ibritumomab tiuxetan, Zevalin, Rituximab , Rituxan, Trastuzumab, Herceptin; monoclonal antibodies for the treatment of rheumatoid arthritis (RA) e.g.
- RA rheumatoid arthritis
- MS multiple sclerosis
- palifermin, Kepivance drug for the treatment of dystonia e.g., neurotoxin, Botulinum Toxin Type A, BOTOX, BOTOX Cosmetic, Botulinum Toxin Type B, MYOBLOC; drugs for the treatment of osteoporosis e.g. teriparatide. Forteo; drugs for the treatment of psoriasis e.g. Alefacept, Amevive; drugs for the treatment of RA e.g. abatacept, Orencia, Anakinra, Kineret, Etanercept, Enbrel; thrombolytics e.g.
- Alteplase Activase, rtPA, Anistreplase, Eminase, Reteplase, Retavase, Streptokinase, Streptase, Tenecteplase, TNKase, Urokinase, Abbokinase, Kinlytic; drugs for the treatment of osteoporosis e.g. calcitonin (e.g. salmon), Miacalcin, Fortical, drugs for the treatment of skin ulcers e.g. Becaplermin, Regranex, Collagenase, Santyl.
- drugs for the treatment of osteoporosis e.g. calcitonin (e.g. salmon), Miacalcin, Fortical, drugs for the treatment of skin ulcers e.g. Becaplermin, Regranex, Collagenase, Santyl.
- Such polypeptides and chemical compounds may be referred to as diagnostic moieties, therapeutic moieties, prophylactic moieties or beneficial moieties.
- the fusion partner and/or conjugation partner is not an albumin, variant or fragment thereof.
- One or more (several) therapeutic or prophylactic polypeptides may be fused to the N- terminus, the C-terminus of albumin , inserted into a loop in the albumin structure or any combination thereof. It may or it may not comprise linker sequences separating the various components of the fusion polypeptide.
- Variants of albumin were prepared using techniques known to the skilled person, for example using the methods of WO201 1/051489 (PCT/EP10/066572) or by PCR using mutagenic oligonucleotide primers.
- Production of shFcRn The construction and production of recombinant variants of shFcRn, such as GST-tagged shFcRn, have previously been described (36).
- HIS-tagged shFcRn heterodimer was prepared as described in WO201 1/124718.
- ELISA using microtiter plates coated with HSA variants.
- GST-tagged shFcRn and horse radish peroxidase conjugated goat anti GST antibody was carried out according to Andersen et al (2012; Nature Communications 3:610; DOI: 10.1038/ncomms1607).
- Kinetic measurements were performed by injecting serial dilutions of HSA variants (80- 0.1 ⁇ ) at 25 °C at a flow rate of50 ⁇ /min . In all experiments, data were zero adjusted, and the reference cell value was subtracted. Kinetic rate values were calculated using predefined models (Langmuir 1 : 1 ligand model and steady-state affinity model) provided by using the BIAevaluation 4.1 software. Competitive binding was measured by injecting shFcRn (100 nM) alone or together with titrated amounts of HSA variants (1 000-0.015 nM ) over immobilized HSA (-2000-2500 R U ) .
- the percentage (%) binding of shFcRn to HSA immobilised on the chip was calculated by dividing the total SPR response given by injecting the shFcRn alone by the response when pre-incubated with HSA variant. Circular dichroism spectroscopy
- Circular dichroism (CD) spectra were recorded using a Jasco J-810 spectropolarimeter (Jasco International Co. , Ltd., Tokyo Japan) calibrated with ammonium d-camphor-10-sulfonate (lcatayama Chemicals, Tokyo Japan). All measurements were performed with a HSA concentration of 2 mg ml "1 in 10 mM PBS (pH 6.0) without NaCI added, at 23°C using a quartz cuvette (Starna, Essex, UK) with a path length of 0.1 cm. Each sample was scanned 7 times at 20 nm min " (band width of 1 nm) at a response time of 1 s, and the wavelength range was set to 190-260 nm.
- the collected data were averaged and the spectrum of a sample-free control was subtracted.
- the content of secondary structural elements was calculated after smoothing (means-movement, convolution width 5) from ellipticity data, using the neural network program CDNN version 2.1 and the supplied neural network based on the 33-member basis set (Bohm etl al (1992) Protein Eng 5, 191-195).
- HSA and shFcRn were generated using the ZDOCK Fast Fourier Transform based protein docking progra m (Chen R et al (2003) Proteins 52(1 ):80-87).
- the coordinates for HSA DIM (residues 382-582) were retrieved from the crystal structure of HSA at 2.5A (PDB code 1 bm0 (Sugio S et al (1999) Protein Eng 12(6):439-446).
- the software returned one model for the docking of sub-domain DIM against shFcRn with an ordered loop at pH 4.2 and eight models for shFcRn at pH 8.2, lacking loop residues 52-59.
- eight models five evidently showed erroneous (incompatible) poses as judged by the position of HSA domains Dl and DM , and were rejected.
- the three remaining models were closely related and had the same general structural pose.
- Superposition of the low pH form of FcRn on these then showed that the structured loop made no severe conflicts with the docked HSA.
- the final selected model (coordinates are shown in Fig. 18 and 19) reveals interaction areas that fit very well with the obtained binding data (Fig. 8A).
- the long loop between sub-domains Dll la and Dl llb (490-510) as well as the C-terminal part (last C-terminal a-helix) of HSA form a crevice on the surface of HSA into which the pH-dependent and flexible loop in shFcRn (residues 51 -60) may bind (Fig. 8S).
- sh FcRn reveals that His-166 stabilizes the loop through intramolecular interaction with Glu-54 (Fig. 7A), however the docking model suggests that His-166 may additionally be engaged in binding to Glu-505 of HSA (Fig. 8S).
- Glu-505 may also interact with Arg- 162 of the receptor.
- His-510 A key role of His-510 is supported by the fact that it is predicted to interact with Glu-54 within the pH-dependent a1 -domain loop (Fig. 8S). Mutation of His-510 (H510Q) reduced binding by 14-fold (Fig. 3c, Table 1 ). Thus, His-166 in hFcRn and His-510 in HSA seem to be involved in regulating an ionic network in the core of the hFcRn-HSA interaction interface.
- the model also predicts possible salt-bridges between Lys-150 and Glu-151 of shFcRn with
- Glu-501 and Lys-500 of HSA respectively (Fig. 8S). This is in line with the binding data that show reduced binding capacity of HSA variants mutated at these positions (Fig. 6S). Furthermore, the model proposes a key role of the alpha helix at the C-terminal end of HSA. This is supported by the fact that deletion of the last 17 amino acids of Dl llb almost eliminated binding to shFcRn (Fig. 14).
- the HSA-shFcRn complex could further be reinforced by a salt-bridge formed between Glu-168 of shFcRn and Lys-524 of DI M , a prediction that is supported by the fact that mutation of Glu-168 moderately reduces binding to HSA (Fig. 15).
- His-535 may interact favorably with Phe-157 while His-464 is localized close to a ⁇ -hairpin within FcRn encompassing residues 99-102 that is wedged in-between domains Dl and the sub-domain Dllla in HSA (Fig. 8C).
- shFcRn Asp-101 has several possible partners in Dl such as Arg-197 and Lys-190, however, they must necessarily undergo some conformational chang es i n o rder to get close to Asp-101.
- the ⁇ -hairpin has two different conformations, depending on the pH (West et al (2000)). This suggests that Asp-101 is indeed located in a flexible element of shFcRn.
- the MHC class l-related FcRn has evolved to protect IgG and albumin from catabolism (5,
- HSA polymorphisms may affect receptor binding and consequently their levels in blood.
- Introduction of the mutation in rabbit albumin resulted in a variant with 50% reduction in half-life when injected into rabbits (24).
- a HSA variant mimicking Casebrook was prepared (WO201 1/051489 (PCT/EP10/066572), incorporated herein by reference) and was found that it had a 2-fold reduction in affinity for shFcRn.
- the docking model suggests that several residues in the C-terminal end of the loop are in direct contact with the a1-a2-platform of the receptor, with predicted key residues being His-510 and Glu-505 on HSA, as well as Glu-54 on shFcRn.
- His-510 is one of the three conserved histidine residues, and mutation of this residue (i.e. H510Q) reduced binding to shFcRn significantly.
- His-535 may reinforce the HSA-FcRn complex by aromatic stacking or stabilization of the loop between sub-domains Dl I la and Dl l lb in HSA.
- His-464 may interact, directly or indirectly, with a flexible ⁇ -hairpin element in FcRn.
- this ⁇ -hairpin loop is the most flexible part in FcRn, except for the pH- dependent loop stabilized by His-166, as judged by a comparison of the low and high pH crystal structures.
- the flexible ⁇ hairpin loop is the most flexible part in FcRn, except for the pH-dependent loop stabilized by His-166, as judged by a comparison of the low and high pH crystal structures.
- albumin The principal function of albumin is to transport fatty acids that are bound asymmetrically to hydrophobic pockets within or between the three domains (1 , 26, 27).
- HSA DIM harbors two high affinity binding sites, and the fatty acids bind close to the loop between HSA Dllla and Dlllb, which also includes several residues found to affect FcRn binding.
- Comparison of the fatty acid bound and the free state of HSA (19, 27) shows no substantial rearrangements within sub-domain DIM of HSA upon binding, but a considerable shift in orientation of HSA Dl relative to HSA DIN (Fig. 17). In effect, superposition of DIM in the fatty acid binding HSA onto the corresponding FcRn-binding domain in the docking model reveals that Dl may move away from FcRn when binding fatty acids.
- FcRn The half-life regulatory function of FcRn may be utilized for therapeutic and diagnostic purposes, as discussed elsewhere (28, 29).
- bioactive peptides and small proteins obtained from combinatorial libraries or molecular engineering are promising candidates, however, they (and all drugs) may fail to show convincing effects in vivo due to very short half-lives as a consequence of their size being below the renal clearance threshold as well as susceptibility to degradation by proteases (30, 31 ). This limits transition of such molecules from lead candidate to a drug(s) on the market.
- a solution to these obstacles may be to take advantage of the prolonged half-life of IgG or albumin controlled by FcRn.
- genetic fusion of therapeutic proteins to the IgG Fc or HSA improves bio-distribution and pharmacokinetics (29).
- the serum half-life of IgG may also be extensively improved beyond that evolved by nature. This is an intense area of research that has generated engineered IgG variants with point mutations in their Fc portion resulted in improved pH-dependent FcRn binding, and consequently extended half-life in vivo (4, 5, 32). No examples have so far been presented for albumin, except for the observation that mouse albumin binds much stronger to shFcRn than HSA (21 ). The docking model presented in this study may guide the development of novel HSA variants with increased serum half-life, which could be attractive for delivery of both chemical and biological drugs.
- WO201 1/051489 shows that a given position of albumin (e.g. position 573 of HSA) can be substituted by any other amino acid to alter the binding affinity for FcRn.
- alteration of a signal position provides a group of albumin variants having binding affinity different to the binding affinity of the parent albumin (WT HSA, SEQ I D NO: 2).
- WT HSA parent albumin
- SEQ I D NO: 2 For position 573, all variants showed improved binding to shFcRn compared with WT HSA.
- the variants K573F, K573H, K573P, K573W and K573Y had a more than 10 fold lower KD to shFcRn than the parent HSA.
- the variant K573STOP is a truncated albumin having a stop codon in position 573 and has significantly reduced binding compare to WT HSA.
- Example 2 Identification of the regions of HSA that are required for optimal binding to FcRn and therefore whose alteration will alter binding affinity between FcRn and albumin.
- DIM is involved in pH dependent binding to FcRn
- Albumin consists of three homologous domains (Dl , DM and DI M ), comprising a-helices stabilized by a complex network of twelve cysteine residues forming six disulfide bridges (19). The three domains are linked by loops and form a heart shaped structure (Fig. AB).
- DI M of albumin Two previous studies have pointed to DI M of albumin as being important for FcRn binding (2, 17). To confirm this and further investigate how each individual domain contributes to the FcRn binding site, several domain variants (DI-DI II , DI I-DI M, DI-DII , DI N) as well as full length HSA (Fig. AC) were produced in yeast (Fig. AD).
- Table 2a SPR-derived kinetics for binding of HSA variants to shFcRn-GST.
- HSA is normally non-glycosylated, but a few exceptions exist due to rare polymorphisms (16).
- One such variant (Casebrook) has a single nucleotide substitution that changes the coding from Asp to Asn at amino acid residue 494 (20), localized in the stretch of amino acids (residue 490-510) that form a long loop connecting the sub-domains Dl l la and Dl l lb (Fig. 5A and QA).
- This natural polymorphism introduces a glycosylation motif ( 494 Asn-Glu-Thr 496 ) and attachment of an relinked oligosaccharide.
- Histidine residues are key players in the strictly pH-dependent IgG- FcRn interaction (4, 5), the role of the four histidine residues found within HSA DIM were assessed. Of these, three are highly conserved across species (His-464, His-510 and His-535) and one is not (His-440) ( Figure 2). While His-440 and His-464 are found within sub-domain Dl I la, His-51 0 is localized to the end of the loop connecting sub-domains Dl l la and Dl l lb, and His-535 is found in one of the a-helices of D l l l b (Fig. 6A). All four histidine residues were mutated individually to glutamine (Fig .
- Glu-54 is also involved in an interaction with Gln-56 (Fig. 7A). To address the importance of
- Glu-54 and Gln-56 both residues were individually mutated to glutamine or alanine, respectively, and the two resulting receptor variants (shFcRn E54Q and shFcRn Q56A) were tested for binding to HSA by ELISA at pH 6.0 (using the method described in WO201 1/051489 (PCT/EP10/066572), incorporated herein by reference).
- the impact of the E54Q mutation was striking, as almost no receptor binding to HSA was detected, whereas the Q56A variant partially lost binding to HSA (Fig. 7C).
- albumin variants are named such that 'HSA 585stop' is an HSA variant in which the native amino acid at position 585 is substituted with a stop codon.
- oligonucleotides xAP314 and xAP307 were used to amplify a 493 bp fragment from pDB3927, containing DNA sequence encoding HSA D I M , according to the manufacturer's instructions.
- a stop codon was engineered into oligonucleotide xAP307 so that translation of the DNA sequence encoding HSA terminated following amino acid 567.
- the PCR fragment was digested with AvMBsu36 ⁇ purified using a Qiagen PCR-clean up kit (according to the manufacturer's instructions) and ligated into / i rll/Sstv36l-digested pDB3927. Ligations were transformed into E.
- HSA572stop and HSA574stop to HSA581 stop expression constructs were made in the same manner as the HSA568stop construct using the oligonucleotides (Table 5) to produce plasmids pDB4548 to pDB4556 (Table 4).
- HSA582stop to HSA585stop constructs (1 .122kb) fragments were PCR amplified from pDB3927 using oligonucleotides (Table 5). The PCR-fragments were each digested with Bgl ⁇ IHind ⁇ isolated and ligated into pDB2923 (Finnis, C. J. et al. (2010). High-level production of animal-free recombinant transferrin from Saccharomyces cerevisiae. Microb Cell Fact 9, 87) to produce plasmids #10D, #1 1 B, #12C and #13D, respectively.
- Plasmids #10D to #13D were digested with AvMSph ⁇ and 666bp fragments (containing the DNA encoding the C-terminal end of albumin) were isolated from each and ligated into / i/rll/Spfrl-digested pDB3927 to produce the gap- repair constructs pDB4544 - pDB4547, respectively (Table 4).
- Plasmids pDB4544 - pDB4557 were digested with Nsi ⁇ /Pvu ⁇ , the DNA was purified (Qiagen PCR Purification kit as per the manufacturer's instructions), before being used, along with /Acc65l/SamHI-digested pDB3936, to co-transform S. cerevisiae BXPI Ocir 0 as described above generating expression plasmids in the yeast by gap-repair. Stocks were prepared for each resultant yeast strain.
- Table 6 SPR-derived kinetics for binding of HSA truncation variants to shFcRn-GST.
- HSA mutants were generated by PCR and gap-repair. This was achieved by generating PCR products using Phusion Polymerase (New England Biolabs), according to the manufacturer's instruction, using pDB3927 as a template and oligonucleotides (Table 7 and 8). Each PCR-fragment was digested with AvN/Bsu36 ⁇ , purified (Qiagen PCR-clean up kit (accordi ng to the man ufactu rer's instructions)) and ligated into /Ai rll/Sstv36l-digested pDB3927. Ligations were transformed into E. coli DH5a, subsequently plasmids were isolated from transformants (Qiagen miniprep kit (according to the manufacturer's instructions)) and the correct constructs were identified by sequencing.
- Plasmids, pDB4535 to pDB4537, containing the desired substitutions (Table 7) were digested with Nsi ⁇ /Pvu ⁇ , the D NA was pu rified (Qiagen PCR Purification kit as per the manufacturer's instructions), before being used, along with /Acc65l/SamHI-digested pDB3936, to co-transform S. cerevisiae BXP10cir° as described above generating expression plasmids in the yeast by gap-repair. Stocks were prepared for each resultant yeast strain as described above.
- Table 9 SPR-derived kinetics for binding of HSA variants to shFcRn-GST.
- Variants of albumin were generated according to the methods below.
- HSA variants were expressed using several standard molecular biology techniques, such as described in Sambrook, J. and D.W. Russell, 2001 (Molecular Cloning: a laboratory manual, 3 rd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y). Described below are two methods employed to introduce mutations within the HSA sequence, depending on the proximity of suitable restriction sites in the plasmid encoding WT HSA, pDB3964 (described in WO2010/092135, incorporated herein by reference).
- Method 1 Where restriction sites proximal to the desired mutation existed, mutagenic oligonucleotides were designed, incorporating both the desired change and relevant restriction sites (Tables 10 and 1 1 ).
- the relevant primers were employed in the PCR reaction (described in Tables 12 and 13), utilising the New England Biolabs Phusion kit and pDB3964 as template.
- the resulting products were purified (QIAquick PC R Purification Kit, according to the manufacturer's instructions).
- the products were digested with appropriate restriction enzymes (Table 10) and purified (QIAquick Gel Extraction Kit (according to the manufacturer's instructions)).
- the resulting fragments were ligated into appropriately digested pDB3964 such that the WT HSA sequence was substituted with the HSA sequence containing the desired mutation.
- Ligations were transformed into E. coli DH5a cells and plasmids were isolated (Qiagen Plasmid Plus Kit (according to the manufacturer's instructions)). All plasmids were sequenced to confirm that the HSA sequence was only mutated at the desired position(s).
- Table 10 Plasmid and amino acid substitution and relevant primers (see also Table 2)
- XAP445 CATTTGGATCCCACTTTTCCTAGGTTTCTTGAGACAGCTACAAGAGTTGG 107
- XAP481 ATAAGCCTAAGGCAGCTTGACTTGCAGCAACAAGTTTTTTACCCTCCTCAA 125
- the ligated plasmids were transformed into E. coli DH5a cells and plasmids were isolated (Qiagen Plasmid Plus Kit (according to the manufacturer's instructions)). All plasmids were sequenced to confirm that the HSA sequence was only mutated at the desired position(s). Table 14: Plasmid and amino acid substitution
- Combination mutants were produced to combine a subset of the mutations described in Tables 10 and 14 with the HSA K573P variant (plasmid pDB41 10).
- the 0.358kb fragment encoding the K573P variant DNA was isolated from plasmid pDB41 10 by digestion with the Sac ⁇ /Sph ⁇ restriction enzymes, purified using a QIAquick Gel Extraction Kit and ligated into pDB4704, pDB4716 and pDB4753 (see Table 10) digested with the same enzymes, to produce HSA variants E505Q/K573P, E425A/K573P and T527M/K573P, respectively.
- combination mutants were prepared by digestion of pDB41 10 with the Nae ⁇ /Nco ⁇ restriction enzymes, isolation as described above and ligation of equivalent fragments from pDB4745, pDB4746 and pDB4747 (described in Table 14) to produce combination mutants N 1 1 1 D/K573P, N 1 1 1 G/K573P and N1 1 1 H/K573P, respectively.
- synthetic DNA was produced containing both desired mutations by gene assembly (GeneArt, Life Technologies). The fragment was digested via the Sal ⁇ /Bsu36 ⁇ restriction sites, isolated as described above and ligated into appropriately digested pDB3964.
- N1 1 1 R/K573P, N1 1 1 Q/K573P and N 1 1 1 E/K573P fragments containing the N 1 1 1 mutations were removed from GeneArt constructs via the Sac ⁇ /Nhe ⁇ restriction sites and cloned into appropriately digested pDB3964 containing the Sac ⁇ /Sph ⁇ fragment of pDB41 10, encoding the K573P mutation (designated pDB4852) as described above.
- the ligated plasmids were transformed into E. coli cells and plasmids were then isolated (Qiagen Plasmid Plus Kit (according to the manufacturer's instructions)). All plasmids underwent sequencing to confirm that the HSA sequence was only mutated at the desired positions.
- Stocks were prepared either by the 48 hour method described above (pDB4703-pDB4720, pDB4737-pDB4756, pDB4849-pDB4855) or the 24 hour method described in WO 201 1 /051489 (pDB4860-pDB4876), with the modification that BMMS broth (0.17% (w/v) yeast nitrogen base without amino acid and ammonium sulphate (Difco), 37.8mM ammonium sulphate, 36 mM citric acid, 126mM disodium hydrogen orthophosphate pH6.5, 2% (w/v) sucrose, adjusted to pH 6.5 with NaOH) was used in both cases.
- BMMS broth 0.17% (w/v) yeast nitrogen base without amino acid and ammonium sulphate (Difco)
- 37.8mM ammonium sulphate 36 mM citric acid, 126mM disodium hydrogen orthophosphate pH6.5, 2% (w/v) sucrose, adjusted to pH 6.5 with Na
- Chip surface was left to stabilize with a constant flow (5 ⁇ _/ ⁇ ) of running buffer - HBS-EP buffer (0.01 M HEPES, 0.15 M NaCI, 3mM EDTA, 0.005% surfactant P20) at pH 7.4 (GE Healthcare)) ) at 25 °C for ⁇ 1 -2hours.
- the chip surface was primed (x2) with Di-basic/Mono-basic phosphate buffer pH5.5 and conditioned by injecting 5-12 x 45 ⁇ _ Di-basic/Mono-basic phosphate buffer at 30 ⁇ _/ ⁇ followed by HBS_EP regeneration steps (12s) in between each injection.
- the variants were albumin (SEQ ID NO: 2), each with one point mutation selected from: D108A, N1 1 1 D, N1 1 1 G, N1 1 1 H, N1 1 1 K, K190A, R197A, K276N, R410A, Y41 1A, P416A, E425A, E425K, K466A, D471A, R472A, N503D, N503K, E505K, E505Q, H510D, H510E, D512A, D512E, K524A, K525A, T527A, T527D, T527M, E531A, E531 H, K534V, H535F, E565V, A569L, A569S, A569V, and V576F.
- variants were analysed by SPR to determine their binding response (RU) to shFcRn. Only variants showing a binding response more than 20% higher or lower than the binding response of wild-type albumin were analysed to identify the KD (Table 18, below). Wild-type HSA and HSA with mutation K573P were used as controls.
- variants with a lower KD than wild-type HSA have a higher binding affinity to shFcRn
- variants with a higher KD than wild-type HSA have a lower binding affinity to shFcRn.
- the data for positions 108 and 111 support the involvement of a loop including positions 105 to 120 in interaction with FcRn and therefore predicts that alteration at any position within this loop will modulate the binding affinity of albumin to FcRn.
- Example 7 SPR analysis of binding affinity of albumin variants to shFcRn-HIS
- the variants were albumin (SEQ ID NO: 2), each with one point mutation selected from: N111D, N111G, N111H, N111D/K573P, N111G/K573P, N111H/K573P, E505Q, E425A, T527M, E505Q/K573P, E425A/K573P and T527M/K573P were prepared as described above.
- variants with a lower KD than wild-type HSA have a higher binding affinity to shFcRn.
- variants with a higher KD than wild-type HSA have a lower binding affinity to shFcRn.
- the variants were albumin (SEQ I D NO: 2), each with one point mutation selected from: N1 1 1 R, N1 1 1 Q, N1 1 1 E, N1 1 1 R/K573P, N1 1 1 Q/K573P, N1 1 1 E/K573P, N109D, N109E, N109Q, N 109R, N 109K, N 109H, N 109G, D108E, T83N, L575F and K534V/K573P were prepared as described above.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims
Priority Applications (31)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2830660A CA2830660A1 (en) | 2011-05-05 | 2012-05-04 | Albumin variants |
MX2013012358A MX353816B (en) | 2011-05-05 | 2012-05-04 | Albumin variants. |
BR112013028536A BR112013028536A2 (en) | 2011-05-05 | 2012-05-04 | albumin variants |
KR1020137031062A KR20140027307A (en) | 2011-05-05 | 2012-05-04 | Albumin variants |
RU2013153816A RU2650784C2 (en) | 2011-05-05 | 2012-05-04 | Versions of albumin |
EP12718995.9A EP2705051A1 (en) | 2011-05-05 | 2012-05-04 | Albumin variants |
CN201280033529.2A CN104011072B (en) | 2011-05-05 | 2012-05-04 | albumin variants |
AU2012251583A AU2012251583B2 (en) | 2011-05-05 | 2012-05-04 | Albumin variants |
JP2014508813A JP6430828B2 (en) | 2011-05-05 | 2012-05-04 | Albumin variant |
JP2014561473A JP6441682B2 (en) | 2012-03-16 | 2013-03-15 | Albumin variant |
CA2861592A CA2861592A1 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
EP13709457.9A EP2825556B1 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
EP17209116.7A EP3330283A3 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
CN201380011295.6A CN104736559B (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
PCT/EP2013/055487 WO2013135896A1 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
AU2013234299A AU2013234299B2 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
MX2014010278A MX2014010278A (en) | 2012-03-16 | 2013-03-15 | Albumin variants. |
BR112014018679A BR112014018679A2 (en) | 2012-03-16 | 2013-03-15 | albumin variants |
ES13709457.9T ES2664328T3 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
PL13709457T PL2825556T3 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
KR1020147024412A KR20140136934A (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
DK13709457.9T DK2825556T3 (en) | 2012-03-16 | 2013-03-15 | albumin Variants |
US14/385,631 US9944691B2 (en) | 2012-03-16 | 2013-03-15 | Albumin variants |
IL228737A IL228737B (en) | 2011-05-05 | 2013-10-06 | Albumin variants |
ZA2013/08255A ZA201308255B (en) | 2011-05-05 | 2013-11-04 | Albumin variants |
IL233689A IL233689A0 (en) | 2012-03-16 | 2014-07-17 | Albumin variants |
AU2017225014A AU2017225014A1 (en) | 2011-05-05 | 2017-09-05 | Albumin variants |
AU2017228726A AU2017228726A1 (en) | 2012-03-16 | 2017-09-18 | Albumin variants |
US15/915,977 US10329340B2 (en) | 2012-03-16 | 2018-03-08 | Albumin variants |
JP2018057628A JP6657284B2 (en) | 2012-03-16 | 2018-03-26 | Albumin variant |
US16/403,862 US20190315836A1 (en) | 2012-03-16 | 2019-05-06 | Albumin variants |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11164991.9 | 2011-05-05 | ||
EP11164991 | 2011-05-05 | ||
EP11185064 | 2011-10-13 | ||
EP11185064.0 | 2011-10-13 | ||
EP12160007 | 2012-03-16 | ||
EP12160007.6 | 2012-03-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012150319A1 true WO2012150319A1 (en) | 2012-11-08 |
Family
ID=46027974
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2012/058206 WO2012150319A1 (en) | 2011-05-05 | 2012-05-04 | Albumin variants |
Country Status (14)
Country | Link |
---|---|
US (3) | US8822417B2 (en) |
EP (1) | EP2705051A1 (en) |
JP (1) | JP6430828B2 (en) |
KR (1) | KR20140027307A (en) |
CN (2) | CN110272484A (en) |
AU (2) | AU2012251583B2 (en) |
BR (1) | BR112013028536A2 (en) |
CA (1) | CA2830660A1 (en) |
GB (1) | GB2491006A (en) |
IL (1) | IL228737B (en) |
MX (1) | MX353816B (en) |
RU (1) | RU2650784C2 (en) |
WO (1) | WO2012150319A1 (en) |
ZA (1) | ZA201308255B (en) |
Cited By (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2536756A1 (en) * | 2010-02-16 | 2012-12-26 | MedImmune, LLC | Hsa-related compositions and methods of use |
WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2014072481A1 (en) * | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2014125082A1 (en) | 2013-02-16 | 2014-08-21 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
WO2015036579A1 (en) * | 2013-09-13 | 2015-03-19 | Novozymes Biopharma Dk A/S | Albumin variants |
US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
WO2016166360A1 (en) | 2015-04-17 | 2016-10-20 | Bayer Pharma Aktiengesellschaft | Bispecific antibody constructs for cdh3 and cd3 |
WO2017021356A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding mesothelin and cd3 |
WO2017021362A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for flt3 and cd3 |
WO2017021349A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding dll3 and cd3 |
WO2017021354A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for cd70 and cd3 |
WO2017021370A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding egfrviii and cd3 |
WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
WO2017117631A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated truncated von willebrand factor |
WO2018082758A1 (en) | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
WO2018096396A1 (en) * | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
WO2018102668A1 (en) * | 2016-12-02 | 2018-06-07 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
WO2018234518A1 (en) | 2017-06-22 | 2018-12-27 | CSL Behring Lengnau AG | Modulation of fviii immunogenicity by truncated vwf |
WO2018234349A1 (en) | 2017-06-20 | 2018-12-27 | Albumedix Ltd | Improved protein expression strains |
US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
EP3421491A3 (en) * | 2009-10-30 | 2019-03-27 | Albumedix Ltd | Albumin variants |
CN109553684A (en) * | 2017-09-25 | 2019-04-02 | 中国科学院过程工程研究所 | A kind of nano-carrier albumen and its preparation method and application |
WO2019140196A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
WO2020092202A2 (en) | 2018-10-29 | 2020-05-07 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
US10711050B2 (en) | 2011-11-18 | 2020-07-14 | Albumedix Ltd | Variant serum albumin with improved half-life and other properties |
WO2021044362A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Therapeutic fusion proteins |
EP3819007A1 (en) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
WO2021111143A1 (en) | 2019-12-04 | 2021-06-10 | Albumedix Limited | Methods and compositions produced thereby |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
EP3697812A4 (en) * | 2017-10-18 | 2021-09-22 | CSL Limited | Human serum albumin variants and uses thereof |
WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
WO2022096700A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
WO2022096698A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Polypeptide constructs binding to cd3 |
WO2022103781A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
US11541103B2 (en) | 2017-08-03 | 2023-01-03 | Amgen Inc. | Interleukin-21 mutein/ anti-PD-1 antibody conjugates |
US11555061B2 (en) | 2009-02-11 | 2023-01-17 | Albumedix, Ltd | Albumin variants and conjugates |
US11661462B2 (en) | 2014-07-31 | 2023-05-30 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody contructs |
WO2024089258A1 (en) | 2022-10-28 | 2024-05-02 | Aarhus Universitet | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA037095B1 (en) | 2010-07-09 | 2021-02-05 | Биовератив Терапьютикс Инк. | Method of treating hemophilia b and bleeding episodes |
AU2014228938B2 (en) | 2013-03-15 | 2019-05-02 | Bioverativ Therapeutics Inc. | Factor IX polypeptide formulations |
US10208102B2 (en) * | 2013-11-01 | 2019-02-19 | University Of Oslo | Albumin variants and uses thereof |
US10105442B2 (en) * | 2014-05-07 | 2018-10-23 | Novo Nordisk A/S | Treatment of diabetes type 1 using GLP-1 and anti-IL-21 |
JP2018517708A (en) | 2015-06-05 | 2018-07-05 | ニューヨーク・ユニバーシティ | Compositions and methods for anti-staphylococcal biological agents |
MA43571A (en) | 2015-12-23 | 2018-11-14 | Biogen Ma Inc | PROTEINS CONTAINING A FIELD RICH IN CYSTEINE 2 DKK2 AND THEIR USES |
US11110122B2 (en) | 2016-06-03 | 2021-09-07 | New York University | Methods and reagents for modulating macrophage phenotype |
KR20190102011A (en) | 2016-12-21 | 2019-09-02 | 프로메틱 파마 에스엠티 리미티드 | Methods and compositions for preventing or minimizing epithelial-mesenchymal metastasis |
WO2024025958A1 (en) * | 2022-07-27 | 2024-02-01 | Terraferma Foods, Inc. | Compositions and methods for producing protein |
CN117720671B (en) * | 2024-01-30 | 2024-06-14 | 南通大学 | Recombinant proteins IIB-IIAIB having self-assembling repeat unitsrQTYApplication and application thereof |
CN117720670B (en) * | 2024-01-30 | 2024-06-11 | 南通大学 | Recombinant protein IIIAIIB-IIIAIIB with self-assembly performancerQTYApplication and application thereof |
Citations (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992006204A1 (en) | 1990-09-28 | 1992-04-16 | Ixsys, Inc. | Surface expression libraries of heteromeric receptors |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1995017413A1 (en) | 1993-12-21 | 1995-06-29 | Evotec Biosystems Gmbh | Process for the evolutive design and synthesis of functional polymers based on designer elements and codes |
WO1995022625A1 (en) | 1994-02-17 | 1995-08-24 | Affymax Technologies N.V. | Dna mutagenesis by random fragmentation and reassembly |
WO2000069902A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting fusion peptide inhibitors or viral infection |
WO2001079480A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003066824A2 (en) | 2002-02-07 | 2003-08-14 | Aventis Behring Gmbh | Albumin-fused kunitz domain peptides |
WO2004071536A1 (en) | 2003-02-17 | 2004-08-26 | Upperton Limited | Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent |
US20040171154A1 (en) | 2001-07-27 | 2004-09-02 | Francesca Storici | Systems for in vivo site-directed mutagenesis using oligonucleotides |
WO2006066595A2 (en) | 2004-12-22 | 2006-06-29 | Novozymes A/S | Recombinant production of serum albumin |
WO2008007146A1 (en) | 2006-07-13 | 2008-01-17 | Upperton Limited | Process for preparing particles of proteinaceous material |
WO2009019314A1 (en) | 2007-08-08 | 2009-02-12 | Novozymes A/S | Transferrin variants and conjugates |
WO2009126920A2 (en) * | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
WO2010118169A2 (en) | 2009-04-08 | 2010-10-14 | The Regents Of The University Of California | Human protein scaffold with controlled serum pharmacokinetics |
WO2011051489A2 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2011054148A1 (en) | 2009-11-06 | 2011-05-12 | 华为技术有限公司 | Method and device for resource configuration |
WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE63424B1 (en) | 1987-04-09 | 1995-04-19 | Delta Biotechnology Ltd | Yeast vector |
CA2058820C (en) | 1991-04-25 | 2003-07-15 | Kotikanyad Sreekrishna | Expression cassettes and vectors for the secretion of human serum albumin in pichia pastoris cells |
GB9404270D0 (en) | 1994-03-05 | 1994-04-20 | Delta Biotechnology Ltd | Yeast strains and modified albumins |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
US6274305B1 (en) * | 1996-12-19 | 2001-08-14 | Tufts University | Inhibiting proliferation of cancer cells |
US5948609A (en) | 1997-12-03 | 1999-09-07 | Carter; Daniel C. | Oxygen-transporting albumin-based blood replacement composition and blood volume expander |
GB9902000D0 (en) | 1999-01-30 | 1999-03-17 | Delta Biotechnology Ltd | Process |
AU2001288301A1 (en) * | 2000-08-18 | 2002-03-04 | Human Genome Sciences, Inc. | Binding polypeptides and methods based thereon |
WO2002079415A2 (en) * | 2001-03-30 | 2002-10-10 | Lexigen Pharmaceuticals Corp. | Reducing the immunogenicity of fusion proteins |
WO2005003296A2 (en) | 2003-01-22 | 2005-01-13 | Human Genome Sciences, Inc. | Albumin fusion proteins |
GB0217347D0 (en) | 2002-07-26 | 2002-09-04 | Univ Edinburgh | Novel albumins |
WO2004082640A2 (en) | 2003-03-19 | 2004-09-30 | New Century Pharmaceuticals, Inc. | Human serum albumin conjugates with therapeutic compounds |
CN102816241B (en) | 2004-02-09 | 2015-07-22 | 人类基因科学公司 | Albumin fusion proteins |
JP4492156B2 (en) | 2004-03-03 | 2010-06-30 | ニプロ株式会社 | Protein containing serum albumin domain |
US20060051859A1 (en) | 2004-09-09 | 2006-03-09 | Yan Fu | Long acting human interferon analogs |
EP1924596A4 (en) | 2005-08-12 | 2009-07-29 | Human Genome Sciences Inc | Albumin fusion proteins |
WO2007112940A2 (en) | 2006-03-31 | 2007-10-11 | Ablynx N.V. | Albumin-derived amino acid sequence, use thereof for increasing the half-life of therapeutic proteins and of other therapeutic compounds and entities, and constructs comprising the same |
GB0607798D0 (en) * | 2006-04-20 | 2006-05-31 | Alligator Bioscience Ab | Novel polypeptides and use thereof |
JP5840345B2 (en) * | 2006-09-08 | 2016-01-06 | アンブルックス, インコーポレイテッドAmbrx, Inc. | Modified human plasma polypeptides or modified human Fc scaffold proteins and uses thereof |
WO2010059315A1 (en) | 2008-11-18 | 2010-05-27 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
EP2370473B1 (en) | 2008-12-10 | 2016-05-11 | The Scripps Research Institute | Production of carrier-peptide conjugates using chemically reactive unnatural amino acids |
WO2010138814A2 (en) | 2009-05-29 | 2010-12-02 | The Brigham And Women's Hospital, Inc. | Disrupting fcrn-albumin interactions |
KR20120097481A (en) | 2009-07-20 | 2012-09-04 | 내셔날 쳉쿵 유니버시티 | POLYPEPTIDES SELECTIVE FOR alpha;v beta;3 INTEGRIN CONJUGATED WITH A VARIANT OF HUMAN SERUM ALBUMIN(HSA) AND PHARMACEUTICAL USES THEREOF |
CN103124788B (en) | 2010-05-21 | 2016-01-13 | 梅里麦克制药股份有限公司 | Bispecific fusion protein |
WO2011161127A1 (en) | 2010-06-21 | 2011-12-29 | Medimmune, Llc | Protease variants of human neprilysin |
WO2012059486A1 (en) * | 2010-11-01 | 2012-05-10 | Novozymes Biopharma Dk A/S | Albumin variants |
-
2012
- 2012-05-04 GB GB1207836.6A patent/GB2491006A/en not_active Withdrawn
- 2012-05-04 CA CA2830660A patent/CA2830660A1/en not_active Abandoned
- 2012-05-04 MX MX2013012358A patent/MX353816B/en active IP Right Grant
- 2012-05-04 KR KR1020137031062A patent/KR20140027307A/en active IP Right Grant
- 2012-05-04 AU AU2012251583A patent/AU2012251583B2/en not_active Ceased
- 2012-05-04 US US13/463,944 patent/US8822417B2/en active Active
- 2012-05-04 WO PCT/EP2012/058206 patent/WO2012150319A1/en active Application Filing
- 2012-05-04 BR BR112013028536A patent/BR112013028536A2/en not_active Application Discontinuation
- 2012-05-04 JP JP2014508813A patent/JP6430828B2/en active Active
- 2012-05-04 CN CN201811052791.7A patent/CN110272484A/en active Pending
- 2012-05-04 RU RU2013153816A patent/RU2650784C2/en not_active IP Right Cessation
- 2012-05-04 CN CN201280033529.2A patent/CN104011072B/en not_active Expired - Fee Related
- 2012-05-04 EP EP12718995.9A patent/EP2705051A1/en not_active Withdrawn
-
2013
- 2013-10-06 IL IL228737A patent/IL228737B/en active IP Right Grant
- 2013-11-04 ZA ZA2013/08255A patent/ZA201308255B/en unknown
-
2014
- 2014-07-02 US US14/322,547 patent/US20140315816A1/en not_active Abandoned
-
2017
- 2017-09-05 AU AU2017225014A patent/AU2017225014A1/en not_active Abandoned
-
2019
- 2019-10-22 US US16/660,618 patent/US20200102368A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
WO1992006204A1 (en) | 1990-09-28 | 1992-04-16 | Ixsys, Inc. | Surface expression libraries of heteromeric receptors |
WO1995017413A1 (en) | 1993-12-21 | 1995-06-29 | Evotec Biosystems Gmbh | Process for the evolutive design and synthesis of functional polymers based on designer elements and codes |
WO1995022625A1 (en) | 1994-02-17 | 1995-08-24 | Affymax Technologies N.V. | Dna mutagenesis by random fragmentation and reassembly |
WO2000069902A1 (en) | 1999-05-17 | 2000-11-23 | Conjuchem, Inc. | Long lasting fusion peptide inhibitors or viral infection |
WO2001079480A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2001079271A1 (en) | 2000-04-12 | 2001-10-25 | Principia Pharmaceutical Corporation | Albumin fusion proteins |
US20040171154A1 (en) | 2001-07-27 | 2004-09-02 | Francesca Storici | Systems for in vivo site-directed mutagenesis using oligonucleotides |
WO2003060071A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003059934A2 (en) | 2001-12-21 | 2003-07-24 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2003066824A2 (en) | 2002-02-07 | 2003-08-14 | Aventis Behring Gmbh | Albumin-fused kunitz domain peptides |
WO2004071536A1 (en) | 2003-02-17 | 2004-08-26 | Upperton Limited | Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent |
WO2006066595A2 (en) | 2004-12-22 | 2006-06-29 | Novozymes A/S | Recombinant production of serum albumin |
WO2008007146A1 (en) | 2006-07-13 | 2008-01-17 | Upperton Limited | Process for preparing particles of proteinaceous material |
WO2009019314A1 (en) | 2007-08-08 | 2009-02-12 | Novozymes A/S | Transferrin variants and conjugates |
WO2009126920A2 (en) * | 2008-04-11 | 2009-10-15 | Merrimack Pharmaceuticals, Inc. | Human serum albumin linkers and conjugates thereof |
WO2010092135A2 (en) | 2009-02-11 | 2010-08-19 | Novozymes Biopharma Uk Ltd. | Albumin variants and conjugates |
WO2010118169A2 (en) | 2009-04-08 | 2010-10-14 | The Regents Of The University Of California | Human protein scaffold with controlled serum pharmacokinetics |
WO2011051489A2 (en) | 2009-10-30 | 2011-05-05 | Novozymes Biopharma Dk A/S | Albumin variants |
WO2011054148A1 (en) | 2009-11-06 | 2011-05-12 | 华为技术有限公司 | Method and device for resource configuration |
WO2011103076A1 (en) | 2010-02-16 | 2011-08-25 | Medlmmune, Llc | Hsa-related compositions and methods of use |
WO2011124718A1 (en) | 2010-04-09 | 2011-10-13 | Novozymes A/S | Albumin derivatives and variants |
Non-Patent Citations (118)
Title |
---|
ANDERSEN ET AL., CLINICAL BIOCHEMISTRY, vol. 43, 2010, pages 367 - 372 |
ANDERSEN ET AL., EUR. J. IMMUNOL, vol. 36, 2006, pages 3044 - 3051 |
ANDERSEN ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 285, no. 7, 2010, pages 4826 - 36 |
ANDERSEN ET AL., NATURE COMMUNICATIONS, vol. 3, 2012, pages 610 |
ANDERSEN JT ET AL.: "Ligand binding and antigenic properties of a human neonatal Fc receptor with mutation of two unpaired cysteine residues", FEBS J, vol. 275, no. 16, 2008, pages 4097 - 4110 |
ANDERSEN JT ET AL.: "The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin", EUR J IMMUNOL, vol. 36, no. 11, 2006, pages 3044 - 3051 |
ANDERSEN JT; DABA MB; BERNTZEN G; MICHAELSEN TE; SANDLIE I: "Cross-species binding analyses of mouse and human neonatal Fc receptor show dramatic differences in immunoglobulin G and albumin binding", J BIOL CHEM, vol. 285, no. 7, 2010, pages 4826 - 4836 |
ANDERSEN JT; DABA MB; SANDLIE I: "FcRn binding properties of an abnormal truncated analbuminemic albumin variant", CLIN BIOCHEM, vol. 43, no. 4-5, 2010, pages 367 - 372 |
ANDERSEN JT; DEE QIAN J; SANDLIE I: "The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin", EUR J IMMUNOL, vol. 36, no. 11, 2006, pages 3044 - 3051 |
ANDERSEN JT; SANDLIE I: "A receptor-mediated mechanism to support clinical observation of altered albumin variants", CLIN CHEM, vol. 53, no. 12, 2007, pages 2216 |
ANDERSEN JT; SANDLIE I: "The versatile MHC class I-related FcRn protects IgG and albumin from degradation: implications for development of new diagnostics and therapeutics", DRUG METAB PHARMACOKINET, vol. 24, no. 4, 2009, pages 318 - 332 |
ANDERSON CL ET AL.: "Perspective-- FcRn transports albumin: relevance to immunology and medicine", TRENDS IMMUNOL, vol. 27, no. 7, 2006, pages 343 - 348 |
ATSCHUL ET AL., NUCLEIC ACIDS RES., vol. 25, 1997, pages 3389 - 3402 |
BARASH, TRANSGENIC RESEARCH, vol. 2, 1993, pages 266 - 276 |
BARTON ET AL., NUCLEIC ACIDS RES., vol. 18, 1990, pages 7349 - 4966 |
BIOCHEMISTRY, vol. 39, no. 32, pages 9698 - 9708 |
BOHM, PROTEIN ENG, vol. 5, 1992, pages 191 - 195 |
BOLTON; MCCARTHY, PROC. NATL. ACAD. SCI. USA, vol. 48, 1962, pages 1390 |
BOWIE; SAUER, PROC. NATL. ACAD. SCI. USA, vol. 86, 1989, pages 2152 - 2156 |
BURMEISTER WP; GASTINEL LN; SIMISTER NE; BLUM ML; BJORKMAN PJ: "Crystal structure at 2.2 A resolution of the MHC-related neonatal Fc receptor", NATURE, vol. 372, no. 6504, 1994, pages 336 - 343 |
BURMEISTER WP; HUBER AH; BJORKMAN PJ: "Crystal structure of the complex of rat neonatal Fc receptor with Fc", NATURE, vol. 372, no. 6504, 1994, pages 379 - 383 |
CALISSANO; MACINO, FUNGAL GENET. NEWSLETT., vol. 43, 1996, pages 15 - 16 |
CARLSON ET AL., PROC. NAT. ACAD. SCI. USA, vol. 89, 1992, pages 8225 - 8229 |
CHAITY CHAUDHURY ET AL: "Albumin Binding to FcRn: Distinct from the FcRn-IgG Interaction", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 45, no. 15, 18 April 2006 (2006-04-18), pages 4983 - 4990, XP002629973, ISSN: 0006-2960, [retrieved on 20060322], DOI: 10.1021/BI052628Y * |
CHAUDHURY C ET AL.: "The major histocompatibility complex-related Fc receptor for IgG (FcRn) binds albumin and prolongs its lifespan", J EXP MED, vol. 197, no. 3, 2003, pages 315 - 322 |
CHAUDHURY C; BROOKS CL; CARTER DC; ROBINSON JM; ANDERSON CL: "Albumin binding to FcRn: distinct from the FcRn-IgG interaction", BIOCHEMISTRY, vol. 45, no. 15, 2006, pages 4983 - 4990 |
CHAUDHURY ET AL., BIOCHEMISTRY, vol. 45, 2006, pages 4983 - 4990 |
CHEN R ET AL., PROTEINS, vol. 52, no. 1, 2003, pages 80 - 87 |
CHEN R; LI L; WENG Z: "ZDOCK: an initial-stage protein-docking algorithm", PROTEINS, vol. 52, no. 1, 2003, pages 80 - 87 |
CHEN RONG ET AL: "ZDOCK: An initial-stage protein-docking algorithm.", PROTEINS, vol. 52, no. 1, 1 July 2003 (2003-07-01), pages 80 - 87, XP002660220, ISSN: 0887-3585 * |
CURRY S; MANDELKOW H; BRICK P; FRANKS N: "Crystal structure of human serum albumin complexed with fatty acid reveals an asymmetric distribution of binding sites", NAT STRUCT BIOL, vol. 5, no. 9, 1998, pages 827 - 835 |
DATABASE OMIM [Online] NCBI; XP002660221, Database accession no. 103600 * |
DERBYSHIRE ET AL., GENE, vol. 46, 1986, pages 145 |
DOCKAL ET AL., THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 274, no. 41, 1999, pages 29303 - 29310 |
EDGAR, BMC BIOINFORMATICS, vol. 5, no. 1, 2004, pages 113 |
EDGAR, NUCLEIC ACIDS RESEARCH, vol. 32, no. 5, 2004, pages 1792 - 97 |
FARRAN, TRANSGENIC RESEARCH, vol. 11, 2002, pages 337 - 346 |
FINNIS, C. J. ET AL.: "High-level production of animal-free recombinant transferrin from Saccharomyces cerevisiae", MICROB CELL FACT, vol. 9, 2010, pages 87 |
FLEER, BIOLTECHNOLOGY, vol. 9, 1991, pages 968 - 975 |
GALLIANO ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1225, 1993, pages 27 - 32 |
GALLIANO M ET AL: "Protein and DNA sequence analysis of a 'private' genetic variant: albumin Ortonovo (Glu-505 -> Lys)", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR BASIS OF DISEASE, AMSTERDAM, NL, vol. 1225, no. 1, 25 November 1993 (1993-11-25), pages 27 - 32, XP023554812, ISSN: 0925-4439, [retrieved on 19931125], DOI: 10.1016/0925-4439(93)90117-J * |
GOUGH ET AL., J. MOL. BIOL., vol. 313, 2000, pages 903 - 919 |
GUO; SHERMAN, MOL. CELLULAR BIOL., vol. 15, 1995, pages 5983 - 5990 |
HE XM; CARTER DC: "Atomic structure and chemistry of human serum albumin", NATURE, vol. 358, no. 6383, July 1992 (1992-07-01), pages 209 - 15 |
HO, J.X. ET AL.: "X-ray and primary structure of horse serum albumin (Equus caballus) at 0.27-nm resolution", EUR J BIOCHEM., vol. 215, no. 1, 2001, pages 205 - 12 |
HOLM; PARK, BIOINFORMATICS, vol. 16, 2000, pages 566 - 567 |
HOLM; SANDER, PROTEINS, vol. 33, 1998, pages 88 - 96 |
HUSSAIN, R.; SILIGARDI, G., INTERNATIONAL JOURNAL OF PEPTIDE RESEARCH AND THERAPEUTICS, vol. 12, no. 3, 2006, pages 311 - 315 |
IWAO ET AL: "Changes of net charge and alpha-helical content affect the pharmacokinetic properties of human serum albumin", BIOCHIMICA ET BIOPHYSICA ACTA (BBA) - PROTEINS & PROTEOMICS, ELSEVIER, NETHERLANDS, vol. 1774, no. 12, 1 December 2007 (2007-12-01), pages 1582 - 1590, XP022385158, ISSN: 1570-9639, DOI: 10.1016/J.BBAPAP.2007.09.001 * |
IWAO, B.B.A. PROTEINS AND PROTEOMICS, vol. 1774, 2007, pages 1582 - 1590 |
J EXP MED., vol. 197, no. 3, 2003, pages 315 - 22 |
J. SAMBROOK; E.F. FRITSCH; T. MANIATIS: "Molecular Cloning, A Laboratory Manual", 1989, COLD SPRING HARBOR |
JONES, J. MOL. BIOL., vol. 287, 1999, pages 797 - 815 |
KENANOVA ET AL., J. NUCL. MED., vol. 50, no. 2, 2009, pages 1582 |
KENANOVA ET AL., PROTEIN ENGINEERING, DESIGN & SELECTION, vol. 23, no. 10, 2010, pages 789 - 798 |
KENANOVA V ET AL.: "Radioiodinated versus radiometal-labeled anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments: optimal pharmacokinetics for therapy", CANCER RES, vol. 67, no. 2, 2007, pages 718 - 726 |
KENANOVA V ET AL.: "Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments", CANCER RES, vol. 65, no. 2, 2005, pages 622 - 631 |
KENANOVA VE ET AL.: "Tuning the serum persistence of human serum albumin domain III:diabody fusion proteins", PROTEIN ENG DES SEL, vol. 23, no. 10, 2010, pages 789 - 798 |
KJELDSEN ET AL., PROTEIN EXPRESSION AND PURIFICATION, vol. 13, 1998, pages 163 - 169 |
KOBAYASHI, THERAPEUTIC APHERESIS, vol. 2, 1998, pages 257 - 262 |
KRAGH-HANSEN ET AL., BIOL. PHARM. BULL., vol. 25, 2002, pages 695 |
KRATZ, JOURNAL OF CONTROLLED RELEASE, vol. 132, 2008, pages 171 - 183 |
KREN ET AL., NAT. MED., vol. 4, 1998, pages 285 - 290 |
KRISSINEL ET AL., ACTA CRYST., vol. D60, 2004, pages 2256 - 2268 |
KRISSINEL, BIOINFORMATICS, vol. 23, 2007, pages 717 - 723 |
KUO TT ET AL.: "Neonatal Fc receptor: from immunity to therapeutics", J CLIN IMMUNOL, vol. 30, no. 6, 2010, pages 777 - 789 |
KURTZHALS P ET AL., BIOCHEM. J., vol. 312, 1995, pages 725 - 731 |
LARKIN ET AL., BIOINFORMATICS, vol. 23, 2007, pages 2947 - 2948 |
LINDAHL; ELOFSSON, J. MOL. BIOL., vol. 295, 2000, pages 613 - 615 |
LOWMAN ET AL., BIOCHEMISTRY, vol. 30, 1991, pages 10832 - 10837 |
MCGREGOR DP: "Discovering and improving novel peptide therapeutics", CURR OPIN PHARMACOL, vol. 8, no. 5, 2008, pages 616 - 619 |
MCGUFFIN; JONES, BIOINFORMATICS, vol. 19, 2003, pages 874 - 881 |
MEZO AR ET AL., J BIOL CHEM, vol. 285, no. 36, 2010, pages 27694 - 27701 |
MEZO AR ET AL.: "X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn", J BIOL CHEM, vol. 285, no. 36, 2010, pages 27694 - 27701 |
MEZO AR; SRIDHAR V; BADGER J; SAKORAFAS P; NIENABER V: "X-ray crystal structures of monomeric and dimeric peptide inhibitors in complex with the human neonatal Fc receptor, FcRn", J BIOL CHEM, vol. 285, no. 36, 2010, pages 27694 - 27701 |
MINCHIOTTI ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 916, 1987, pages 411 - 418 |
MINCHIOTTI L; GALLIANO M; KRAGH-HANSEN U; PETERS T, JR.: "Mutations and polymorphisms of the gene of the major human blood protein, serum albumin", HUM MUTAT, vol. 29, no. 8, 2008, pages 1007 - 1016 |
MONTOYO HP ET AL.: "Conditional deletion of the MHC class I-related receptor FcRn reveals the sites of IgG homeostasis in mice", PROC NATL ACAD SCI U S A, vol. 106, no. 8, 2009, pages 2788 - 2793 |
NEEDLEMAN; WUNSCH, J. MOL. BIOL., vol. 48, 1970, pages 443 - 453 |
NER ET AL., DNA, vol. 7, 1988, pages 127 |
NESS ET AL., NATURE BIOTECHNOLOGY, vol. 17, 1999, pages 893 - 896 |
OBER ET AL., INT. IMMUNOL, vol. 13, 2001, pages 1551 - 1559 |
OBER RJ; MARTINEZ C; LAI X; ZHOU J; WARD ES: "Exocytosis of IgG as mediated by the receptor, FcRn: an analysis at the single-molecule level", PROC NATL ACAD SCI U S A, vol. 101, no. 30, 2004, pages 11076 - 11081 |
OBER RJ; MARTINEZ C; VACCARO C; ZHOU J; WARD ES: "Visualizing the site and dynamics of IgG salvage by the MHC class I-related receptor, FcRn", J IMMUNOL, vol. 172, no. 4, 2004, pages 2021 - 2029 |
ONER; GROVES, PHARMACEUTICAL RESEARCH, vol. 10, no. 9, 1993, pages 1387 - 1388 |
OTAGIRI ET AL., BIOL. PHARM. BULL., vol. 32, no. 4, 2009, pages 527 - 534 |
PANDJAITAB, J. ALLERGY CLIN. IMMUNOL., vol. 105, 2000, pages 279 - 285 |
PEACH RJ; BRENNAN SO: "Structural characterization of a glycoprotein variant of human serum albumin: albumin Casebrook (494 Asp----Asn", BIOCHIM BIOPHYS ACTA, vol. 1097, no. 1, 1991, pages 49 - 54 |
PEACH, R. J.; BRENNAN, S. 0., BIOCHIM BIOPHYS ACTA, vol. 1097, 1991, pages 49 - 54 |
PETERS T, JR.: "Serum albumin", ADV PROTEIN CHEM, vol. 37, 1985, pages 161 - 245 |
PETERS, T., JR.: "All about Albumin: Biochemistry, Genetics and Medical, Applications", 1996, ACADEMIC PRESS, INC., pages: 10 |
PRABHAT P ET AL.: "Elucidation of intracellular recycling pathways leading to exocytosis of the Fc receptor, FcRn, by using multifocal plane microscopy", PROC NATL ACAD SCI U S A, vol. 104, no. 14, 2007, pages 5889 - 5894 |
REIDHAAR-OLSON; SAUER, SCIENCE, vol. 241, 1988, pages 53 - 57 |
RICE ET AL., TRENDS GENET., vol. 16, 2000, pages 276 - 277 |
ROMANOS ET AL., YEAST, vol. 8, 1992, pages 423 - 488 |
ROOPENIAN D. C.; AKILESH, S., NAT. REV. IMMUNOL, vol. 7, 2007, pages 715 - 725 |
ROOPENIAN DC ET AL.: "The MHC class I-like IgG receptor controls perinatal IgG transport, IgG homeostasis, and fate of IgG-Fc-coupled drugs", J IMMUNOL, vol. 170, no. 7, 2003, pages 3528 - 3533 |
ROOPENIAN DC; AKILESH S: "FcRn: the neonatal Fc receptor comes of age", NAT REV IMMUNOL, vol. 7, no. 9, 2007, pages 715 - 725 |
SAMBROOK, J.; D.W. RUSSELL: "Molecular Cloning: a laboratory manual", 2001, COLD SPRING HARBOR LABORATORY PRESS |
SCHERER; DAVIS, PROC. NATL. ACAD. SCI. USA, vol. 76, 1979, pages 4949 - 4955 |
SHEFFIELD WP; MARQUES JA; BHAKTA V; SMITH IJ: "Modulation of clearance of recombinant serum albumin by either glycosylation or truncation", THROMB RES, vol. 99, no. 6, 2000, pages 613 - 621 |
SHINDYALOV; BOURNE, PROTEIN ENGINEERING, vol. 11, 1998, pages 739 - 747 |
SIJMONS, BIOLTECHNOLOGY, vol. 8, 1990, pages 217 |
SIMARD JR ET AL.: "Locating high-affinity fatty acid-binding sites on albumin by x-ray crystallography and NMR spectroscopy", PROC NATL ACAD SCI U S A, vol. 102, no. 50, 2005, pages 17958 - 17963 |
SLEEP, BIOLTECHNOLOGY, vol. 8, 1990, pages 42 - 46 |
STEHLE G ET AL.: "Plasma protein (albumin) catabolism by the tumor itself--implications for tumor metabolism and the genesis of cachexia", CRIT REV ONCOL HEMATOL, vol. 26, no. 2, 1997, pages 77 - 100 |
STORICI ET AL., NATURE BIOTECHNOL., vol. 19, 2001, pages 773 - 776 |
SUGIO S ET AL., PROTEIN ENG, vol. 12, no. 6, 1999, pages 439 - 446 |
SUGIO S ET AL: "Crystal structure of human serum albumin at 2.5 angstroms resolution", PROTEIN ENGINEERING, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 12, no. 6, 1 January 1999 (1999-01-01), pages 439 - 446, XP002964157, ISSN: 0269-2139, DOI: 10.1093/PROTEIN/12.6.439 * |
SUGIO S; KASHIMA A; MOCHIZUKI S; NODA M; KOBAYASHI K: "Crystal structure of human serum albumin at 2.5 A resolution", PROTEIN ENG, vol. 12, no. 6, 1999, pages 439 - 446 |
TAKAHASHI ET AL., PROC. NATL. ACAD. SCI. USA, vol. 84, 1987, pages 4413 - 4417 |
TIAN ET AL., NATURE, vol. 432, 2004, pages 1050 - 1054 |
WANI MA ET AL.: "Familial hypercatabolic hypoproteinemia caused by deficiency of the neonatal Fc receptor, FcRn, due to a mutant beta2-microglobulin gene", PROC NATL ACAD SCI U S A, vol. 103, no. 13, 2006, pages 5084 - 5089 |
WARD ES; OBER RJ: "Adv Immunol", vol. 103, 2009, article "Multitasking by exploitation of intracellular transport functions the many faces of FcRn", pages: 77 - 115 |
WERLE M; BERNKOP-SCHNURCH A: "Strategies to improve plasma half life time of peptide and protein drugs", AMINO ACIDS, vol. 30, no. 4, 2006, pages 351 - 367 |
WEST AP, JR.; BJORKMAN PJ: "Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor", BIOCHEMISTRY, vol. 39, no. 32, 2000, pages 9698 - 9708 |
WEST ET AL., BIOCHEMISTRY, vol. 39, no. 32, 2000, pages 9698 - 9708 |
ZALEVSKY J ET AL.: "Enhanced antibody half-life improves in vivo activity", NAT BIOTECHNOL, vol. 28, no. 2, 2010, pages 157 - 159 |
Cited By (88)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11555061B2 (en) | 2009-02-11 | 2023-01-17 | Albumedix, Ltd | Albumin variants and conjugates |
EP3421491A3 (en) * | 2009-10-30 | 2019-03-27 | Albumedix Ltd | Albumin variants |
US10696732B2 (en) | 2009-10-30 | 2020-06-30 | Albumedix, Ltd | Albumin variants |
EP2536756A4 (en) * | 2010-02-16 | 2013-08-14 | Medimmune Llc | Hsa-related compositions and methods of use |
US8697650B2 (en) | 2010-02-16 | 2014-04-15 | Medimmune, Llc | HSA-related compositions and methods of use |
EP2536756A1 (en) * | 2010-02-16 | 2012-12-26 | MedImmune, LLC | Hsa-related compositions and methods of use |
US9120875B2 (en) | 2010-02-16 | 2015-09-01 | Medimmune, Llc | HSA-related compositions and methods of use |
US10233228B2 (en) | 2010-04-09 | 2019-03-19 | Albumedix Ltd | Albumin derivatives and variants |
US9045564B2 (en) | 2011-02-15 | 2015-06-02 | Medimmune, Llc | HSA-related compositions and methods of use |
US10711050B2 (en) | 2011-11-18 | 2020-07-14 | Albumedix Ltd | Variant serum albumin with improved half-life and other properties |
AU2013234299B2 (en) * | 2012-03-16 | 2017-06-22 | Albumedix Ltd. | Albumin variants |
EP3330283A2 (en) | 2012-03-16 | 2018-06-06 | Albumedix A/S | Albumin variants |
WO2013135896A1 (en) | 2012-03-16 | 2013-09-19 | Novozymes Biopharma Dk A/S | Albumin variants |
US10329340B2 (en) | 2012-03-16 | 2019-06-25 | Albumedix Ltd | Albumin variants |
EP3330283A3 (en) * | 2012-03-16 | 2018-07-11 | Albumedix A/S | Albumin variants |
US9944691B2 (en) | 2012-03-16 | 2018-04-17 | Albumedix A/S | Albumin variants |
GB2512156A (en) * | 2012-11-08 | 2014-09-24 | Novozymes Biopharma Dk As | Albumin variants |
JP2015535300A (en) * | 2012-11-08 | 2015-12-10 | ノボザイムス バイオファーマ デーコー アクティーゼルスカブ | Albumin variant |
US10934341B2 (en) | 2012-11-08 | 2021-03-02 | Albumedix, Ltd. | Albumin variants |
WO2014072481A1 (en) * | 2012-11-08 | 2014-05-15 | Novozymes Biopharma Dk A/S | Albumin variants |
US10501524B2 (en) | 2012-11-08 | 2019-12-10 | Albumedix Ltd | Albumin variants |
EP2917233A1 (en) * | 2012-11-08 | 2015-09-16 | Novozymes Biopharma DK A/S | Albumin variants |
WO2014125082A1 (en) | 2013-02-16 | 2014-08-21 | Novozymes Biopharma Dk A/S | Pharmacokinetic animal model |
EP3318124A2 (en) | 2013-02-16 | 2018-05-09 | Albumedix A/S | Pharmacokinetic animal model |
WO2015036579A1 (en) * | 2013-09-13 | 2015-03-19 | Novozymes Biopharma Dk A/S | Albumin variants |
US11661462B2 (en) | 2014-07-31 | 2023-05-30 | Amgen Research (Munich) Gmbh | Optimized cross-species specific bispecific single chain antibody contructs |
US11028171B2 (en) | 2015-04-17 | 2021-06-08 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs for CDH3 and CD3 |
EP4276116A2 (en) | 2015-04-17 | 2023-11-15 | Amgen Research (Munich) GmbH | Bispecific antibody constructs for cdh3 and cd3 |
US11926666B2 (en) | 2015-04-17 | 2024-03-12 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs for CDH3 and CD3 |
WO2016166360A1 (en) | 2015-04-17 | 2016-10-20 | Bayer Pharma Aktiengesellschaft | Bispecific antibody constructs for cdh3 and cd3 |
US10683351B2 (en) | 2015-07-31 | 2020-06-16 | Amgen Research (Munich) Gmbh | Antibody constructs for DLL3 and CD3 |
US11591396B2 (en) | 2015-07-31 | 2023-02-28 | Amgen Research (Munich) Gmbh | Antibody constructs for DLL3 and CD3 |
EP4382169A2 (en) | 2015-07-31 | 2024-06-12 | Amgen Research (Munich) GmbH | Antibody constructs for dll3 and cd3 |
WO2017021356A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding mesothelin and cd3 |
US10294300B2 (en) | 2015-07-31 | 2019-05-21 | Amgen Research (Munich) Gmbh | Antibody constructs for DLL3 and CD3 |
US11155629B2 (en) | 2015-07-31 | 2021-10-26 | Amgen Research (Munich) Gmbh | Method for treating glioblastoma or glioma with antibody constructs for EGFRVIII and CD3 |
EP4327885A2 (en) | 2015-07-31 | 2024-02-28 | Amgen Research (Munich) GmbH | Antibody constructs for msln and cd3 |
US11884720B2 (en) | 2015-07-31 | 2024-01-30 | Amgen Research (Munich) Gmbh | Antibody constructs for MSLN and CD3 |
US10519241B2 (en) | 2015-07-31 | 2019-12-31 | Amgen Research (Munich) Gmbh | Antibody constructs for EGFRVIII and CD3 |
WO2017021362A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for flt3 and cd3 |
EP4219562A2 (en) | 2015-07-31 | 2023-08-02 | Amgen Research (Munich) GmbH | Antibody constructs for flt3 and cd3 |
EP3912999A1 (en) | 2015-07-31 | 2021-11-24 | Amgen Research (Munich) GmbH | Bispecific antibody constructs binding egfrviii and cd3 |
WO2017021349A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding dll3 and cd3 |
EP3865514A1 (en) | 2015-07-31 | 2021-08-18 | Amgen Research (Munich) GmbH | Bispecific antibody constructs binding dll3 and cd3 |
WO2017021370A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Bispecific antibody constructs binding egfrviii and cd3 |
US11447567B2 (en) | 2015-07-31 | 2022-09-20 | Amgen Research (Munich) Gmbh | Antibody constructs for FLT3 and CD3 |
WO2017021354A1 (en) | 2015-07-31 | 2017-02-09 | Amgen Research (Munich) Gmbh | Antibody constructs for cd70 and cd3 |
US10851170B2 (en) | 2015-07-31 | 2020-12-01 | Amgen Research (Munich) Gmbh | Antibody constructs for CD70 and CD3 |
US10633428B2 (en) | 2015-08-20 | 2020-04-28 | Albumedix Ltd | Albumin variants and conjugates |
WO2017112847A1 (en) | 2015-12-22 | 2017-06-29 | Albumedix A/S | Improved protein expression strains |
US10023618B2 (en) | 2015-12-22 | 2018-07-17 | Albumedix A/S | Protein expression strains |
US10806774B2 (en) | 2016-01-07 | 2020-10-20 | CSL Behring Lengnau AG | Mutated truncated von Willebrand Factor |
WO2017117631A1 (en) | 2016-01-07 | 2017-07-13 | Csl Limited | Mutated truncated von willebrand factor |
US11434302B2 (en) | 2016-02-03 | 2022-09-06 | Amgen Research (Munich) Gmbh | Bispecific T cell engaging antibody constructs |
WO2018082758A1 (en) | 2016-11-04 | 2018-05-11 | Aarhus Universitet | Identification and treatment of tumors characterized by an overexpression of the neonatal fc receptor |
WO2018096396A1 (en) * | 2016-11-22 | 2018-05-31 | University Of Oslo | Albumin variants and uses thereof |
US11459396B2 (en) | 2016-12-02 | 2022-10-04 | The Texas A&M University System | Fusion proteins (Seldegs) for selectively depleting antigen-specific antibodies and methods of use thereof |
WO2018102668A1 (en) * | 2016-12-02 | 2018-06-07 | The Texas A&M University System | Fusion proteins for selectively depleting antigen-specific antibodies |
WO2018234349A1 (en) | 2017-06-20 | 2018-12-27 | Albumedix Ltd | Improved protein expression strains |
US11396670B2 (en) | 2017-06-20 | 2022-07-26 | Albumedix Limited | Protein expression strains |
US11130979B2 (en) | 2017-06-20 | 2021-09-28 | Albumedix Ltd | Protein expression strains |
EP4026908A1 (en) | 2017-06-20 | 2022-07-13 | Albumedix Ltd | Improved protein expression strains |
US11141466B2 (en) | 2017-06-22 | 2021-10-12 | CSL Behring Lengnau AG | Modulation of FVIII immunogenicity by truncated VWF |
WO2018234518A1 (en) | 2017-06-22 | 2018-12-27 | CSL Behring Lengnau AG | Modulation of fviii immunogenicity by truncated vwf |
US11541103B2 (en) | 2017-08-03 | 2023-01-03 | Amgen Inc. | Interleukin-21 mutein/ anti-PD-1 antibody conjugates |
US10640504B2 (en) | 2017-09-08 | 2020-05-05 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
CN109553684A (en) * | 2017-09-25 | 2019-04-02 | 中国科学院过程工程研究所 | A kind of nano-carrier albumen and its preparation method and application |
EP3697812A4 (en) * | 2017-10-18 | 2021-09-22 | CSL Limited | Human serum albumin variants and uses thereof |
WO2019140196A1 (en) | 2018-01-12 | 2019-07-18 | Amgen Inc. | Anti-pd-1 antibodies and methods of treatment |
US11518808B2 (en) | 2018-01-12 | 2022-12-06 | Amgen Inc. | Anti-PD-1 antibodies and methods of treatment |
WO2020025792A1 (en) | 2018-08-03 | 2020-02-06 | Amgen Research (Munich) Gmbh | Antibody constructs for cldn18.2 and cd3 |
US11692031B2 (en) | 2018-08-03 | 2023-07-04 | Amgen Research (Munich) Gmbh | Antibody constructs for CLDN18.2 and CD3 |
WO2020049151A1 (en) | 2018-09-06 | 2020-03-12 | Bavarian Nordic A/S | Storage improved poxvirus compositions |
WO2020092202A2 (en) | 2018-10-29 | 2020-05-07 | Biogen Ma Inc. | Humanized and stabilized fc5 variants for enhancement of blood brain barrier transport |
WO2021044362A1 (en) | 2019-09-06 | 2021-03-11 | Novartis Ag | Therapeutic fusion proteins |
WO2021094000A1 (en) | 2019-11-11 | 2021-05-20 | Amgen Research (Munich) Gmbh | Dosing regimen for anti-bcma agents |
EP3819007A1 (en) | 2019-11-11 | 2021-05-12 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
EP4424709A2 (en) | 2019-11-11 | 2024-09-04 | Amgen Research (Munich) GmbH | Dosing regimen for anti-bcma agents |
WO2021111143A1 (en) | 2019-12-04 | 2021-06-10 | Albumedix Limited | Methods and compositions produced thereby |
WO2021150824A1 (en) | 2020-01-22 | 2021-07-29 | Amgen Research (Munich) Gmbh | Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof |
WO2021183861A1 (en) | 2020-03-12 | 2021-09-16 | Amgen Inc. | Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor |
WO2021180943A1 (en) | 2020-03-12 | 2021-09-16 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
WO2021236638A1 (en) | 2020-05-19 | 2021-11-25 | Amgen Inc. | Mageb2 binding constructs |
WO2022096698A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Polypeptide constructs binding to cd3 |
WO2022096704A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Inc. | Antigen binding domain with reduced clipping rate |
WO2022096700A1 (en) | 2020-11-06 | 2022-05-12 | Amgen Research (Munich) Gmbh | Polypeptide constructs selectively binding to cldn6 and cd3 |
WO2022103781A1 (en) | 2020-11-10 | 2022-05-19 | Amgen Inc. | Methods for administering a bcma x cd3 binding molecule |
WO2024089258A1 (en) | 2022-10-28 | 2024-05-02 | Aarhus Universitet | Albumin conjugated to cpg oligodeoxynucleotides as super-boosters of immune response |
Also Published As
Publication number | Publication date |
---|---|
MX2013012358A (en) | 2014-04-25 |
JP6430828B2 (en) | 2018-11-28 |
JP2014515614A (en) | 2014-07-03 |
US20200102368A1 (en) | 2020-04-02 |
US20120322739A1 (en) | 2012-12-20 |
CN104011072A (en) | 2014-08-27 |
RU2650784C2 (en) | 2018-04-17 |
IL228737B (en) | 2019-03-31 |
US20140315816A1 (en) | 2014-10-23 |
GB2491006A (en) | 2012-11-21 |
RU2013153816A (en) | 2015-06-10 |
BR112013028536A2 (en) | 2016-11-29 |
MX353816B (en) | 2018-01-30 |
EP2705051A1 (en) | 2014-03-12 |
CA2830660A1 (en) | 2012-11-08 |
AU2012251583B2 (en) | 2017-06-08 |
IL228737A0 (en) | 2013-12-31 |
KR20140027307A (en) | 2014-03-06 |
CN110272484A (en) | 2019-09-24 |
GB201207836D0 (en) | 2012-06-20 |
ZA201308255B (en) | 2018-11-28 |
AU2017225014A1 (en) | 2017-09-28 |
AU2012251583A1 (en) | 2013-10-10 |
US8822417B2 (en) | 2014-09-02 |
CN104011072B (en) | 2018-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200102368A1 (en) | Albumin variants | |
US10934341B2 (en) | Albumin variants | |
US10329340B2 (en) | Albumin variants | |
US20160222087A1 (en) | Albumin variants | |
EP2635598A1 (en) | Albumin variants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 12718995 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2830660 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2012251583 Country of ref document: AU Date of ref document: 20120504 Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2013/012358 Country of ref document: MX |
|
ENP | Entry into the national phase |
Ref document number: 2014508813 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137031062 Country of ref document: KR Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2012718995 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2013153816 Country of ref document: RU Kind code of ref document: A |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112013028536 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 112013028536 Country of ref document: BR Kind code of ref document: A2 Effective date: 20131105 |